From c79bd92fbd6da4a0932a07fe4c1c29574a9b7482 Mon Sep 17 00:00:00 2001 From: Gowtham Rao Date: Thu, 19 Oct 2023 17:02:32 -0400 Subject: [PATCH] Release Version 3.30.0 --- docs/404.html | 2 +- ...ohortDefinitionSubmissionRequirements.html | 4 +- ...ortDefinitionsInOhdsiPhenotypeLibrary.html | 10 +- .../react-18.2.0/AUTHORS | 696 ++++ .../react-18.2.0/LICENSE.txt | 21 + .../react-18.2.0/react-dom.min.js | 267 ++ .../react-18.2.0/react.min.js | 31 + ...SetDefinitionsInOhdsiPhenotypeLibrary.html | 10 +- .../react-18.2.0/AUTHORS | 696 ++++ .../react-18.2.0/LICENSE.txt | 21 + .../react-18.2.0/react-dom.min.js | 267 ++ .../react-18.2.0/react.min.js | 31 + ...icalDescriptionForConditionPhenotypes.html | 4 +- .../GuidanceOnCohortDefinitionSetRObject.html | 4 +- docs/articles/GuidanceOnLiteratureReview.html | 4 +- .../GuidanceOnPerformingPeerReview.html | 4 +- .../GuidanceOnWritingAnEvaluationReport.html | 4 +- ...itingCohortDefinitionLogicDescription.html | 4 +- .../HowToUsePhenotypeLibraryRPackage.html | 8 +- ...dWordsWithSpecialMeaningToPhenotypers.html | 4 +- docs/articles/SubmittedCohortDefinitions.html | 4 +- .../ValidityChecksForCohortDefinitions.html | 4 +- docs/articles/index.html | 2 +- docs/authors.html | 2 +- docs/index.html | 2 +- docs/news/index.html | 2825 +++++++++-------- docs/pkgdown.yml | 2 +- docs/reference/PhenotypeLibrary-package.html | 2 +- docs/reference/getPhenotypeLog.html | 2 +- docs/reference/getPlCohortDefinitionSet.html | 2 +- docs/reference/getPlConceptDefinitionSet.html | 2 +- docs/reference/index.html | 2 +- docs/reference/listPhenotypes.html | 6 +- extras/PhenotypeLibrary.pdf | Bin 86519 -> 86364 bytes inst/doc/HowToUsePhenotypeLibraryRPackage.pdf | Bin 196904 -> 196804 bytes 35 files changed, 3496 insertions(+), 1453 deletions(-) create mode 100644 docs/articles/CohortDefinitionsInOhdsiPhenotypeLibrary_files/react-18.2.0/AUTHORS create mode 100644 docs/articles/CohortDefinitionsInOhdsiPhenotypeLibrary_files/react-18.2.0/LICENSE.txt create mode 100644 docs/articles/CohortDefinitionsInOhdsiPhenotypeLibrary_files/react-18.2.0/react-dom.min.js create mode 100644 docs/articles/CohortDefinitionsInOhdsiPhenotypeLibrary_files/react-18.2.0/react.min.js create mode 100644 docs/articles/ConceptSetDefinitionsInOhdsiPhenotypeLibrary_files/react-18.2.0/AUTHORS create mode 100644 docs/articles/ConceptSetDefinitionsInOhdsiPhenotypeLibrary_files/react-18.2.0/LICENSE.txt create mode 100644 docs/articles/ConceptSetDefinitionsInOhdsiPhenotypeLibrary_files/react-18.2.0/react-dom.min.js create mode 100644 docs/articles/ConceptSetDefinitionsInOhdsiPhenotypeLibrary_files/react-18.2.0/react.min.js diff --git a/docs/404.html b/docs/404.html index 6800ee2f..df88ee9f 100644 --- a/docs/404.html +++ b/docs/404.html @@ -32,7 +32,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 diff --git a/docs/articles/CohortDefinitionSubmissionRequirements.html b/docs/articles/CohortDefinitionSubmissionRequirements.html index 6a407c5e..1c05b649 100644 --- a/docs/articles/CohortDefinitionSubmissionRequirements.html +++ b/docs/articles/CohortDefinitionSubmissionRequirements.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 @@ -121,7 +121,7 @@

Cohort Definition Submission Requirements

Gowtham A. Rao

-

2023-10-16

+

2023-10-19

Source: vignettes/CohortDefinitionSubmissionRequirements.Rmd diff --git a/docs/articles/CohortDefinitionsInOhdsiPhenotypeLibrary.html b/docs/articles/CohortDefinitionsInOhdsiPhenotypeLibrary.html index 3b960bc9..7af57bba 100644 --- a/docs/articles/CohortDefinitionsInOhdsiPhenotypeLibrary.html +++ b/docs/articles/CohortDefinitionsInOhdsiPhenotypeLibrary.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 @@ -114,7 +114,7 @@ - +
@@ -114,7 +114,7 @@ - +
@@ -122,7 +122,7 @@

Guidance on writing clinical description for

Gowtham A. Rao

-

2023-10-16

+

2023-10-19

Source: vignettes/GuidanceOnClinicalDescriptionForConditionPhenotypes.Rmd diff --git a/docs/articles/GuidanceOnCohortDefinitionSetRObject.html b/docs/articles/GuidanceOnCohortDefinitionSetRObject.html index 30bab432..1c5ca992 100644 --- a/docs/articles/GuidanceOnCohortDefinitionSetRObject.html +++ b/docs/articles/GuidanceOnCohortDefinitionSetRObject.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0
@@ -121,7 +121,7 @@

Guidance on Cohort Definition Set R Object

Gowtham A. Rao

-

2023-10-16

+

2023-10-19

Source: vignettes/GuidanceOnCohortDefinitionSetRObject.Rmd diff --git a/docs/articles/GuidanceOnLiteratureReview.html b/docs/articles/GuidanceOnLiteratureReview.html index c042ebf3..80ed18f4 100644 --- a/docs/articles/GuidanceOnLiteratureReview.html +++ b/docs/articles/GuidanceOnLiteratureReview.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0
@@ -121,7 +121,7 @@

Guidance on literature review

Gowtham A. Rao

-

2023-10-16

+

2023-10-19

Source: vignettes/GuidanceOnLiteratureReview.Rmd diff --git a/docs/articles/GuidanceOnPerformingPeerReview.html b/docs/articles/GuidanceOnPerformingPeerReview.html index 9eae2e8e..959457b3 100644 --- a/docs/articles/GuidanceOnPerformingPeerReview.html +++ b/docs/articles/GuidanceOnPerformingPeerReview.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0
@@ -121,7 +121,7 @@

Guidance on performing peer review

Gowtham A. Rao

-

2023-10-16

+

2023-10-19

Source: vignettes/GuidanceOnPerformingPeerReview.Rmd diff --git a/docs/articles/GuidanceOnWritingAnEvaluationReport.html b/docs/articles/GuidanceOnWritingAnEvaluationReport.html index 14b06260..7675d64a 100644 --- a/docs/articles/GuidanceOnWritingAnEvaluationReport.html +++ b/docs/articles/GuidanceOnWritingAnEvaluationReport.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0
@@ -121,7 +121,7 @@

Guidance on writing an evaluation report

Gowtham A. Rao

-

2023-10-16

+

2023-10-19

Source: vignettes/GuidanceOnWritingAnEvaluationReport.Rmd diff --git a/docs/articles/GuidanceOnWritingCohortDefinitionLogicDescription.html b/docs/articles/GuidanceOnWritingCohortDefinitionLogicDescription.html index b7901e50..9b17149f 100644 --- a/docs/articles/GuidanceOnWritingCohortDefinitionLogicDescription.html +++ b/docs/articles/GuidanceOnWritingCohortDefinitionLogicDescription.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 @@ -122,7 +122,7 @@

Guidance on writing Cohort Definition Logic

Gowtham A. Rao

-

2023-10-16

+

2023-10-19

Source: vignettes/GuidanceOnWritingCohortDefinitionLogicDescription.Rmd diff --git a/docs/articles/HowToUsePhenotypeLibraryRPackage.html b/docs/articles/HowToUsePhenotypeLibraryRPackage.html index adc37ba3..3463e784 100644 --- a/docs/articles/HowToUsePhenotypeLibraryRPackage.html +++ b/docs/articles/HowToUsePhenotypeLibraryRPackage.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 @@ -121,7 +121,7 @@

How to Use PhenotypeLibrary R Package

Gowtham A. Rao

-

2023-10-16

+

2023-10-19

Source: vignettes/HowToUsePhenotypeLibraryRPackage.Rmd @@ -151,7 +151,7 @@

Retrieval
 PhenotypeLibrary::getPhenotypeLog()
-
#> # A tibble: 563 x 81
+
#> # A tibble: 571 x 81
 #>    cohortId cohortName        cohortNameAtlas cohortNameFormatted cohortNameLong
 #>       <dbl> <chr>             <chr>           <chr>               <chr>         
 #>  1        3 Cough or Sputum   [P] Cough or S~ Cough or Sputum     Cough or Sput~
@@ -164,7 +164,7 @@ 

Retrieval#> 8 10 Nausea or Vomiti~ [P] Nausea or ~ Nausea or Vomiting Nausea or Vom~ #> 9 11 Malaise and or f~ [P] Malaise an~ Malaise and or fat~ Malaise and o~ #> 10 12 Rhinitis or comm~ [P] Rhinitis o~ Rhinitis or common~ Rhinitis or c~ -#> # i 553 more rows +#> # i 561 more rows #> # i 76 more variables: librarian <chr>, status <chr>, addedVersion <chr>, #> # logicDescription <chr>, hashTag <chr>, isCirceJson <dbl>, #> # contributors <chr>, contributorOrcIds <chr>, diff --git a/docs/articles/ReservedWordsWithSpecialMeaningToPhenotypers.html b/docs/articles/ReservedWordsWithSpecialMeaningToPhenotypers.html index c9f51db1..2f3e2576 100644 --- a/docs/articles/ReservedWordsWithSpecialMeaningToPhenotypers.html +++ b/docs/articles/ReservedWordsWithSpecialMeaningToPhenotypers.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 @@ -122,7 +122,7 @@

Reserved Words With Special Meaning To

Gowtham A. Rao

-

2023-10-16

+

2023-10-19

Source: vignettes/ReservedWordsWithSpecialMeaningToPhenotypers.Rmd diff --git a/docs/articles/SubmittedCohortDefinitions.html b/docs/articles/SubmittedCohortDefinitions.html index 55b13973..acb870be 100644 --- a/docs/articles/SubmittedCohortDefinitions.html +++ b/docs/articles/SubmittedCohortDefinitions.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 @@ -121,7 +121,7 @@

Submitted Cohort Definitions

Gowtham A. Rao

-

2023-10-16

+

2023-10-19

Source: vignettes/SubmittedCohortDefinitions.Rmd diff --git a/docs/articles/ValidityChecksForCohortDefinitions.html b/docs/articles/ValidityChecksForCohortDefinitions.html index 38ef4886..f16cd100 100644 --- a/docs/articles/ValidityChecksForCohortDefinitions.html +++ b/docs/articles/ValidityChecksForCohortDefinitions.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 @@ -121,7 +121,7 @@

Validity checks for Cohort Definitions

Gowtham A. Rao

-

2023-10-16

+

2023-10-19

Source: vignettes/ValidityChecksForCohortDefinitions.Rmd diff --git a/docs/articles/index.html b/docs/articles/index.html index 1a6d2e03..2a79908e 100644 --- a/docs/articles/index.html +++ b/docs/articles/index.html @@ -17,7 +17,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 diff --git a/docs/authors.html b/docs/authors.html index 5517d8de..71c72934 100644 --- a/docs/authors.html +++ b/docs/authors.html @@ -17,7 +17,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 diff --git a/docs/index.html b/docs/index.html index 67c267d7..3f6da877 100644 --- a/docs/index.html +++ b/docs/index.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 diff --git a/docs/news/index.html b/docs/news/index.html index 5ac7139e..d1aedf27 100644 --- a/docs/news/index.html +++ b/docs/news/index.html @@ -17,7 +17,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 @@ -96,15 +96,28 @@

Changelog

Source: NEWS.md +
+ +

Accepted Cohorts: No cohorts were accepted in this release.

+

New Cohorts: 8 were added.

+
1223: [P] Birdshot chorioretinitis
+1224: [P] CMV Anterior Uveitis (sensitivity analysis)
+1225: [P] VZV Anterior Uveitis (SUN)
+1226: [P] VZV Anterior Uveitis (SUN) sensitive
+1227: [P] HSV Anterior Uveitis (SUN)
+1228: [P] HSV Anterior Uveitis (SUN) sensitive
+1229: [P] Behcet Uveitis (SUN)
+1231: [P] Sickle Cell Crisis
+

Accepted Cohorts: No cohorts were accepted in this release.

New Cohorts: 5 were added.

-
1218: [P] Acute bronchitis
-1219: [P] Hyperlipidemia
-1220: [P] Hypoparathyroidism
-1221: [P] Osteoporosis
-1222: [P] Viral hepatitis type A
+
1218: [P] Acute bronchitis
+1219: [P] Hyperlipidemia
+1220: [P] Hypoparathyroidism
+1221: [P] Osteoporosis
+1222: [P] Viral hepatitis type A
@@ -114,24 +127,24 @@

Accepted Cohorts: No cohorts were accepted in this release.

New Cohorts: 18 were added.

-
1117: [P] Pulmonary fibrosis
-1118: [P] History of Bladder cancer
-1119: [P] Chronic obstructive pulmonary disease (COPD)
-1120: [P] Chronic Interstitial lung disease (ILD)
-1128: [P] Lung Nodule
-1129: [P] Lung Nodule - solitary
-1130: [P] Lung Nodule - multiple
-1131: [P] Lung Mass (not acute, necrotic, atlectatic, abscess, fibrosis)
-1132: [P] Lung Lesion (not acute, necrotic, atlectatic, abscess, fibrosis)
-1133: [P] Non Small Cell Lung Cancer as lung cancer without small cell
-1134: [P] Lung Cancer (primary maliganancy)
-1135: [P] Small Cell Lung Cancer
-1136: [P] Non Small Cell Lung Cancer
-1137: [P] Hoarseness
-1138: [P] Bone Pain
-1139: [P] Weight loss
-1216: [P] Primary Lung Cancer, 2nd dx 365 d after, excl SCLC signs all d before 1y after
-1217: [P] Primary Lung Cancer, excl SCLC signs all d before 1y after
+
1117: [P] Pulmonary fibrosis
+1118: [P] History of Bladder cancer
+1119: [P] Chronic obstructive pulmonary disease (COPD)
+1120: [P] Chronic Interstitial lung disease (ILD)
+1128: [P] Lung Nodule
+1129: [P] Lung Nodule - solitary
+1130: [P] Lung Nodule - multiple
+1131: [P] Lung Mass (not acute, necrotic, atlectatic, abscess, fibrosis)
+1132: [P] Lung Lesion (not acute, necrotic, atlectatic, abscess, fibrosis)
+1133: [P] Non Small Cell Lung Cancer as lung cancer without small cell
+1134: [P] Lung Cancer (primary maliganancy)
+1135: [P] Small Cell Lung Cancer
+1136: [P] Non Small Cell Lung Cancer
+1137: [P] Hoarseness
+1138: [P] Bone Pain
+1139: [P] Weight loss
+1216: [P] Primary Lung Cancer, 2nd dx 365 d after, excl SCLC signs all d before 1y after
+1217: [P] Primary Lung Cancer, excl SCLC signs all d before 1y after
@@ -142,421 +155,421 @@

Accepted Cohorts: No cohorts were accepted in this release.

New Cohorts: 64 were added. These Cohorts are part of the prediction study and contributed by Jenna Reps

-
1152: Deep Vein Thrombosis DVT 10
-1153: Seizure 10
-1154: Heart failure 10
-1155: Non-hemorrhagic Stroke 10
-1156: Hemorrhagic stroke 10
-1157: peripheral vascular disease 10
-1158: Aspirin 10
-1159: Angina 10
-1160: Atrial Fibrillation 10
-1161: Major depressive disorder with NO occurrence of certain psychiatric disorder 10
-1162: Coronary artery disease (CAD) 10
-1163: Acute Kidney Injury 10
-1164: Asthma 10
-1165: Alcoholism 10
-1166: Smoking 10
-1167: sleep apnea 10
-1168: skin ulcer 10
-1169: Chronic hepatitis 10
-1170: hyperlipidemia 10
-1171: hypothyroidism 10
-1172: Heart valve disorder 10
-1173: Low back pain 10
-1174: neuropathy 10
-1175: Psychotic disorder 10
-1176: Sepsis 10
-1177: Acute Respiratory failure 10
-1178: Gastroesophageal reflux disease 10
-1179: obesity 10
-1180: Inflammatory Bowel Disease 10
-1181: STEROIDS 10
-1182: Opioids 10
-1183: ANTIEPILEPTICS 10
-1184: Osteoarthritis 10
-1185: Osteoporosis 10
-1186: Urinary tract infectious 10
-1187: acetaminophen exposure 10
-1188: Anemia 10
-1189: Anxiety 10
-1190: HORMONAL CONTRACEPTIVES 10
-1191: Chronic kidney disease or end stage renal disease 10
-1192: Chronic obstructive pulmonary disease (COPD) 10
-1193: Type 1 diabetes and no prior specific nonT1DM diabetes 10
-1194: Type 2 Diabetes Mellitus with no type 1 or secondary DM 10
-1195: Dyspnea 10
-1196: Edema 10
-1197: Acute gastrointestinal bleeding 10
-1198: Hypertension 10
-1199: Pneumonia 10
-1200: Rheumatoid Arthritis 10
-1201: Antibiotics Aminoglycosides 10
-1202: Antibiotics Carbapenems 10
-1203: Antibiotics Cephalosporins 10
-1204: Antibiotics Fluoroquinolones 10
-1205: Antibiotics Glycopeptides and lipoglycopeptides 10
-1206: Antibiotics Macrolides 10
-1207: Antibiotics Monobactams 10
-1208: Antibiotics Oxazolidinones 10
-1209: Antibiotics Penicillins 10
-1210: Antibiotics Polypeptides 10
-1211: Antibiotics Rifamycins 10
-1212: Antibiotics Sulfonamides 10
-1213: Antibiotics Streptogramins 10
-1214: Antibiotics Tetracyclines 10
-1215: Any cancer (excl. prostate cancer and benign cancer) 10
+
1152: Deep Vein Thrombosis DVT 10
+1153: Seizure 10
+1154: Heart failure 10
+1155: Non-hemorrhagic Stroke 10
+1156: Hemorrhagic stroke 10
+1157: peripheral vascular disease 10
+1158: Aspirin 10
+1159: Angina 10
+1160: Atrial Fibrillation 10
+1161: Major depressive disorder with NO occurrence of certain psychiatric disorder 10
+1162: Coronary artery disease (CAD) 10
+1163: Acute Kidney Injury 10
+1164: Asthma 10
+1165: Alcoholism 10
+1166: Smoking 10
+1167: sleep apnea 10
+1168: skin ulcer 10
+1169: Chronic hepatitis 10
+1170: hyperlipidemia 10
+1171: hypothyroidism 10
+1172: Heart valve disorder 10
+1173: Low back pain 10
+1174: neuropathy 10
+1175: Psychotic disorder 10
+1176: Sepsis 10
+1177: Acute Respiratory failure 10
+1178: Gastroesophageal reflux disease 10
+1179: obesity 10
+1180: Inflammatory Bowel Disease 10
+1181: STEROIDS 10
+1182: Opioids 10
+1183: ANTIEPILEPTICS 10
+1184: Osteoarthritis 10
+1185: Osteoporosis 10
+1186: Urinary tract infectious 10
+1187: acetaminophen exposure 10
+1188: Anemia 10
+1189: Anxiety 10
+1190: HORMONAL CONTRACEPTIVES 10
+1191: Chronic kidney disease or end stage renal disease 10
+1192: Chronic obstructive pulmonary disease (COPD) 10
+1193: Type 1 diabetes and no prior specific nonT1DM diabetes 10
+1194: Type 2 Diabetes Mellitus with no type 1 or secondary DM 10
+1195: Dyspnea 10
+1196: Edema 10
+1197: Acute gastrointestinal bleeding 10
+1198: Hypertension 10
+1199: Pneumonia 10
+1200: Rheumatoid Arthritis 10
+1201: Antibiotics Aminoglycosides 10
+1202: Antibiotics Carbapenems 10
+1203: Antibiotics Cephalosporins 10
+1204: Antibiotics Fluoroquinolones 10
+1205: Antibiotics Glycopeptides and lipoglycopeptides 10
+1206: Antibiotics Macrolides 10
+1207: Antibiotics Monobactams 10
+1208: Antibiotics Oxazolidinones 10
+1209: Antibiotics Penicillins 10
+1210: Antibiotics Polypeptides 10
+1211: Antibiotics Rifamycins 10
+1212: Antibiotics Sulfonamides 10
+1213: Antibiotics Streptogramins 10
+1214: Antibiotics Tetracyclines 10
+1215: Any cancer (excl. prostate cancer and benign cancer) 10

Accepted Cohorts: No cohorts were accepted in this release.

New Cohorts: 2 were added.

-
1150: Emergency room only or Emergency room and inpatient visits (0Pe, 0Era)
-1151: [P] Autism
+
1150: Emergency room only or Emergency room and inpatient visits (0Pe, 0Era)
+1151: [P] Autism

Following cohorts were hidden: 325 were added. To retrieve use PhenotypeLibrary::getPhenotypeLog(showHidden = TRUE).

-
2: [W] COVID-19 diagnosis or SARS-CoV-2 test (1pos)
-15: [P][R] Exposure to viral disease 
-16: [W] Exposure to SARS-Cov 2 and coronavirus
-17: [P][R] Exposure to SARS-CoV-2 
-18: [P][R] Multisystem inflammatory syndrome (MIS) 
-22: [W] SARS-CoV-2 testing
-29: [W] Autoimmune condition (FP)
-35: [W] Chronic kidney disease (FP)
-39: [W] End stage renal disease (FP)
-41: [W] Chronic kidney disease broad (FP)
-42: [W] End stage renal disease broad (FP)
-44: [P][R] COVID-19 
-45: [W] COVID-19 diagnosis with SARS-Cov-2 test (-3d to 3d)
-46: [W] COVID-19 diagnosis and SARS-CoV-2 test (1pos) within 3d
-47: [W] COVID-19 diagnosis and SARS-CoV-2 test (1pos) (0neg) within 3d
-48: [W] COVID-19 diagnosis and SARS-CoV-2 test (0pos upto 3d, 1neg within 3d)
-51: [W] SARS-CoV-2 test positive result
-52: [W] SARS-CoV-2 test negative result
-53: [W] SARS-CoV-2 test positive or negative result - keep persons with positive
-57: [P][R] Bleeding 
-59: [W] COVID-19 diagnosis with no SARS-CoV-2 test
-60: [W] SARS-CoV-2 test positive and negative result
-62: [P][R] Seizure related finding 
-65: [W] Acute pancreatitis with inpatient admission
-66: [W] Acute renal failure with inpatient admission
-67: [W] Hepatic failure with inpatient admission
-68: [W] Heart failure with inpatient admission
-69: [W] Angioedema with inpatient admission
-86: [W] SARS-CoV-2 test positive or negative result
-87: [W] SARS-CoV-2 test
-100: [P][R] Alzheimer's disease
-189: [P][R] Right upper quadrant pain 
-190: [P][R] Swollen abdomen 
-226: [P][R] Drug reaction with eosinophilia and systemic symptoms 
-231: [P][R] Erythema multiforme 
-238: [P][R] Optic neuritis 
-241: [P][R] Urticaria 
-327: [P][R] Pharyngitis 
-330: [P][R] Abdominal bloating 
-339: [P][R] Low blood pressure 
-342: [P][R] Urinary incontinence
-348: [P][R] Blood in urine 
-350: [P][R] Hemoptysis
-352: [P][R] Inflamed tonsils 
-353: [P][R] Conjunctivitis 
-357: [P][R] Pulmonary edema 
-361: [P][R] Restless legs 
-363: [P][R] Joint stiffness 
-364: [P][R] Sleep disorder 
-368: [P][R] Sinusitis 
-369: [P][R] Allergic condition 
-374: [P][R] Drug dependence 
-376: [P][R] Bleeding skin 
-377: [P][R] Petechiae 
-378: [P][R] Purpuric disorder 
-380: [P][R] Jaundice 
-384: [P][R] Contact dermatitis 
-385: [P][R] Intertrigo 
-386: [P][R] Seborrheic dermatitis 
-387: [P][R] Photodermatitis 
-388: [P][R] Peripheral neuritis 
-396: [P][R] Osteoarthritis 
-397: [P][R] Hyperplasia of prostate 
-399: [P][R] Urolithiasis 
-400: [P][R] Malignant tumor of prostate 
-406: [P][R] Intellectual disability 
-407: [P][R] Hemorrhoids 
-415: [P][R] Erythema of skin 
-444: [P][R] Neck pain
-445: [P][R] Hypoglycemia
-446: [P][R] Eosinophilic esophagitis
-447: [P][R] Esophagitis
-448: [P][R] Dysphagia
-449: [P][R] Nausea
-450: [P][R] Constipation
-451: [P][R] Myasthenia gravis
-452: [P][R] Joint pain
-453: [P][R] Osteoarthritis
-454: [P][R] Dermatomyositis
-455: [P][R] Fetal growth restriction
-456: [P][R] Osteoporosis
-457: [P][R] Rheumatoid arthritis
-458: [P][R] Ulcerative colitis
-459: [P][R] Urinary tract infectious disease
-460: [P][R] Psoriasis with arthropathy
-461: [P][R] Erythema multiforme
-462: [P][R] Lichen planus
-463: [P][R] Sepsis
-464: [P][R] Myelofibrosis
-465: [P][R] Thyroiditis
-466: [P][R] Atopic dermatitis
-467: [P][R] Systemic sclerosis
-468: [P][R] Pityriasis rubra pilaris
-469: [P][R] Jaundice
-470: [P][R] Chronic lymphoid leukemia, disease
-471: [P][R] Vitiligo
-472: [P][R] Myelodysplastic syndrome (clinical)
-473: [P][R] Acute transverse myelitis
-474: [P][R] Pemphigoid
-475: [P][R] Psoriasis
-476: [P][R] Acute myeloid leukemia, disease
-477: [P][R] Hypothyroidism
-478: [P][R] Malignant melanoma of skin
-479: [P][R] Chilblains
-480: [P][R] Alopecia areata
-481: [P][R] Renal failure syndrome
-482: [P][R] Gastrointestinal hemorrhage
-483: [P][R] Biliary cirrhosis
-484: [P][R] End-stage renal disease
-485: [P][R] Low back pain
-486: [P][R] Premature rupture of membranes
-487: [P][R] Celiac disease
-488: [P][R] Diarrhea
-489: [P][R] Acute renal failure syndrome
-490: [P][R] Viral hepatitis C
-491: [P][R] Malignant tumor of urinary bladder
-492: [P][R] Cardiogenic shock
-493: [P][R] Malignant tumor of cervix
-494: [P][R] Primary malignant neoplasm of kidney
-495: [P][R] Acute pancreatitis
-496: [P][R] Abdominal pain
-497: [P][R] Autoimmune hepatitis
-498: [P][R] Toxic shock syndrome
-499: [P][R] Type 1 diabetes mellitus
-500: [P][R] Gastritis
-501: [P][R] Crohn's disease
-502: [P][R] Kidney stone
-503: [P][R] Type 2 diabetes mellitus
-504: [P][R] Sj?gren's syndrome
-505: [P][R] Cough
-506: [P][R] Chronic obstructive lung disease
-507: [P][R] Pneumonia
-508: [P][R] Allergic rhinitis
-509: [P][R] Systemic lupus erythematosus
-510: [P][R] Acute myocardial infarction
-511: [P][R] Dyspnea
-512: [P][R] Thromboangiitis obliterans
-513: [P][R] Atrial fibrillation
-514: [P][R] Granulomatosis with polyangiitis
-515: [P][R] Sleep apnea
-516: [P][R] Thrombotic microangiopathy
-517: [P][R] Acute febrile mucocutaneous lymph node syndrome
-518: [P][R] Myocarditis
-519: [P][R] Heart failure
-520: [P][R] Hypertensive disorder
-521: [P][R] Asthma
-522: [P][R] Coronary arteriosclerosis
-523: [P][R] Arteriosclerotic vascular disease
-524: [P][R] Migraine
-525: [P][R] Gastroesophageal reflux disease
-526: [P][R] Orthostatic hypotension
-527: [P][R] Acute respiratory failure
-528: [P][R] Polyarteritis nodosa
-529: [P][R] Cardiac arrest
-530: [P][R] Peripheral vascular disease
-531: [P][R] Angina pectoris
-532: [P][R] Heart disease
-533: [P][R] Otitis media
-534: [P][R] Transient cerebral ischemia
-535: [P][R] Acute disseminated encephalomyelitis
-536: [P][R] Age related macular degeneration
-537: [P][R] Sensorineural hearing loss
-538: [P][R] Paralytic syndrome
-539: [P][R] Multiple sclerosis
-540: [P][R] Optic neuritis
-541: [P][R] Idiopathic peripheral neuropathy
-542: [P][R] Cerebral hemorrhage
-543: [P][R] Seizure
-544: [P][R] Encephalitis
-545: [P][R] Headache
-546: [P][R] Retinal detachment
-547: [P][R] Retinal disorder
-549: [P][R] Epilepsy
-550: [P][R] Chronic inflammatory demyelinating polyradiculoneuropathy
-551: [P][R] Microcephaly
-552: [P][R] Parkinson's disease
-553: [P][R] Cerebrovascular accident
-554: [P][R] Cerebrovascular disease
-555: [P][R] Blood coagulation disorder
-556: [P][R] Amyloidosis
-557: [P][R] Angioedema
-558: [P][R] Hyperlipidemia
-559: [P][R] Thrombocytopenic disorder
-560: [P][R] Pancytopenia
-561: [P][R] Myasthenic syndrome due to another disorder
-562: [P][R] Edema
-563: [P][R] Obesity
-564: [P][R] Hidradenitis
-565: [P][R] Tuberculosis
-566: [P][R] Kaposi's sarcoma (clinical)
-567: [P][R] B-cell lymphoma (clinical)
-568: [P][R] Hyperkalemia
-569: [P][R] Systemic inflammatory response syndrome
-570: [P][R] Leukopenia
-571: [P][R] Schizophrenia
-572: [P][R] Psychotic disorder
-573: [P][R] Chronic pain
-574: [P][R] Narcolepsy
-575: [P][R] Behcet's syndrome
-576: [P][R] Bipolar disorder
-577: [P][R] Posttraumatic stress disorder
-578: [P][R] Insomnia
-579: [P][R] Ankylosing spondylitis
-580: [P][R] Respiratory syncytial virus infection
-581: [P][R] Multiple myeloma
-582: [P][R] Bleeding
-583: [P][R] Glaucoma
-584: [P][R] Fever
-585: [P][R] Hypokalemia
-586: [P][R] Opioid dependence
-587: [P][R] Opioid abuse
-588: [P][R] Attention deficit hyperactivity disorder
-589: [P][R] Pre-eclampsia
-590: [P][R] Human immunodeficiency virus infection
-591: [P][R] Autism spectrum disorder
-592: [P][R] Anemia
-593: [P][R] Paralysis
-594: [P][R] Depressive disorder
-595: [P][R] Pulmonary embolism
-596: [P][R] Gout
-597: [P][R] Takayasu's disease
-598: [P][R] Methicillin resistant Staphylococcus aureus infection
-599: [P][R] Anaphylaxis
-600: [P][R] Open-angle glaucoma
-601: [P][R] Vomiting
-602: [P][R] Anxiety
-603: [P][R] Human papilloma virus infection
-604: [P][R] Cranial nerve disorder
-605: [P][R] Muscle pain
-606: [P][R] Stillbirth
-607: [P][R] Malignant tumor of stomach
-608: [P][R] Malignant neoplastic disease
-609: [P][R] Cerebral infarction
-610: [P][R] Eclampsia
-611: [P][R] Diabetic ketoacidosis
-612: [P][R] Acute tubular necrosis
-613: [P][R] Tachycardia
-614: [P][R] Venous thrombosis
-615: [P][R] Herpes simplex
-616: [P][R] Acute arthritis
-617: [P][R] Monoclonal gammopathy (clinical)
-618: [P][R] Pulmonary arterial hypertension
-619: [P][R] Gestational diabetes mellitus
-620: [P][R] Uveitis
-621: [P][R] Renal impairment
-622: [P][R] Non-Hodgkin's lymphoma (clinical)
-623: [P][R] Motor neuropathy with multiple conduction block
-624: [P][R] Primary sclerosing cholangitis
-625: [P][R] Pustular psoriasis
-626: [P][R] Cirrhosis of liver
-627: [P][R] Miscarriage
-628: [P][R] Fisher's syndrome
-629: [P][R] Inflammatory bowel disease
-630: [P][R] Facial palsy
-631: [P][R] Livebirth
-632: [P][R] Antiphospholipid syndrome
-633: [P][R] Waldenstr?m macroglobulinemia
-634: [P][R] Immunoglobulin A vasculitis
-635: [P][R] Ventricular tachycardia
-636: [P][R] Malignant tumor of breast
-637: [P][R] Peripheral ischemia
-638: [P][R] Neoplasm of thyroid gland
-639: [P][R] Deep venous thrombosis
-640: [P][R] Vasculitis
-641: [P][R] Pericarditis
-642: [P][R] Immune reconstitution syndrome
-643: [P][R] Follicular non-Hodgkin's lymphoma
-644: [P][R] Malignant tumor of prostate
-645: [P][R] Guillain-Barr? syndrome
-646: [P][R] Bradycardia
-647: [P][R] Retinopathy due to diabetes mellitus
-648: [P][R] Malignant tumor of colon
-649: [P][R] Malignant tumor of esophagus
-650: [P][R] Malignant tumor of ovary
-651: [P][R] Dementia
-652: [P][R] Vasculitis of the skin
-653: [P][R] Loss of sense of smell
-654: [P][R] Ischemic heart disease
-655: [P][R] Aseptic meningitis
-656: [P][R] Fatigue
-657: [P][R] Paresthesia
-658: [P][R] Hepatic failure
-659: [P][R] Malignant neoplasm of liver
-660: [P][R] Juvenile rheumatoid arthritis
-661: [P][R] Respiratory failure
-662: [P][R] Diverticulitis of large intestine
-663: [P][R] Influenza
-664: [P][R] Malaise
-665: [P][R] Suicidal thoughts
-666: [P][R] Type B viral hepatitis
-667: [P][R] Guttate psoriasis
-668: [P][R] SLE glomerulonephritis syndrome
-669: [P][R] Schizoaffective disorder
-670: [P][R] Temporal arteritis
-671: [P][R] Pregnant
-672: [P][R] Sense of smell impaired
-673: [P][R] Primary malignant neoplasm of respiratory tract
-674: [P][R] Degeneration of retina
-675: [P][R] Pulmonary hypertension
-676: [P][R] Necrosis of artery
-677: [P][R] Preterm labor with preterm delivery
-678: [P][R] COVID-19
-679: [P][R] Takotsubo cardiomyopathy
-680: [P][R] Mantle cell lymphoma
-681: [P][R] Malignant neoplasm of anorectum
-682: [P][R] Marginal zone lymphoma
-683: [P][R] Antineutrophil cytoplasmic antibody positive vasculitis
-684: [P][R] Sensory disorder of smell and/or taste
-685: [P][R] Cardiac arrhythmia
-686: [P][R] Fracture of bone of hip region
-687: [P][R] Chronic kidney disease
-688: [P][R] Death
-689: [P][R] Newborn death
-690: [P][R] Suicide
-695: [P][R] Optic nerve glioma
-696: [P][R] Neurofibromatosis type 2
-697: [P][R] Neurofibromatosis type 1
-698: [P][R] Neurofibromatosis syndrome
-699: [P][R] Major Depressive Disorder
-701: [P][R] Ascites
-709: [P][R] Chronic liver disease
-711: [P][R] Transplanted liver present
-714: [P][R] Endometriosis (clinical)
-794: [W] Hemorrhage of digestive system
+
2: [W] COVID-19 diagnosis or SARS-CoV-2 test (1pos)
+15: [P][R] Exposure to viral disease 
+16: [W] Exposure to SARS-Cov 2 and coronavirus
+17: [P][R] Exposure to SARS-CoV-2 
+18: [P][R] Multisystem inflammatory syndrome (MIS) 
+22: [W] SARS-CoV-2 testing
+29: [W] Autoimmune condition (FP)
+35: [W] Chronic kidney disease (FP)
+39: [W] End stage renal disease (FP)
+41: [W] Chronic kidney disease broad (FP)
+42: [W] End stage renal disease broad (FP)
+44: [P][R] COVID-19 
+45: [W] COVID-19 diagnosis with SARS-Cov-2 test (-3d to 3d)
+46: [W] COVID-19 diagnosis and SARS-CoV-2 test (1pos) within 3d
+47: [W] COVID-19 diagnosis and SARS-CoV-2 test (1pos) (0neg) within 3d
+48: [W] COVID-19 diagnosis and SARS-CoV-2 test (0pos upto 3d, 1neg within 3d)
+51: [W] SARS-CoV-2 test positive result
+52: [W] SARS-CoV-2 test negative result
+53: [W] SARS-CoV-2 test positive or negative result - keep persons with positive
+57: [P][R] Bleeding 
+59: [W] COVID-19 diagnosis with no SARS-CoV-2 test
+60: [W] SARS-CoV-2 test positive and negative result
+62: [P][R] Seizure related finding 
+65: [W] Acute pancreatitis with inpatient admission
+66: [W] Acute renal failure with inpatient admission
+67: [W] Hepatic failure with inpatient admission
+68: [W] Heart failure with inpatient admission
+69: [W] Angioedema with inpatient admission
+86: [W] SARS-CoV-2 test positive or negative result
+87: [W] SARS-CoV-2 test
+100: [P][R] Alzheimer's disease
+189: [P][R] Right upper quadrant pain 
+190: [P][R] Swollen abdomen 
+226: [P][R] Drug reaction with eosinophilia and systemic symptoms 
+231: [P][R] Erythema multiforme 
+238: [P][R] Optic neuritis 
+241: [P][R] Urticaria 
+327: [P][R] Pharyngitis 
+330: [P][R] Abdominal bloating 
+339: [P][R] Low blood pressure 
+342: [P][R] Urinary incontinence
+348: [P][R] Blood in urine 
+350: [P][R] Hemoptysis
+352: [P][R] Inflamed tonsils 
+353: [P][R] Conjunctivitis 
+357: [P][R] Pulmonary edema 
+361: [P][R] Restless legs 
+363: [P][R] Joint stiffness 
+364: [P][R] Sleep disorder 
+368: [P][R] Sinusitis 
+369: [P][R] Allergic condition 
+374: [P][R] Drug dependence 
+376: [P][R] Bleeding skin 
+377: [P][R] Petechiae 
+378: [P][R] Purpuric disorder 
+380: [P][R] Jaundice 
+384: [P][R] Contact dermatitis 
+385: [P][R] Intertrigo 
+386: [P][R] Seborrheic dermatitis 
+387: [P][R] Photodermatitis 
+388: [P][R] Peripheral neuritis 
+396: [P][R] Osteoarthritis 
+397: [P][R] Hyperplasia of prostate 
+399: [P][R] Urolithiasis 
+400: [P][R] Malignant tumor of prostate 
+406: [P][R] Intellectual disability 
+407: [P][R] Hemorrhoids 
+415: [P][R] Erythema of skin 
+444: [P][R] Neck pain
+445: [P][R] Hypoglycemia
+446: [P][R] Eosinophilic esophagitis
+447: [P][R] Esophagitis
+448: [P][R] Dysphagia
+449: [P][R] Nausea
+450: [P][R] Constipation
+451: [P][R] Myasthenia gravis
+452: [P][R] Joint pain
+453: [P][R] Osteoarthritis
+454: [P][R] Dermatomyositis
+455: [P][R] Fetal growth restriction
+456: [P][R] Osteoporosis
+457: [P][R] Rheumatoid arthritis
+458: [P][R] Ulcerative colitis
+459: [P][R] Urinary tract infectious disease
+460: [P][R] Psoriasis with arthropathy
+461: [P][R] Erythema multiforme
+462: [P][R] Lichen planus
+463: [P][R] Sepsis
+464: [P][R] Myelofibrosis
+465: [P][R] Thyroiditis
+466: [P][R] Atopic dermatitis
+467: [P][R] Systemic sclerosis
+468: [P][R] Pityriasis rubra pilaris
+469: [P][R] Jaundice
+470: [P][R] Chronic lymphoid leukemia, disease
+471: [P][R] Vitiligo
+472: [P][R] Myelodysplastic syndrome (clinical)
+473: [P][R] Acute transverse myelitis
+474: [P][R] Pemphigoid
+475: [P][R] Psoriasis
+476: [P][R] Acute myeloid leukemia, disease
+477: [P][R] Hypothyroidism
+478: [P][R] Malignant melanoma of skin
+479: [P][R] Chilblains
+480: [P][R] Alopecia areata
+481: [P][R] Renal failure syndrome
+482: [P][R] Gastrointestinal hemorrhage
+483: [P][R] Biliary cirrhosis
+484: [P][R] End-stage renal disease
+485: [P][R] Low back pain
+486: [P][R] Premature rupture of membranes
+487: [P][R] Celiac disease
+488: [P][R] Diarrhea
+489: [P][R] Acute renal failure syndrome
+490: [P][R] Viral hepatitis C
+491: [P][R] Malignant tumor of urinary bladder
+492: [P][R] Cardiogenic shock
+493: [P][R] Malignant tumor of cervix
+494: [P][R] Primary malignant neoplasm of kidney
+495: [P][R] Acute pancreatitis
+496: [P][R] Abdominal pain
+497: [P][R] Autoimmune hepatitis
+498: [P][R] Toxic shock syndrome
+499: [P][R] Type 1 diabetes mellitus
+500: [P][R] Gastritis
+501: [P][R] Crohn's disease
+502: [P][R] Kidney stone
+503: [P][R] Type 2 diabetes mellitus
+504: [P][R] Sj?gren's syndrome
+505: [P][R] Cough
+506: [P][R] Chronic obstructive lung disease
+507: [P][R] Pneumonia
+508: [P][R] Allergic rhinitis
+509: [P][R] Systemic lupus erythematosus
+510: [P][R] Acute myocardial infarction
+511: [P][R] Dyspnea
+512: [P][R] Thromboangiitis obliterans
+513: [P][R] Atrial fibrillation
+514: [P][R] Granulomatosis with polyangiitis
+515: [P][R] Sleep apnea
+516: [P][R] Thrombotic microangiopathy
+517: [P][R] Acute febrile mucocutaneous lymph node syndrome
+518: [P][R] Myocarditis
+519: [P][R] Heart failure
+520: [P][R] Hypertensive disorder
+521: [P][R] Asthma
+522: [P][R] Coronary arteriosclerosis
+523: [P][R] Arteriosclerotic vascular disease
+524: [P][R] Migraine
+525: [P][R] Gastroesophageal reflux disease
+526: [P][R] Orthostatic hypotension
+527: [P][R] Acute respiratory failure
+528: [P][R] Polyarteritis nodosa
+529: [P][R] Cardiac arrest
+530: [P][R] Peripheral vascular disease
+531: [P][R] Angina pectoris
+532: [P][R] Heart disease
+533: [P][R] Otitis media
+534: [P][R] Transient cerebral ischemia
+535: [P][R] Acute disseminated encephalomyelitis
+536: [P][R] Age related macular degeneration
+537: [P][R] Sensorineural hearing loss
+538: [P][R] Paralytic syndrome
+539: [P][R] Multiple sclerosis
+540: [P][R] Optic neuritis
+541: [P][R] Idiopathic peripheral neuropathy
+542: [P][R] Cerebral hemorrhage
+543: [P][R] Seizure
+544: [P][R] Encephalitis
+545: [P][R] Headache
+546: [P][R] Retinal detachment
+547: [P][R] Retinal disorder
+549: [P][R] Epilepsy
+550: [P][R] Chronic inflammatory demyelinating polyradiculoneuropathy
+551: [P][R] Microcephaly
+552: [P][R] Parkinson's disease
+553: [P][R] Cerebrovascular accident
+554: [P][R] Cerebrovascular disease
+555: [P][R] Blood coagulation disorder
+556: [P][R] Amyloidosis
+557: [P][R] Angioedema
+558: [P][R] Hyperlipidemia
+559: [P][R] Thrombocytopenic disorder
+560: [P][R] Pancytopenia
+561: [P][R] Myasthenic syndrome due to another disorder
+562: [P][R] Edema
+563: [P][R] Obesity
+564: [P][R] Hidradenitis
+565: [P][R] Tuberculosis
+566: [P][R] Kaposi's sarcoma (clinical)
+567: [P][R] B-cell lymphoma (clinical)
+568: [P][R] Hyperkalemia
+569: [P][R] Systemic inflammatory response syndrome
+570: [P][R] Leukopenia
+571: [P][R] Schizophrenia
+572: [P][R] Psychotic disorder
+573: [P][R] Chronic pain
+574: [P][R] Narcolepsy
+575: [P][R] Behcet's syndrome
+576: [P][R] Bipolar disorder
+577: [P][R] Posttraumatic stress disorder
+578: [P][R] Insomnia
+579: [P][R] Ankylosing spondylitis
+580: [P][R] Respiratory syncytial virus infection
+581: [P][R] Multiple myeloma
+582: [P][R] Bleeding
+583: [P][R] Glaucoma
+584: [P][R] Fever
+585: [P][R] Hypokalemia
+586: [P][R] Opioid dependence
+587: [P][R] Opioid abuse
+588: [P][R] Attention deficit hyperactivity disorder
+589: [P][R] Pre-eclampsia
+590: [P][R] Human immunodeficiency virus infection
+591: [P][R] Autism spectrum disorder
+592: [P][R] Anemia
+593: [P][R] Paralysis
+594: [P][R] Depressive disorder
+595: [P][R] Pulmonary embolism
+596: [P][R] Gout
+597: [P][R] Takayasu's disease
+598: [P][R] Methicillin resistant Staphylococcus aureus infection
+599: [P][R] Anaphylaxis
+600: [P][R] Open-angle glaucoma
+601: [P][R] Vomiting
+602: [P][R] Anxiety
+603: [P][R] Human papilloma virus infection
+604: [P][R] Cranial nerve disorder
+605: [P][R] Muscle pain
+606: [P][R] Stillbirth
+607: [P][R] Malignant tumor of stomach
+608: [P][R] Malignant neoplastic disease
+609: [P][R] Cerebral infarction
+610: [P][R] Eclampsia
+611: [P][R] Diabetic ketoacidosis
+612: [P][R] Acute tubular necrosis
+613: [P][R] Tachycardia
+614: [P][R] Venous thrombosis
+615: [P][R] Herpes simplex
+616: [P][R] Acute arthritis
+617: [P][R] Monoclonal gammopathy (clinical)
+618: [P][R] Pulmonary arterial hypertension
+619: [P][R] Gestational diabetes mellitus
+620: [P][R] Uveitis
+621: [P][R] Renal impairment
+622: [P][R] Non-Hodgkin's lymphoma (clinical)
+623: [P][R] Motor neuropathy with multiple conduction block
+624: [P][R] Primary sclerosing cholangitis
+625: [P][R] Pustular psoriasis
+626: [P][R] Cirrhosis of liver
+627: [P][R] Miscarriage
+628: [P][R] Fisher's syndrome
+629: [P][R] Inflammatory bowel disease
+630: [P][R] Facial palsy
+631: [P][R] Livebirth
+632: [P][R] Antiphospholipid syndrome
+633: [P][R] Waldenstr?m macroglobulinemia
+634: [P][R] Immunoglobulin A vasculitis
+635: [P][R] Ventricular tachycardia
+636: [P][R] Malignant tumor of breast
+637: [P][R] Peripheral ischemia
+638: [P][R] Neoplasm of thyroid gland
+639: [P][R] Deep venous thrombosis
+640: [P][R] Vasculitis
+641: [P][R] Pericarditis
+642: [P][R] Immune reconstitution syndrome
+643: [P][R] Follicular non-Hodgkin's lymphoma
+644: [P][R] Malignant tumor of prostate
+645: [P][R] Guillain-Barr? syndrome
+646: [P][R] Bradycardia
+647: [P][R] Retinopathy due to diabetes mellitus
+648: [P][R] Malignant tumor of colon
+649: [P][R] Malignant tumor of esophagus
+650: [P][R] Malignant tumor of ovary
+651: [P][R] Dementia
+652: [P][R] Vasculitis of the skin
+653: [P][R] Loss of sense of smell
+654: [P][R] Ischemic heart disease
+655: [P][R] Aseptic meningitis
+656: [P][R] Fatigue
+657: [P][R] Paresthesia
+658: [P][R] Hepatic failure
+659: [P][R] Malignant neoplasm of liver
+660: [P][R] Juvenile rheumatoid arthritis
+661: [P][R] Respiratory failure
+662: [P][R] Diverticulitis of large intestine
+663: [P][R] Influenza
+664: [P][R] Malaise
+665: [P][R] Suicidal thoughts
+666: [P][R] Type B viral hepatitis
+667: [P][R] Guttate psoriasis
+668: [P][R] SLE glomerulonephritis syndrome
+669: [P][R] Schizoaffective disorder
+670: [P][R] Temporal arteritis
+671: [P][R] Pregnant
+672: [P][R] Sense of smell impaired
+673: [P][R] Primary malignant neoplasm of respiratory tract
+674: [P][R] Degeneration of retina
+675: [P][R] Pulmonary hypertension
+676: [P][R] Necrosis of artery
+677: [P][R] Preterm labor with preterm delivery
+678: [P][R] COVID-19
+679: [P][R] Takotsubo cardiomyopathy
+680: [P][R] Mantle cell lymphoma
+681: [P][R] Malignant neoplasm of anorectum
+682: [P][R] Marginal zone lymphoma
+683: [P][R] Antineutrophil cytoplasmic antibody positive vasculitis
+684: [P][R] Sensory disorder of smell and/or taste
+685: [P][R] Cardiac arrhythmia
+686: [P][R] Fracture of bone of hip region
+687: [P][R] Chronic kidney disease
+688: [P][R] Death
+689: [P][R] Newborn death
+690: [P][R] Suicide
+695: [P][R] Optic nerve glioma
+696: [P][R] Neurofibromatosis type 2
+697: [P][R] Neurofibromatosis type 1
+698: [P][R] Neurofibromatosis syndrome
+699: [P][R] Major Depressive Disorder
+701: [P][R] Ascites
+709: [P][R] Chronic liver disease
+711: [P][R] Transplanted liver present
+714: [P][R] Endometriosis (clinical)
+794: [W] Hemorrhage of digestive system

Accepted Cohorts: No cohorts were accepted in this release.

New Cohorts: 14 were added.

-
1093: [P] Abdominal Aoritc Aneurysm repair - post op new Afib (any)
-1094: [P] Lower Extremity Bypass - post op new Afib (any)
-1095: [P] Carotid Endarterectomy - post op new Afib (any)
-1096: [P] Lung Resection - post op new Afib (any)
-1097: [P] Esophagectomy - post op new Afib (any)
-1098: [P] Pancreatectomy - post op new Afib (any)
-1099: [P] Colectomy - post op new Afib (any)
-1100: [P] Cystectomy - post op new Afib (any)
-1101: [P] Nephrectomy - post op new Afib (any)
-1102: [P] Coronary Artery Bypass Graft Surgery - post op new Afib (any)
-1103: [P] Aortic or Mitral Valve Repair or Replacement - post op new Afib (any)
-1104: [P] RBC Transfusion (adult relevant, no auto 1yr clean window)
-1105: [P] Clostridium difficile - first episode
-1106: [P] Non-Emergent Major Non Cardiac Surgery no prior Opioid
+
1093: [P] Abdominal Aoritc Aneurysm repair - post op new Afib (any)
+1094: [P] Lower Extremity Bypass - post op new Afib (any)
+1095: [P] Carotid Endarterectomy - post op new Afib (any)
+1096: [P] Lung Resection - post op new Afib (any)
+1097: [P] Esophagectomy - post op new Afib (any)
+1098: [P] Pancreatectomy - post op new Afib (any)
+1099: [P] Colectomy - post op new Afib (any)
+1100: [P] Cystectomy - post op new Afib (any)
+1101: [P] Nephrectomy - post op new Afib (any)
+1102: [P] Coronary Artery Bypass Graft Surgery - post op new Afib (any)
+1103: [P] Aortic or Mitral Valve Repair or Replacement - post op new Afib (any)
+1104: [P] RBC Transfusion (adult relevant, no auto 1yr clean window)
+1105: [P] Clostridium difficile - first episode
+1106: [P] Non-Emergent Major Non Cardiac Surgery no prior Opioid
@@ -584,343 +597,343 @@

Accepted Cohorts: No cohorts were accepted in this release.

New Cohorts: 20 were added.

-
1072: [P] CMV Anterior Uveitis
-1073: [P] Serious Infection, opportunistic infections and other infections of interest event
-1074: [P] Serious Infection
-1075: [P] FDA AESI Narcolepsy
-1076: [P] FDA AESI Anaphylaxis
-1077: [P] FDA AESI Anaphylaxis v2
-1078: [P] FDA AESI Bells Palsy
-1079: [P] FDA AESI Encephalomyelitis
-1080: [P] FDA AESI Guillain Barre Syndrome
-1081: [P] FDA AESI Acute Myocardial Infarction
-1082: [P] FDA AESI Myocarditis Pericarditis
-1083: [P] FDA AESI Immune Thrombocytopenia (ITP)
-1084: [P] FDA AESI Disseminated Intravascular Coagulation
-1085: [P] FDA AESI Appendicitis
-1086: [P] FDA AESI Transverse Myelitis
-1087: [P] FDA AESI Hemorrhagic Stroke
-1088: [P] FDA AESI Deep Vein Thrombosis (DVT)
-1089: [P] FDA AESI Non-hemorrhagic Stroke
-1090: [P] FDA AESI Pulmonary Embolism
-1091: [P] FDA AESI Thrombosis with Thrombocytopenia (TWT)
+
1072: [P] CMV Anterior Uveitis
+1073: [P] Serious Infection, opportunistic infections and other infections of interest event
+1074: [P] Serious Infection
+1075: [P] FDA AESI Narcolepsy
+1076: [P] FDA AESI Anaphylaxis
+1077: [P] FDA AESI Anaphylaxis v2
+1078: [P] FDA AESI Bells Palsy
+1079: [P] FDA AESI Encephalomyelitis
+1080: [P] FDA AESI Guillain Barre Syndrome
+1081: [P] FDA AESI Acute Myocardial Infarction
+1082: [P] FDA AESI Myocarditis Pericarditis
+1083: [P] FDA AESI Immune Thrombocytopenia (ITP)
+1084: [P] FDA AESI Disseminated Intravascular Coagulation
+1085: [P] FDA AESI Appendicitis
+1086: [P] FDA AESI Transverse Myelitis
+1087: [P] FDA AESI Hemorrhagic Stroke
+1088: [P] FDA AESI Deep Vein Thrombosis (DVT)
+1089: [P] FDA AESI Non-hemorrhagic Stroke
+1090: [P] FDA AESI Pulmonary Embolism
+1091: [P] FDA AESI Thrombosis with Thrombocytopenia (TWT)

Accepted Cohorts: No cohorts were accepted in this release.

New Cohorts: 37 were added.

-
1035: [P] New users of Thiazide diuretics
-1036: [P] New users of Beta blockers
-1037: [P] New users of SGLT2 inhibitor
-1038: [P] New users of GLP-1 receptor antagonists
-1039: [P] New users of DPP-4 inhibitors
-1040: [P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors
-1041: [P] New users of JAK inhibitors
-1042: [P] New users of IL-23 inhibitors
-1043: [P] New users of Fluoroquinolone systemic
-1044: [P] New users of Cephalosporin systemetic
-1045: [P] New users of Trimethoprim systemetic
-1046: [P] New users of Thiazide diuretics nested in essential hypertension
-1047: [P] New users of dihydropyridine calcium channel blockers nested in essential hypertension
-1048: [P] New users of dihydropyridine calcium channel blockers
-1049: [P] New users of Beta blockers nested in essential hypertension
-1050: [P] New users of Beta blockers nested in Left Heart Failure
-1051: [P] New users of SGLT2 inhibitor nested in Left Heart Failure
-1052: [P] New users of Beta blockers nested in Acute Myocardial Infarction
-1053: [P] New users of GLP-1 receptor antagonists nested in Type 2 diabetes mellitus
-1054: [P] New users of SGLT2 inhibitor nested in Type 2 diabetes mellitus
-1055: [P] New users of DPP-4 inhibitors nested in Type 2 diabetes mellitus
-1056: [P] New users of GLP-1 receptor antagonists nested in obesity
-1057: [P] New users of IL-23 inhibitors nested in Plaque psoriasis
-1058: [P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Plaque psoriasis
-1059: [P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Psoriatic Arthritis
-1060: [P] New users of Fluoroquinolone systemic nested in Urinary Tract Infection
-1061: [P] New users of Cephalosporin systemetic nested in Urinary Tract Infection
-1062: [P] New users of Trimethoprim systemetic nested in Urinary Tract Infection
-1063: [P] New users of Fluoroquinolone systemic nested in Acute Typical Pneumonia
-1064: [P] New users of Cephalosporin systemetic nested in Acute Typical Pneumonia
-1065: [P] New users of Trimethoprim systemetic nested in Acute Typical Pneumonia
-1066: [P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Rheumatoid arthritis
-1067: [P] New users of JAK inhibitors nested in Ulcerative colitis
-1068: [P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Ulcerative colitis
-1069: [P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Crohns disease
-1070: [P] New users of JAK inhibitors nested in Rheumatoid arthritis
-1071: [P] persons at risk at start of year 2012-2022 with 365d prior observation
+
1035: [P] New users of Thiazide diuretics
+1036: [P] New users of Beta blockers
+1037: [P] New users of SGLT2 inhibitor
+1038: [P] New users of GLP-1 receptor antagonists
+1039: [P] New users of DPP-4 inhibitors
+1040: [P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors
+1041: [P] New users of JAK inhibitors
+1042: [P] New users of IL-23 inhibitors
+1043: [P] New users of Fluoroquinolone systemic
+1044: [P] New users of Cephalosporin systemetic
+1045: [P] New users of Trimethoprim systemetic
+1046: [P] New users of Thiazide diuretics nested in essential hypertension
+1047: [P] New users of dihydropyridine calcium channel blockers nested in essential hypertension
+1048: [P] New users of dihydropyridine calcium channel blockers
+1049: [P] New users of Beta blockers nested in essential hypertension
+1050: [P] New users of Beta blockers nested in Left Heart Failure
+1051: [P] New users of SGLT2 inhibitor nested in Left Heart Failure
+1052: [P] New users of Beta blockers nested in Acute Myocardial Infarction
+1053: [P] New users of GLP-1 receptor antagonists nested in Type 2 diabetes mellitus
+1054: [P] New users of SGLT2 inhibitor nested in Type 2 diabetes mellitus
+1055: [P] New users of DPP-4 inhibitors nested in Type 2 diabetes mellitus
+1056: [P] New users of GLP-1 receptor antagonists nested in obesity
+1057: [P] New users of IL-23 inhibitors nested in Plaque psoriasis
+1058: [P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Plaque psoriasis
+1059: [P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Psoriatic Arthritis
+1060: [P] New users of Fluoroquinolone systemic nested in Urinary Tract Infection
+1061: [P] New users of Cephalosporin systemetic nested in Urinary Tract Infection
+1062: [P] New users of Trimethoprim systemetic nested in Urinary Tract Infection
+1063: [P] New users of Fluoroquinolone systemic nested in Acute Typical Pneumonia
+1064: [P] New users of Cephalosporin systemetic nested in Acute Typical Pneumonia
+1065: [P] New users of Trimethoprim systemetic nested in Acute Typical Pneumonia
+1066: [P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Rheumatoid arthritis
+1067: [P] New users of JAK inhibitors nested in Ulcerative colitis
+1068: [P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Ulcerative colitis
+1069: [P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Crohns disease
+1070: [P] New users of JAK inhibitors nested in Rheumatoid arthritis
+1071: [P] persons at risk at start of year 2012-2022 with 365d prior observation

This release includes the bulk of the cohorts submitted to the OHDSI PhenotypeLibrary in the month of September 2023, as part of the push for HowOften.

Accepted Cohorts: No cohorts were accepted in this release.

New Cohorts: 252 were added.

-
311: [P] Parasomnia
-742: [P] Parasomnia or Sleep dysfunction with arousal disturbance
-743: [P] Diabetic ketoacidosis IP-ER (SNOMED concept)
-744: [P] Pulmonary Hypertension
-745: [P] Inflammatory Bowel Disease
-746: [P] Chronic Thromboembolic Pulmonary Hypertension
-747: [P] Pulmonary Arterial Hypertension
-748: [P] Psoriatic arthritis
-749: [P] Plaque Psoriasis
-750: [P] Pulmonary hypertension associated with left heart disease (WHO Group 2)
-751: [P] Pulmonary hypertension associated with lung diseases and or hypoxia (WHO Group 3)
-752: [P] Firearm Accidents (FA)
-753: [P] Motor Vehicle Accidents (MVA)
-754: [P] Down Syndrome
-755: [P] Non-infectious uveitis and iridocyclitis
-756: [P] Cystic Fibrosis
-757: [P] Concomitant TNF - alpha Inhibitors and IL23 Inhibitors - GE 30D overlap
-759: [P] Concomitant TNF - alpha Inhibitors and IL12_23 Inhibitors - GE 30D overlap
-760: [P] Concomitant IL 23 Inhibitors and IL12_23 Inhibitors - GE 30D overlap
-761: [P] Pulmonary arterial hypertension with Prior Left Heart or Vice Versa
-762: [P] Endothelin receptor antagonists
-763: [P] Phosphodiesterase 5 inhibitors and guanylate cyclase stimulators
-764: [P] Prostacyclin analogues and prostacyclin receptor agonists
-765: [P] Earliest event of Left Heart Failure
-766: [P] Earliest event of Right Heart Failure
-767: [P] Earliest event of Sarcoidosis
-768: [P] Earliest event of Sickle Cell Anemia
-769: [P] Scleroderma, first occurrence
-770: [P] Essential Hypertension, first occurrence
-771: [P] Pulmonary Hypertension (Group 2 Left heart disease, encompassing)
-772: [P] Pulmonary Hypertension (Group 3 Chronic lung disease, encompassing)
-773: [P] Congenital Heart Disease
-774: [P] Portal Hypertension, first occurrence
-775: [P] First Inflammatory Bowel Disease
-776: [P] Antisynthetase syndrome
-777: [P] Mixed connective tissue disease
-778: [P] Undifferentiated connective tissue disease
-779: [P] Overlap syndrome
-780: [P] Raynaud?s disease or Raynaud's phenomenon
-781: [P] Antiphospholipid syndrome
-782: [P] CTEPH Prevalent (with Echo or RHC) with 2nd dx code 31-365 days after first dx
-783: [P] Pulmonary endarterectomy
-784: [P] Balloon Pulmonary Angioplasty
-785: [P] Skin Burns
-786: [P] Non-small cell lung cancer (NSCLC)
-787: [P] Lung cancer
-788: [P] Breast cancer
-789: [P] Glioblastoma multiforme (GBM)
-790: [P] Colorectal Cancer
-791: [P] Multiple Myeloma
-792: [P] Metastatic Hormone-Sensitive Prostate Cancer Synchronous
-793: [P] Metastatic Hormone-Sensitive Prostate Cancer Metachronus
-794: COPY OF [P][R] Bleeding
-795: [P] Antineoplastic drugs against colorectal cancer
-796: [P] Potential curative surgery for colorectal cancer
-797: [P] Radiotherapy against colorectal cancer
-798: [P] Primary adenocarcinoma of the colon or rectum
-802: [P] Acute Respiratory Failure 2
-803: [P] Fascial dehiscence and evisceration
-804: [P] Anastomotic leak or dehiscence
-805: [P] Intestinal obstruction (broad)
-806: [P] Intraabdominal abscess
-807: [P] Perioperative aspiration
-808: [P] Postoperative hemorrhage
-809: [P] Surgical wound infection (narrow)
-810: [P] Distant metastasis following colorectal cancer (wide)
-811: [P] Local recurrence after colorectal cancer
-812: [P] Primary adenocarcinoma of the colon or rectum, MSI-H or dMMR, no surgery or oncological treatment
-813: [P] Primary adenocarcinoma of the colon or rectum treated with potentially curative surgery
-814: [P] Primary adenocarcinoma of the colon or rectum, no curative intended surgery and oncological treatment
-817: [P] Primary adenocarcinoma of the colon or rectum, no curative intended surgery and oncological treatment2
-818: [P] Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR
-819: [P] Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, treated with curative intended surgery
-820: [P] Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment, no curative surgery
-821: [P] Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment
-822: [P] Primary adenocarcinoma of colon or rectum, MSI-H or dMMR, surgical treatment
-823: [P] Primary adenocarcinoma of colon or rectum, MSI-H or dMMR, oncological treatment no surgery
-824: [P] Primary adenocarcinoma of colon or rectum,  MSI-H or dMMR
-825: [P] Primary adenocarcinoma of colon
-826: [P] Primary adenocarcinoma of colon, no surgery or oncological treatment
-827: [P] Primary adenocarcinoma of colon surgical treatment
-828: [P] Primary adenocarcinoma of colon oncological treatment, no surgery
-829: [P] Primary adenocarcinoma of colon, MSI-L, MSI-indeterminate, MSS or pMMR
-830: [P] Primary adenocarcinoma of colon, MSI-L, MSI-indeterminate, MSS or pMMR, surgically treated
-831: [P] Primary adenocarcinoma of colon MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment, no surgery
-832: [P] Primary adenocarcinoma of colon MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment
-833: [P] Primary adenocarcinoma of colon MSI-H or dMMR
-834: [P] Primary adenocarcinoma of colon MSI-H or dMMR, surgical treatment
-835: [P] Primary adenocarcinoma of colon MSI-H or dMMR, oncological treatment, no surgery
-836: [P] Primary adenocarcinoma of colon MSI-H or dMMR, no surgery or oncological treatment
-837: [P] Primary adenocarcinoma of rectum
-838: [P] Primary adenocarcinoma of rectum MSI-H or dMMR
-839: [P] Primary adenocarcinoma of rectum, MSI-H or dMMR, no surgery or oncological treatment
-840: [P] Primary adenocarcinoma of rectum MSI-H or dMMR, oncological treatment, no surgery
-841: [P] Primary adenocarcinoma of rectum, MSI-H or dMMR, surgical treatment
-842: [P] Primary adenocarcinoma of rectum, MSI-L, MSI-indeterminate, MSS or pMMR
-843: [P] Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment,  no surgery
-844: [P] Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, no surgery and no oncological treatment
-845: [P] Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, treated with potentially curative surgery
-846: [P] Primary adenocarcinoma of rectum oncological treatment, no surgery
-847: [P] Primary adenocarcinoma of rectum surgical treatment
-848: [P] Primary adenocarcinoma of rectum, no surgery or oncological treatment
-850: [P] Intestinal obstruction (broad 2)
-851: [P] Intraabdominal obstruction (broad)
-852: [P] Surgical wound infection (broad)
-854: [P] Distant metastasis following colorectal cancer (medium)
-855: [P] Distant metastasis following colorectal cancer (narrow)
-856: [P] Earliest event of Migraine, including history of migraine
-857: [P] Earliest event of Migraine
-858: [P] Earliest event of Rheumatoid Arthritis
-859: [P] Earliest event of Crohns disease
-860: [P] Earliest event of Ulcerative colitis
-861: [P] Earliest event of Urinary tract infections (UTI)
-862: [P] Earliest event of Alzheimer's disease derived from Imfeld, 2
-863: [P] Cognitive impairment, incident
-864: [P] Earliest event of Dementia
-865: [P] Non-Emergent Major Non Cardiac Surgery
-866: [P] AAA repair
-867: [P] Lower Extremity Bypass
-868: [P] Carotid Endarterectomy
-869: [P] Lung Resection
-870: [P] Esophagectomy
-871: [P] Pancreatectomy
-872: [P] Colectomy
-873: [P] Cystectomy
-874: [P] Nephrectomy
-875: [P] Coronary Artery Bypass Graft Surgery
-876: [P] Aortic or Mitral Valve Repair or Replacement
-877: [P] Non-Emergent MNCS (age 18 or greater), post op Afib (parox)
-878: [P] Non-Emergent MNCS (age 18 or greater), post op Afib (any)
-879: Cxxx Endometriosis indexed on procedure with two or more diagnosis among females 15 to 49
-881: [P] Acute myocardial infarction
-882: [P] Decreased libido
-884: [P] Diarrhea2
-888: [P] Gastrointestinal bleeding
-889: [P] Hyponatremia
-890: [P] Hypotension
-891: [P] Nausea
-892: [P] Stroke
-893: [P] Vertigo
-894: [P] Abdominal pain
-895: [P] Abnormal weight gain
-896: [P] Abnormal weight loss
-898: [P] Acute renal failure
-899: [P] All-cause mortality
-900: [P] Anaphylactoid reaction
-901: [P] Anemia
-907: [P] All-cause mortality2
-910: [P] Anaphylactoid reaction2
-913: [P] Anemia2
-916: [P] Angioedema2
-917: [P] Anxiety
-918: [P] Bradycardia
-919: [P] Cardiac arrhythmia
-920: [P] Cardiovascular disease
-921: [P] Cardiovascular-related mortality
-922: [P] Chest pain or angina
-923: [P] Kidney disease
-924: [P] Coronary heart disease
-925: [P] Cough
-927: [P] Dementia2
-928: [P] Depression2
-929: [P] Edema2
-930: [P] End stage renal disease2
-931: [P] Fall2
-932: [P] Gout2
-933: [P] Headache2
-934: [P] Heart failure2
-935: [P] Hemorrhagic stroke2
-936: [P] Hepatic failure2
-937: [P] Hospitalization with heart failure2
-938: [P] Hospitalization with heart failure
-939: [P] Hospitalization with preinfarction syndrome
-940: [P] Hyperkalemia
-941: [P] Hypokalemia
-942: [P] Hypomagnesemia
-943: [P] Impotence
-944: [P] Ischemic stroke
-945: [P] Malignant neoplasm
-946: [P] Measured renal dysfunction
-947: [P] Neutropenia or agranulocytosis
-948: [P] Rash
-950: [P] Rhabdomyolysis2
-953: [P] Sudden cardiac death
-954: [P] Syncope
-955: [P] Thrombocytopenia
-956: [P] Transient ischemic attack
-957: [P] Type 2 diabetes mellitus
-958: [P] Syncope3
-959: [P] Thrombocytopenia3
-960: [P] Transient ischemic attack3
-961: [P] Type 2 diabetes mellitus3
-963: [P] Vomiting
-964: [P] Chronic kidney disease
-965: [P] 3-point MACE
-967: [P] 4-point MACE
-969: [P] Acute myocardial infarction2
-970: [P] 4-point MACE2
-975: [P] Acute renal failure2
-976: [P] Glycemic control2
-979: [P] Hospitalization with heart failure3
-980: [P] Revascularization
-982: [P] Stroke2
-983: [P] Sudden cardiac death2
-984: [P] Abnormal weight gain2
-985: [P] Abnormal weight loss2
-986: [P] Acute pancreatitis2
-988: [P] All-cause mortality3
-989: [P] Bladder cancer3
-990: [P] Bone fracture3
-991: [P] Breast cancer3
-992: [P] Diabetic ketoacidosis3
-993: [P] Diarrhea3
-994: [P] Genitourinary infection3
-995: [P] Hyperkalemia3
-996: [P] Hypoglycemia3
-997: [P] Hypotension3
-998: [P] Joint pain3
-999: [P] Lower extremity amputation3
-1000: [P] Nausea3
-1001: [P] Peripheral edema3
-1002: [P] Photosensitivity3
-1003: [P] Renal cancer3
-1004: [P] Thyroid tumor3
-1005: [P] Venous thromboembolism3
-1006: [P] Vomiting3
-1007: [P] Earliest event of Epilepsy
-1009: [P] Earliest event of Treatment resistant depression (TRD)
-1010: [P] Earliest event of Chronic Graft Versus Host Disease (GVHD)
-1011: [P] Earliest event of Marginal zone lymphoma
-1012: [P] Earliest event of Waldenstrom macroglobulinemia
-1013: [P] Earliest event of Ankylosing Spondylitis
-1015: [P] Earliest event of Pulmonary arterial hypertension (PAH)2
-1016: [P] Earliest event of Polyarticular juvenile idiopathic arthritis (JIA)
-1017: [P] Earliest event of Neonatal Thrombocytopenia (NT), less than 1 year old
-1018: [P] Earliest event of Warm Autoimmune Hemolytic Anemia (wAIHA), occurring on or after October 2020
-1019: [P] All events of Hemolytic Disease Fetus and Newborn (HDFN), RhD type, with a pregnancy episode
-1020: [P] Earliest event of Major depressive disorder, with NO occurrence of certain psychiatric disorder
-1021: [P] Earliest event of Myasthenia Gravis, inpatient, 2nd diagnosis or treatment, age gte 18
-1022: [P] Earliest event of Depressive and Sleep Disorder
-1023: [P] Earliest Event of Depressive Disorder with Suicidal Ideation or Attempt Prevalent
-1024: [P] Earliest Event of Depressive Disorder with Anhedonia
-1025: [P] First event of Attention-deficit hyperactivity (ADHD) disorder or procedure
-1026: [P] Earliest Event of Multiple Sclerosis
-1027: [P] Earliest event of Chronic Leukocytic Leukemia
-1028: [P] Earliest event of Urothelial carcinoma
-1029: [P] Earliest event of Mantle Cell Lymphoma
-1030: [P] Earliest event of Prostate cancer, among adult males
-1031: [P] Earliest event of Coronary artery disease (CAD)
-1032: [P] Earliest event of Type 2 Diabetes Mellitus (DM), with no type 1 or secondary DM
-1033: [P] Earliest event of Human Immunodeficiency Virus I (HIV), with treatment, lab or 2nd diagnosis
-1034: [P] All events of Respiratory syncytial virus infection, with 30 days washout
+
311: [P] Parasomnia
+742: [P] Parasomnia or Sleep dysfunction with arousal disturbance
+743: [P] Diabetic ketoacidosis IP-ER (SNOMED concept)
+744: [P] Pulmonary Hypertension
+745: [P] Inflammatory Bowel Disease
+746: [P] Chronic Thromboembolic Pulmonary Hypertension
+747: [P] Pulmonary Arterial Hypertension
+748: [P] Psoriatic arthritis
+749: [P] Plaque Psoriasis
+750: [P] Pulmonary hypertension associated with left heart disease (WHO Group 2)
+751: [P] Pulmonary hypertension associated with lung diseases and or hypoxia (WHO Group 3)
+752: [P] Firearm Accidents (FA)
+753: [P] Motor Vehicle Accidents (MVA)
+754: [P] Down Syndrome
+755: [P] Non-infectious uveitis and iridocyclitis
+756: [P] Cystic Fibrosis
+757: [P] Concomitant TNF - alpha Inhibitors and IL23 Inhibitors - GE 30D overlap
+759: [P] Concomitant TNF - alpha Inhibitors and IL12_23 Inhibitors - GE 30D overlap
+760: [P] Concomitant IL 23 Inhibitors and IL12_23 Inhibitors - GE 30D overlap
+761: [P] Pulmonary arterial hypertension with Prior Left Heart or Vice Versa
+762: [P] Endothelin receptor antagonists
+763: [P] Phosphodiesterase 5 inhibitors and guanylate cyclase stimulators
+764: [P] Prostacyclin analogues and prostacyclin receptor agonists
+765: [P] Earliest event of Left Heart Failure
+766: [P] Earliest event of Right Heart Failure
+767: [P] Earliest event of Sarcoidosis
+768: [P] Earliest event of Sickle Cell Anemia
+769: [P] Scleroderma, first occurrence
+770: [P] Essential Hypertension, first occurrence
+771: [P] Pulmonary Hypertension (Group 2 Left heart disease, encompassing)
+772: [P] Pulmonary Hypertension (Group 3 Chronic lung disease, encompassing)
+773: [P] Congenital Heart Disease
+774: [P] Portal Hypertension, first occurrence
+775: [P] First Inflammatory Bowel Disease
+776: [P] Antisynthetase syndrome
+777: [P] Mixed connective tissue disease
+778: [P] Undifferentiated connective tissue disease
+779: [P] Overlap syndrome
+780: [P] Raynaud?s disease or Raynaud's phenomenon
+781: [P] Antiphospholipid syndrome
+782: [P] CTEPH Prevalent (with Echo or RHC) with 2nd dx code 31-365 days after first dx
+783: [P] Pulmonary endarterectomy
+784: [P] Balloon Pulmonary Angioplasty
+785: [P] Skin Burns
+786: [P] Non-small cell lung cancer (NSCLC)
+787: [P] Lung cancer
+788: [P] Breast cancer
+789: [P] Glioblastoma multiforme (GBM)
+790: [P] Colorectal Cancer
+791: [P] Multiple Myeloma
+792: [P] Metastatic Hormone-Sensitive Prostate Cancer Synchronous
+793: [P] Metastatic Hormone-Sensitive Prostate Cancer Metachronus
+794: COPY OF [P][R] Bleeding
+795: [P] Antineoplastic drugs against colorectal cancer
+796: [P] Potential curative surgery for colorectal cancer
+797: [P] Radiotherapy against colorectal cancer
+798: [P] Primary adenocarcinoma of the colon or rectum
+802: [P] Acute Respiratory Failure 2
+803: [P] Fascial dehiscence and evisceration
+804: [P] Anastomotic leak or dehiscence
+805: [P] Intestinal obstruction (broad)
+806: [P] Intraabdominal abscess
+807: [P] Perioperative aspiration
+808: [P] Postoperative hemorrhage
+809: [P] Surgical wound infection (narrow)
+810: [P] Distant metastasis following colorectal cancer (wide)
+811: [P] Local recurrence after colorectal cancer
+812: [P] Primary adenocarcinoma of the colon or rectum, MSI-H or dMMR, no surgery or oncological treatment
+813: [P] Primary adenocarcinoma of the colon or rectum treated with potentially curative surgery
+814: [P] Primary adenocarcinoma of the colon or rectum, no curative intended surgery and oncological treatment
+817: [P] Primary adenocarcinoma of the colon or rectum, no curative intended surgery and oncological treatment2
+818: [P] Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR
+819: [P] Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, treated with curative intended surgery
+820: [P] Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment, no curative surgery
+821: [P] Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment
+822: [P] Primary adenocarcinoma of colon or rectum, MSI-H or dMMR, surgical treatment
+823: [P] Primary adenocarcinoma of colon or rectum, MSI-H or dMMR, oncological treatment no surgery
+824: [P] Primary adenocarcinoma of colon or rectum,  MSI-H or dMMR
+825: [P] Primary adenocarcinoma of colon
+826: [P] Primary adenocarcinoma of colon, no surgery or oncological treatment
+827: [P] Primary adenocarcinoma of colon surgical treatment
+828: [P] Primary adenocarcinoma of colon oncological treatment, no surgery
+829: [P] Primary adenocarcinoma of colon, MSI-L, MSI-indeterminate, MSS or pMMR
+830: [P] Primary adenocarcinoma of colon, MSI-L, MSI-indeterminate, MSS or pMMR, surgically treated
+831: [P] Primary adenocarcinoma of colon MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment, no surgery
+832: [P] Primary adenocarcinoma of colon MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment
+833: [P] Primary adenocarcinoma of colon MSI-H or dMMR
+834: [P] Primary adenocarcinoma of colon MSI-H or dMMR, surgical treatment
+835: [P] Primary adenocarcinoma of colon MSI-H or dMMR, oncological treatment, no surgery
+836: [P] Primary adenocarcinoma of colon MSI-H or dMMR, no surgery or oncological treatment
+837: [P] Primary adenocarcinoma of rectum
+838: [P] Primary adenocarcinoma of rectum MSI-H or dMMR
+839: [P] Primary adenocarcinoma of rectum, MSI-H or dMMR, no surgery or oncological treatment
+840: [P] Primary adenocarcinoma of rectum MSI-H or dMMR, oncological treatment, no surgery
+841: [P] Primary adenocarcinoma of rectum, MSI-H or dMMR, surgical treatment
+842: [P] Primary adenocarcinoma of rectum, MSI-L, MSI-indeterminate, MSS or pMMR
+843: [P] Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment,  no surgery
+844: [P] Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, no surgery and no oncological treatment
+845: [P] Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, treated with potentially curative surgery
+846: [P] Primary adenocarcinoma of rectum oncological treatment, no surgery
+847: [P] Primary adenocarcinoma of rectum surgical treatment
+848: [P] Primary adenocarcinoma of rectum, no surgery or oncological treatment
+850: [P] Intestinal obstruction (broad 2)
+851: [P] Intraabdominal obstruction (broad)
+852: [P] Surgical wound infection (broad)
+854: [P] Distant metastasis following colorectal cancer (medium)
+855: [P] Distant metastasis following colorectal cancer (narrow)
+856: [P] Earliest event of Migraine, including history of migraine
+857: [P] Earliest event of Migraine
+858: [P] Earliest event of Rheumatoid Arthritis
+859: [P] Earliest event of Crohns disease
+860: [P] Earliest event of Ulcerative colitis
+861: [P] Earliest event of Urinary tract infections (UTI)
+862: [P] Earliest event of Alzheimer's disease derived from Imfeld, 2
+863: [P] Cognitive impairment, incident
+864: [P] Earliest event of Dementia
+865: [P] Non-Emergent Major Non Cardiac Surgery
+866: [P] AAA repair
+867: [P] Lower Extremity Bypass
+868: [P] Carotid Endarterectomy
+869: [P] Lung Resection
+870: [P] Esophagectomy
+871: [P] Pancreatectomy
+872: [P] Colectomy
+873: [P] Cystectomy
+874: [P] Nephrectomy
+875: [P] Coronary Artery Bypass Graft Surgery
+876: [P] Aortic or Mitral Valve Repair or Replacement
+877: [P] Non-Emergent MNCS (age 18 or greater), post op Afib (parox)
+878: [P] Non-Emergent MNCS (age 18 or greater), post op Afib (any)
+879: Cxxx Endometriosis indexed on procedure with two or more diagnosis among females 15 to 49
+881: [P] Acute myocardial infarction
+882: [P] Decreased libido
+884: [P] Diarrhea2
+888: [P] Gastrointestinal bleeding
+889: [P] Hyponatremia
+890: [P] Hypotension
+891: [P] Nausea
+892: [P] Stroke
+893: [P] Vertigo
+894: [P] Abdominal pain
+895: [P] Abnormal weight gain
+896: [P] Abnormal weight loss
+898: [P] Acute renal failure
+899: [P] All-cause mortality
+900: [P] Anaphylactoid reaction
+901: [P] Anemia
+907: [P] All-cause mortality2
+910: [P] Anaphylactoid reaction2
+913: [P] Anemia2
+916: [P] Angioedema2
+917: [P] Anxiety
+918: [P] Bradycardia
+919: [P] Cardiac arrhythmia
+920: [P] Cardiovascular disease
+921: [P] Cardiovascular-related mortality
+922: [P] Chest pain or angina
+923: [P] Kidney disease
+924: [P] Coronary heart disease
+925: [P] Cough
+927: [P] Dementia2
+928: [P] Depression2
+929: [P] Edema2
+930: [P] End stage renal disease2
+931: [P] Fall2
+932: [P] Gout2
+933: [P] Headache2
+934: [P] Heart failure2
+935: [P] Hemorrhagic stroke2
+936: [P] Hepatic failure2
+937: [P] Hospitalization with heart failure2
+938: [P] Hospitalization with heart failure
+939: [P] Hospitalization with preinfarction syndrome
+940: [P] Hyperkalemia
+941: [P] Hypokalemia
+942: [P] Hypomagnesemia
+943: [P] Impotence
+944: [P] Ischemic stroke
+945: [P] Malignant neoplasm
+946: [P] Measured renal dysfunction
+947: [P] Neutropenia or agranulocytosis
+948: [P] Rash
+950: [P] Rhabdomyolysis2
+953: [P] Sudden cardiac death
+954: [P] Syncope
+955: [P] Thrombocytopenia
+956: [P] Transient ischemic attack
+957: [P] Type 2 diabetes mellitus
+958: [P] Syncope3
+959: [P] Thrombocytopenia3
+960: [P] Transient ischemic attack3
+961: [P] Type 2 diabetes mellitus3
+963: [P] Vomiting
+964: [P] Chronic kidney disease
+965: [P] 3-point MACE
+967: [P] 4-point MACE
+969: [P] Acute myocardial infarction2
+970: [P] 4-point MACE2
+975: [P] Acute renal failure2
+976: [P] Glycemic control2
+979: [P] Hospitalization with heart failure3
+980: [P] Revascularization
+982: [P] Stroke2
+983: [P] Sudden cardiac death2
+984: [P] Abnormal weight gain2
+985: [P] Abnormal weight loss2
+986: [P] Acute pancreatitis2
+988: [P] All-cause mortality3
+989: [P] Bladder cancer3
+990: [P] Bone fracture3
+991: [P] Breast cancer3
+992: [P] Diabetic ketoacidosis3
+993: [P] Diarrhea3
+994: [P] Genitourinary infection3
+995: [P] Hyperkalemia3
+996: [P] Hypoglycemia3
+997: [P] Hypotension3
+998: [P] Joint pain3
+999: [P] Lower extremity amputation3
+1000: [P] Nausea3
+1001: [P] Peripheral edema3
+1002: [P] Photosensitivity3
+1003: [P] Renal cancer3
+1004: [P] Thyroid tumor3
+1005: [P] Venous thromboembolism3
+1006: [P] Vomiting3
+1007: [P] Earliest event of Epilepsy
+1009: [P] Earliest event of Treatment resistant depression (TRD)
+1010: [P] Earliest event of Chronic Graft Versus Host Disease (GVHD)
+1011: [P] Earliest event of Marginal zone lymphoma
+1012: [P] Earliest event of Waldenstrom macroglobulinemia
+1013: [P] Earliest event of Ankylosing Spondylitis
+1015: [P] Earliest event of Pulmonary arterial hypertension (PAH)2
+1016: [P] Earliest event of Polyarticular juvenile idiopathic arthritis (JIA)
+1017: [P] Earliest event of Neonatal Thrombocytopenia (NT), less than 1 year old
+1018: [P] Earliest event of Warm Autoimmune Hemolytic Anemia (wAIHA), occurring on or after October 2020
+1019: [P] All events of Hemolytic Disease Fetus and Newborn (HDFN), RhD type, with a pregnancy episode
+1020: [P] Earliest event of Major depressive disorder, with NO occurrence of certain psychiatric disorder
+1021: [P] Earliest event of Myasthenia Gravis, inpatient, 2nd diagnosis or treatment, age gte 18
+1022: [P] Earliest event of Depressive and Sleep Disorder
+1023: [P] Earliest Event of Depressive Disorder with Suicidal Ideation or Attempt Prevalent
+1024: [P] Earliest Event of Depressive Disorder with Anhedonia
+1025: [P] First event of Attention-deficit hyperactivity (ADHD) disorder or procedure
+1026: [P] Earliest Event of Multiple Sclerosis
+1027: [P] Earliest event of Chronic Leukocytic Leukemia
+1028: [P] Earliest event of Urothelial carcinoma
+1029: [P] Earliest event of Mantle Cell Lymphoma
+1030: [P] Earliest event of Prostate cancer, among adult males
+1031: [P] Earliest event of Coronary artery disease (CAD)
+1032: [P] Earliest event of Type 2 Diabetes Mellitus (DM), with no type 1 or secondary DM
+1033: [P] Earliest event of Human Immunodeficiency Virus I (HIV), with treatment, lab or 2nd diagnosis
+1034: [P] All events of Respiratory syncytial virus infection, with 30 days washout

This release is a clean up of files and cohorts before adding cohorts from HowOften. getPhenotypeLog() now gives additional information about a cohort. These are programmatically derived from Circe model compatible cohort json.

-
censorWindowStartDate   censorWindowEndDate collapseSettingsType    
-collapseEraPad  exitStrategy    exitDateOffSetField exitDateOffSet  
-numberOfInclusionRules  qualifyingLimitType primaryCriteriaLimit    
-numberOfCohortEntryEvents   numberOfDomainsInEntryEvents    
-domainsInEntryEvents    continousObservationWindowPrior 
-continousObservationWindowPost  numberOfConceptSets 
-demographicCriteria demographicCriteriaAge  demographicCriteriaGender   
-useOfObservationPeriodInclusionRule restrictedByVisit   
-domainConditionOccurrence   domainMeasurement   domainObservation   
-domainVisitOccurrence   domainDeath domainDrugExposure  
-criteriaAgePrimaryCriteria  domainDeviceExposure    
-domainProcedureOccurrence   criteriaAgeInclusionRules   
-criteriaGenderPrimaryCriteria   criteriaGenderInclusionRules
+
censorWindowStartDate   censorWindowEndDate collapseSettingsType    
+collapseEraPad  exitStrategy    exitDateOffSetField exitDateOffSet  
+numberOfInclusionRules  qualifyingLimitType primaryCriteriaLimit    
+numberOfCohortEntryEvents   numberOfDomainsInEntryEvents    
+domainsInEntryEvents    continousObservationWindowPrior 
+continousObservationWindowPost  numberOfConceptSets 
+demographicCriteria demographicCriteriaAge  demographicCriteriaGender   
+useOfObservationPeriodInclusionRule restrictedByVisit   
+domainConditionOccurrence   domainMeasurement   domainObservation   
+domainVisitOccurrence   domainDeath domainDrugExposure  
+criteriaAgePrimaryCriteria  domainDeviceExposure    
+domainProcedureOccurrence   criteriaAgeInclusionRules   
+criteriaGenderPrimaryCriteria   criteriaGenderInclusionRules

Accepted Cohorts: No cohorts were accepted in this release.

New Cohorts: No new cohorts were added in this release.

@@ -932,45 +945,45 @@

Accepted Cohorts: No cohorts were accepted in this release.

New Cohorts: 39 were added.

-
701: [P][R] Ascites
-702: [P] Alanine aminotransferase (ALT) elevated
-703: [P] Aspartate aminotransferase (AST) elevated
-705: [P] Total Bilirubin elevated
-706: [P] Prothrombin time (PT) elevated
-707: Inpatient Hospitalization (0Pe, 1Era)
-708: [P] International normalized ratio (INR) elevated
-709: [P][R] Chronic liver disease
-710: [P] Cirrhosis of liver or its sequela
-711: [P][R] Transplanted liver present
-712: [P] Viral hepatitis including history of
-713: [P] Alcoholic hepatitis or alcohol liver disorder
-714: [P][R] Endometriosis (clinical)
-715: [P] Hepatic fibrosis
-716: [P] Acute Hepatic Injury
-717: [P] Portal hypertension or esophageal varices
-719: [P] Acute Hepatic Injury or jaundice while inpatient with no cooccurring certain liver disease
-720: [P] Aplastic Anemia
-721: [P] Sudden New Onset Blindness
-722: [P] Endometriosis indexed on procedure with two or more diagnosis among females 15 to 49
-723: [P] First Acute Hepatic Failure with no known severe liver disease
-724: [P] First Acute Hepatic Failure with no known liver disease
-725: [P] All events of Acute Kidney Injury (AKI), with a washout period of 30 days
-726: [P] All events of Anaphylaxis, Mini-Sentinel
-727: [P] All events of Angioedema, with a washout period of 180 days
-728: [P] Autoimmune hemolytic anemia events not including evans syndrome
-729: [P] Autoimmune hepatitis, with a washout period of 365 days
-730: [P] Acute pancreatitis, indexed on visit with NO chronic or hereditary pancreatitis
-731: [P] Sudden Hearing Loss, No congenital anomaly or middle or inner ear conditions
-732: [P] Severe Cutaneous Adverse Reaction (SCAR = SJS+TEN+DRESS) with clean window
-733: [P] Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) with clean window
-734: [P] Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)
-735: [P] Acute Liver Injury indexed on diagnosis or symptoms with no chronic hepatic failure
-736: [P] Acute Liver Injury NO viral, alcoholic, chronic hepatic failure
-737: [P] Neutropenic Fever, Inpatient or ER, indexed on fever or Infection, 90 days era
-738: [P] Autoimmune hemolytic anemia
-739: [P] All events of Isolated Immune Thrombocytopenia (ITP), with a washout period of 365 days
-740: [P] Earliest event of Pulmonary arterial hypertension (PAH)
-741: [P] Earliest event of Thrombotic microangiopathy (TMA) or Microangiopathic hemolytic anemia (MAHA)
+
701: [P][R] Ascites
+702: [P] Alanine aminotransferase (ALT) elevated
+703: [P] Aspartate aminotransferase (AST) elevated
+705: [P] Total Bilirubin elevated
+706: [P] Prothrombin time (PT) elevated
+707: Inpatient Hospitalization (0Pe, 1Era)
+708: [P] International normalized ratio (INR) elevated
+709: [P][R] Chronic liver disease
+710: [P] Cirrhosis of liver or its sequela
+711: [P][R] Transplanted liver present
+712: [P] Viral hepatitis including history of
+713: [P] Alcoholic hepatitis or alcohol liver disorder
+714: [P][R] Endometriosis (clinical)
+715: [P] Hepatic fibrosis
+716: [P] Acute Hepatic Injury
+717: [P] Portal hypertension or esophageal varices
+719: [P] Acute Hepatic Injury or jaundice while inpatient with no cooccurring certain liver disease
+720: [P] Aplastic Anemia
+721: [P] Sudden New Onset Blindness
+722: [P] Endometriosis indexed on procedure with two or more diagnosis among females 15 to 49
+723: [P] First Acute Hepatic Failure with no known severe liver disease
+724: [P] First Acute Hepatic Failure with no known liver disease
+725: [P] All events of Acute Kidney Injury (AKI), with a washout period of 30 days
+726: [P] All events of Anaphylaxis, Mini-Sentinel
+727: [P] All events of Angioedema, with a washout period of 180 days
+728: [P] Autoimmune hemolytic anemia events not including evans syndrome
+729: [P] Autoimmune hepatitis, with a washout period of 365 days
+730: [P] Acute pancreatitis, indexed on visit with NO chronic or hereditary pancreatitis
+731: [P] Sudden Hearing Loss, No congenital anomaly or middle or inner ear conditions
+732: [P] Severe Cutaneous Adverse Reaction (SCAR = SJS+TEN+DRESS) with clean window
+733: [P] Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) with clean window
+734: [P] Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)
+735: [P] Acute Liver Injury indexed on diagnosis or symptoms with no chronic hepatic failure
+736: [P] Acute Liver Injury NO viral, alcoholic, chronic hepatic failure
+737: [P] Neutropenic Fever, Inpatient or ER, indexed on fever or Infection, 90 days era
+738: [P] Autoimmune hemolytic anemia
+739: [P] All events of Isolated Immune Thrombocytopenia (ITP), with a washout period of 365 days
+740: [P] Earliest event of Pulmonary arterial hypertension (PAH)
+741: [P] Earliest event of Thrombotic microangiopathy (TMA) or Microangiopathic hemolytic anemia (MAHA)
@@ -982,706 +995,706 @@

Accepted Cohorts: No cohorts were accepted in this release.

New Cohorts: 7 were added.

-
410: [P] Acute Urinary tract infections UTI (1Pe, 30Era)
-411: [P] Sepsis or Septic Shock (1Pe, 7Era)
-412: Transverse myelitis indexed on diagnosis (1Ps, 0Era, 365W)
-414: [P] Acute Skin Eruption symptoms (1Pe, 7Era)
-415: [P] Skin Erythema (1Pe, 7Era)
-416: [P] Skin Rash (1Pe, 7Era)
-417: [P] Acute gastrointestinal bleeding events (7Pe, 30Era)
+
410: [P] Acute Urinary tract infections UTI (1Pe, 30Era)
+411: [P] Sepsis or Septic Shock (1Pe, 7Era)
+412: Transverse myelitis indexed on diagnosis (1Ps, 0Era, 365W)
+414: [P] Acute Skin Eruption symptoms (1Pe, 7Era)
+415: [P] Skin Erythema (1Pe, 7Era)
+416: [P] Skin Rash (1Pe, 7Era)
+417: [P] Acute gastrointestinal bleeding events (7Pe, 30Era)

Accepted Cohorts: No cohorts were accepted in this release.

New Cohorts: 44 were added.

-
363: [P] Joint Stiffness (3Pe, 7Era)
-364: [P] Sleep disorder (3Pe, 7Era)
-365: [P] Dysuria (3Pe, 7Era)
-366: [P] Streptococcal throat infection (14Pe, 30Era)
-367: [P] Allergic Rhinitis (14Pe, 30Era)
-368: [P] Sinusitis (7Pe, 30Era)
-369: [P] Allergic condition (14Pe, 30Era)
-370: [P] Allergic disorder (14Pe, 30Era)
-371: [P] Claudication Pain (365Pe, 365Era)
-372: [P] Otitis media (3Pe, 30Era)
-373: [P] Iron deficiency Anemia (365Pe, 365Era)
-374: [P] Drug Dependence Disorder (30Pe, 365Era)
-375: [P] Gall stone disorder (30Pe, 365Era)
-376: [P] Skin Bleeding (1Pe, 7Era)
-377: [P] Skin Petechiae (1Pe, 7Era)
-378: [P] Skin Purpura (1Pe, 7Era)
-379: [P] Ecchymosis (1Pe, 7Era)
-380: [P] Jaundice (1Pe, 7Era)
-381: [P] Skin Itching  (1Pe, 7Era)
-382: [P] Prurititc Rash (1Pe, 7Era)
-383: [P] Eczematous Atopic Dermatitis and non hyperkeratotic dermatosis (1Pe, 365Era)
-384: [P] Contact Dermatitis (14Pe, 60Era)
-385: [P] Intertrigo (14Pe, 60Era)
-386: [P] Seborrheic dermatitis (14Pe, 60Era)
-387: [P] Photodermatitis (14Pe, 60Era)
-388: [P] Peripheral Neuritis (FP)
-389: [P] Peripheral Neuropathy or Neuritits (FP)
-391: [P] Hearing Loss (30Pe, 365Era)
-392: [P] Otalgia or Otitis (3Pe, 30Era)
-393: [P] Low Back Pain or Injury (3Pe, 7Era)
-394: [P] Gastroesophageal reflux disease (365Pe, 365Era)
-395: [P] Dysmenorrhea (90Pe, 365Era)
-396: [P] Osteoarthritis (FP)
-397: [P] Benign Prostatic Hyperplasia (FP)
-398: [P] Bladder Outflow Obstruction (0Pe, 180Era)
-399: [P] Kidney Stone (1Pe, 30Era)
-400: [P] Prostate Cancer among adult males (FP)
-401: [P] Uterine Fibroids (FP)
-402: [P] Ventilatory assist for respiratory findings with Acute Respiratory Failure (0Pe, 0Era)
-403: [P] Acute Respiratory Failure in inpatient or Emergency room (0Pe, 0Era)
-404: [P] Ventricular Tachycardia, in an Inpatient or Emergency room setting (1Pe, 7Era)
-405: [P] Atrial Fibrillation or Flutter (1Pe, 365Era)
-406: [P] Intellectual Disability (FP)
-407: [P] Hemorrhoids (1Pe, 30Era)
+
363: [P] Joint Stiffness (3Pe, 7Era)
+364: [P] Sleep disorder (3Pe, 7Era)
+365: [P] Dysuria (3Pe, 7Era)
+366: [P] Streptococcal throat infection (14Pe, 30Era)
+367: [P] Allergic Rhinitis (14Pe, 30Era)
+368: [P] Sinusitis (7Pe, 30Era)
+369: [P] Allergic condition (14Pe, 30Era)
+370: [P] Allergic disorder (14Pe, 30Era)
+371: [P] Claudication Pain (365Pe, 365Era)
+372: [P] Otitis media (3Pe, 30Era)
+373: [P] Iron deficiency Anemia (365Pe, 365Era)
+374: [P] Drug Dependence Disorder (30Pe, 365Era)
+375: [P] Gall stone disorder (30Pe, 365Era)
+376: [P] Skin Bleeding (1Pe, 7Era)
+377: [P] Skin Petechiae (1Pe, 7Era)
+378: [P] Skin Purpura (1Pe, 7Era)
+379: [P] Ecchymosis (1Pe, 7Era)
+380: [P] Jaundice (1Pe, 7Era)
+381: [P] Skin Itching  (1Pe, 7Era)
+382: [P] Prurititc Rash (1Pe, 7Era)
+383: [P] Eczematous Atopic Dermatitis and non hyperkeratotic dermatosis (1Pe, 365Era)
+384: [P] Contact Dermatitis (14Pe, 60Era)
+385: [P] Intertrigo (14Pe, 60Era)
+386: [P] Seborrheic dermatitis (14Pe, 60Era)
+387: [P] Photodermatitis (14Pe, 60Era)
+388: [P] Peripheral Neuritis (FP)
+389: [P] Peripheral Neuropathy or Neuritits (FP)
+391: [P] Hearing Loss (30Pe, 365Era)
+392: [P] Otalgia or Otitis (3Pe, 30Era)
+393: [P] Low Back Pain or Injury (3Pe, 7Era)
+394: [P] Gastroesophageal reflux disease (365Pe, 365Era)
+395: [P] Dysmenorrhea (90Pe, 365Era)
+396: [P] Osteoarthritis (FP)
+397: [P] Benign Prostatic Hyperplasia (FP)
+398: [P] Bladder Outflow Obstruction (0Pe, 180Era)
+399: [P] Kidney Stone (1Pe, 30Era)
+400: [P] Prostate Cancer among adult males (FP)
+401: [P] Uterine Fibroids (FP)
+402: [P] Ventilatory assist for respiratory findings with Acute Respiratory Failure (0Pe, 0Era)
+403: [P] Acute Respiratory Failure in inpatient or Emergency room (0Pe, 0Era)
+404: [P] Ventricular Tachycardia, in an Inpatient or Emergency room setting (1Pe, 7Era)
+405: [P] Atrial Fibrillation or Flutter (1Pe, 365Era)
+406: [P] Intellectual Disability (FP)
+407: [P] Hemorrhoids (1Pe, 30Era)

Accepted Cohorts: 5 cohorts were accepted in this release.

-
304: Neurofibromatosis type 1 (FP)
-305: Neurofibromatosis type 1 without Type 2 (FP)
-306: Optical pathway glioma and neurofibromatosis (FP)
-307: Optical pathway glioma or non malignant neoplasm of optic nerve w neurofibromatosis (FP)
-308: Optical pathway glioma with MRI imaging and ophthalmology visits Neurofibromatosis (FP)
+
304: Neurofibromatosis type 1 (FP)
+305: Neurofibromatosis type 1 without Type 2 (FP)
+306: Optical pathway glioma and neurofibromatosis (FP)
+307: Optical pathway glioma or non malignant neoplasm of optic nerve w neurofibromatosis (FP)
+308: Optical pathway glioma with MRI imaging and ophthalmology visits Neurofibromatosis (FP)

New Cohorts: 7 were added.

-
361: [P] Restless Leg Syndrome (FP)
-362: [P] Acute Kidney Injury AKI (7Pe, 30W)
+
361: [P] Restless Leg Syndrome (FP)
+362: [P] Acute Kidney Injury AKI (7Pe, 30W)

Accepted Cohorts: No cohorts were accepted in this release.

New Cohorts: 13 were added.

-
348: [P] Hematuria (7Pe, 30Era)
-349: [P] Lower gastrointestinal bleeding events (7Pe, 30Era)
-350: [P] Hemoptysis (7Pe, 30Era)
-351: [P] Nasal Polyp (365Pe, 365Era)
-352: [P] Inflamed Tonsil (7Pe, 30Era)
-353: [P] Conjunctivitis (3Pe, 7Era)
-354: [P] Nasal Congestion or Rhinitis or Common Cold (3Pe, 7Era)
-355: [P] Laryngitis (3Pe, 7Era)
-356: [P] Epistaxis (3Pe, 7Era)
-357: [P] Pulmonary Edema (3Pe, 30Era)
-358: [P] Acute Respiratory Failure among persons with no chronic respiratory failure (3Pe, 30Era)
-359: [P] Acute Respiratory Failure (3Pe, 30Era)
-360: [P] Pleural Effusion (3Pe, 30Era)
+
348: [P] Hematuria (7Pe, 30Era)
+349: [P] Lower gastrointestinal bleeding events (7Pe, 30Era)
+350: [P] Hemoptysis (7Pe, 30Era)
+351: [P] Nasal Polyp (365Pe, 365Era)
+352: [P] Inflamed Tonsil (7Pe, 30Era)
+353: [P] Conjunctivitis (3Pe, 7Era)
+354: [P] Nasal Congestion or Rhinitis or Common Cold (3Pe, 7Era)
+355: [P] Laryngitis (3Pe, 7Era)
+356: [P] Epistaxis (3Pe, 7Era)
+357: [P] Pulmonary Edema (3Pe, 30Era)
+358: [P] Acute Respiratory Failure among persons with no chronic respiratory failure (3Pe, 30Era)
+359: [P] Acute Respiratory Failure (3Pe, 30Era)
+360: [P] Pleural Effusion (3Pe, 30Era)

Accepted Cohorts: 2 were accepted. 234: Appendicitis (1Pe, 180Era) 213: Acquired Neutropenia or unspecified leukopenia (21Pe, 365Era)

New Cohorts: 9 were added.

-
339: [P] Hypotension (1Pe, 3Era)
-340: [P] Hives, Erythema, Eruption, Urticaria (1Pe, 7Era)
-341: [P] Loss of mentation including coma, loss of consciousness, altered consciousness (1Pe, 3Era)
-342: [P] Urinary Incontinence (1Pe, 3Era)
-343: [P] Fecal Incontinence (1Pe, 3Era)
-344: [P] Doctors office or clinic visit without other overlapping visits (0Pe, 0Era)
-345: [P] Doctors office or clinic visit (0Pe, 0Era)
-346: [P] Non urgent outpatient visit without overlapping inpatient or emergency visit (0Pe, 0Era)
-347: [P] Ambulance utilization (0Pe, 0Era)
+
339: [P] Hypotension (1Pe, 3Era)
+340: [P] Hives, Erythema, Eruption, Urticaria (1Pe, 7Era)
+341: [P] Loss of mentation including coma, loss of consciousness, altered consciousness (1Pe, 3Era)
+342: [P] Urinary Incontinence (1Pe, 3Era)
+343: [P] Fecal Incontinence (1Pe, 3Era)
+344: [P] Doctors office or clinic visit without other overlapping visits (0Pe, 0Era)
+345: [P] Doctors office or clinic visit (0Pe, 0Era)
+346: [P] Non urgent outpatient visit without overlapping inpatient or emergency visit (0Pe, 0Era)
+347: [P] Ambulance utilization (0Pe, 0Era)

Accepted Cohorts: The following cohorts were added

-
119: Systemic lupus erythematosus indexed on signs, symptoms, treatment or diagnosis (FP)
-296: Transverse myelitis or symptoms indexed on symptoms or diagnosis (180Pe, 180Era)
+
119: Systemic lupus erythematosus indexed on signs, symptoms, treatment or diagnosis (FP)
+296: Transverse myelitis or symptoms indexed on symptoms or diagnosis (180Pe, 180Era)

New Cohorts: 17 were added.

-
142: [P] Earliest event of ST elevated myocardial infarction (7P, 1E)
-192: [P] Skin or mucosal bleeding events (1Pe, 7Era)
-298: [P] Urinary bleed events in persons without renal glomerular disease (30Pe, 7Era)
-299: [P] Acute gastrointestinal bleeding events (7Pe, 30Era)
-300: [P] Heavy menstrual bleeding (menorrhagia) events (60Pe, 180Era)
-318: [P] All events of Acute Hepatic Failure in persons without chronic hepatic failure (90Pe, 365Era)
-324: [P] Pain (3Pe, 7Era)
-325: [P] Inpatient Hospitalization By Site of care or type of service (0Pe, 1Era)
-327: [P] Pharyngitis (3Pe, 7Era)
-328: [P] Wheezing (3Pe, 30Era)
-329: [P] Pneumonitis and lung infections (14Pe, 30Era)
-330: [P] Abdominal Bloating (1Pe, 7Era)
-331: [P] Encephalopathy (1Pe, 14Era)
-332: [P] Pain or ache that is Chronic (3Pe, 180Era)
-333: [P] Alcohol Use Disorder (365Pe, 365Era)
-334: [P] Asthma (FP)
-335: [P] Anxiety or Fear (3Pe, 30Era)
+
142: [P] Earliest event of ST elevated myocardial infarction (7P, 1E)
+192: [P] Skin or mucosal bleeding events (1Pe, 7Era)
+298: [P] Urinary bleed events in persons without renal glomerular disease (30Pe, 7Era)
+299: [P] Acute gastrointestinal bleeding events (7Pe, 30Era)
+300: [P] Heavy menstrual bleeding (menorrhagia) events (60Pe, 180Era)
+318: [P] All events of Acute Hepatic Failure in persons without chronic hepatic failure (90Pe, 365Era)
+324: [P] Pain (3Pe, 7Era)
+325: [P] Inpatient Hospitalization By Site of care or type of service (0Pe, 1Era)
+327: [P] Pharyngitis (3Pe, 7Era)
+328: [P] Wheezing (3Pe, 30Era)
+329: [P] Pneumonitis and lung infections (14Pe, 30Era)
+330: [P] Abdominal Bloating (1Pe, 7Era)
+331: [P] Encephalopathy (1Pe, 14Era)
+332: [P] Pain or ache that is Chronic (3Pe, 180Era)
+333: [P] Alcohol Use Disorder (365Pe, 365Era)
+334: [P] Asthma (FP)
+335: [P] Anxiety or Fear (3Pe, 30Era)

Deprecated Cohorts: No new cohorts were added in this release.

New Cohorts: 19 were added.

-
134: [P] Persons with Attention Deficit Hyperactivity Disorder (FP)
-278: [P] Pain that is Non Chronic, Non Generalized (3Pe, 7Era)
-279: [P] Low Back Pain (30Pe, 180Era)
-280: [P] Abdominal Pain (3Pe, 7Era)
-281: [P] Epigastric Pain (3Pe, 7Era)
-282: [P] Joint Pain (3Pe, 30Era)
-283: [P] Prostatitis (180Pe, 365Era)
-284: [P] Myocarditis or Pericarditis (30Pe, 90Era)
-285: [P] Myocarditis or Pericarditis Not due to infections (30Pe, 90Era)
-287: [P] Transverse myelitis includes Myelitis Unspecified and neuromyelitis optica (90Pe, 365Era)
-288: [P] Type 2 Diabetes Mellitus indexed on diagnosis, treatment or lab results (FP)
-289: [P] Presence Of Cardiac Arrhythmia (3Pe, 60Era)
-290: [P] Thyroiditis indexed on diagnosis or treatment without (FP)
-291: [P] Gynecomastia, indexed on diagnosis, procedure or symptoms (FP)
-292: [P] Hepatic Failure (365Pe, 365Era)
-293: [P] Acute Hepatic Injury with no chronic hepatic failure (180Pe, 180Era)
-294: [P] Acute Hepatic Injury with no pre-existing liver disease (180Pe, 180Era)
-295: [P] Acute Hepatic Failure in persons with no pre-existing liver disease (365Pe, 365Era)
-296: Transverse myelitis or symptoms indexed on symptoms or diagnosis (180Pe, 180Era)
+
134: [P] Persons with Attention Deficit Hyperactivity Disorder (FP)
+278: [P] Pain that is Non Chronic, Non Generalized (3Pe, 7Era)
+279: [P] Low Back Pain (30Pe, 180Era)
+280: [P] Abdominal Pain (3Pe, 7Era)
+281: [P] Epigastric Pain (3Pe, 7Era)
+282: [P] Joint Pain (3Pe, 30Era)
+283: [P] Prostatitis (180Pe, 365Era)
+284: [P] Myocarditis or Pericarditis (30Pe, 90Era)
+285: [P] Myocarditis or Pericarditis Not due to infections (30Pe, 90Era)
+287: [P] Transverse myelitis includes Myelitis Unspecified and neuromyelitis optica (90Pe, 365Era)
+288: [P] Type 2 Diabetes Mellitus indexed on diagnosis, treatment or lab results (FP)
+289: [P] Presence Of Cardiac Arrhythmia (3Pe, 60Era)
+290: [P] Thyroiditis indexed on diagnosis or treatment without (FP)
+291: [P] Gynecomastia, indexed on diagnosis, procedure or symptoms (FP)
+292: [P] Hepatic Failure (365Pe, 365Era)
+293: [P] Acute Hepatic Injury with no chronic hepatic failure (180Pe, 180Era)
+294: [P] Acute Hepatic Injury with no pre-existing liver disease (180Pe, 180Era)
+295: [P] Acute Hepatic Failure in persons with no pre-existing liver disease (365Pe, 365Era)
+296: Transverse myelitis or symptoms indexed on symptoms or diagnosis (180Pe, 180Era)

Deprecated Cohorts: No new cohorts were added in this release.

Accepted Cohorts: The following cohorts were added

-
269: Acute Kidney Injury AKI (7Pe, 30W)
+
269: Acute Kidney Injury AKI (7Pe, 30W)

Discussed https://forums.ohdsi.org/t/phenotype-phebruary-day-29-acute-kidney-injury/16067 and peer reviewed by Azza Shoaibi and accepted after modifications. See recording dated August 12th 2022

New Cohorts: 2 were added.

-
276: [P] Sudden Vision Loss (1Pe, 0Era, 365W)
-277: [P] Sudden Hearing Loss (1Pe, 0Era, 365W)
+
276: [P] Sudden Vision Loss (1Pe, 0Era, 365W)
+277: [P] Sudden Hearing Loss (1Pe, 0Era, 365W)

Deprecated Cohorts: No new cohorts were added in this release.

Accepted Cohorts: The following cohorts were added

-
63: Transverse myelitis or symptoms (1Ps, 0Era, 365W)
+
63: Transverse myelitis or symptoms (1Ps, 0Era, 365W)

Deprecated Cohorts: No new cohorts were added in this release.

Modified Cohorts: several symptom and sign based cohorts were updated to support discussion https://forums.ohdsi.org/t/phenotype-submission-symptoms-and-signs/17895

New Cohorts: 2 were added.

-
270: [P] Hemolytic Anemia (7Pe, 0Era, 365W)
-271: [P] Hemolytic Anemia Intra corpuscular (FP)
+
270: [P] Hemolytic Anemia (7Pe, 0Era, 365W)
+271: [P] Hemolytic Anemia Intra corpuscular (FP)

Deprecated Cohorts: No new cohorts were added in this release.

Modified Cohorts: 0 were modified.

New Cohorts: 11 were added.

-
258: [P] Anaphylaxis or Anaphylactic shock events (1Pe, 0Era, 30W)
-259: [P] Anaphylaxis all cause (1Pe, 0Era, 30W)
-260: [P] ST elevated myocardial infarction with inpatient admission (7Pe, 180Era)
-261: [P] Non ST elevated myocardial infarction with inpatient admission (7Pe, 180Era)
-262: [P] Unstable Angina with inpatient admission (7Pe, 180Era)
-263: [P] Unstable Angina OR NSTEMI with inpatient admission (7Pe, 180Era)
-264: [P] Acute Hepatic Failure in persons with liver disease (90Pe, 180W)
-265: [P] Drug Induced Acute Hepatic Failure (90Pe, 180W)
-267: [P] Acute Kidney Injury AKI, in persons with chronic kidney disease (7Pe, 30W)
-268: [P] Acute Kidney Injury AKI, in persons with NO chronic kidney disease (7Pe, 30W)
-269: [P] Acute Kidney Injury (AKI) (7Pe, 30W)
+
258: [P] Anaphylaxis or Anaphylactic shock events (1Pe, 0Era, 30W)
+259: [P] Anaphylaxis all cause (1Pe, 0Era, 30W)
+260: [P] ST elevated myocardial infarction with inpatient admission (7Pe, 180Era)
+261: [P] Non ST elevated myocardial infarction with inpatient admission (7Pe, 180Era)
+262: [P] Unstable Angina with inpatient admission (7Pe, 180Era)
+263: [P] Unstable Angina OR NSTEMI with inpatient admission (7Pe, 180Era)
+264: [P] Acute Hepatic Failure in persons with liver disease (90Pe, 180W)
+265: [P] Drug Induced Acute Hepatic Failure (90Pe, 180W)
+267: [P] Acute Kidney Injury AKI, in persons with chronic kidney disease (7Pe, 30W)
+268: [P] Acute Kidney Injury AKI, in persons with NO chronic kidney disease (7Pe, 30W)
+269: [P] Acute Kidney Injury (AKI) (7Pe, 30W)

Deprecated Cohorts: No new cohorts were added in this release.

Modified Cohorts: 3 were modified.

-
71: [P] Acute myocardial infarction with inpatient admission (7Pe, 180Era)
-221: [P] Anaphylaxis Non Environmental exposure related (1Pe, 0Era, 30W)
-234: [P] Appendicitis (1Pe, 0Era, 365W)
+
71: [P] Acute myocardial infarction with inpatient admission (7Pe, 180Era)
+221: [P] Anaphylaxis Non Environmental exposure related (1Pe, 0Era, 30W)
+234: [P] Appendicitis (1Pe, 0Era, 365W)

Accepted Cohort: 3 cohorts were accepted. cohortId 23, 24 and 25 were considered accepted to the OHDSI Phenotype Library. This cohort is deemed validated as it represents a convention and thus do not need to go through peer review process.

-
23: Inpatient Hospitalization (1Pe, 0Era)
-24: Emergency room visits (0Pe, 0Era)
-25: All cause mortality
+
23: Inpatient Hospitalization (1Pe, 0Era)
+24: Emergency room visits (0Pe, 0Era)
+25: All cause mortality

New Cohorts: 8 were added.

-
100: [P] Alzheimer's disease
-119: [P] Systemic lupus erythematosus (FP)
-251: [P] Acute pancreatitis (7Pe, 0Era, 365W)
-253: [P] Drug Induced Acute pancreatitis (7Pe, 365W)
-254: [P] Drug Resistant Epilepsy
-255: [P] Alzheimer's disease (based on Imfeld, 2013)
-256: [P] Facial Palsy lower motor neuron including Bells Palsy (180Pe, 0Era, 183W)
-257: [P] Emergency room visits or code (0Pe, 0Era)
+
100: [P] Alzheimer's disease
+119: [P] Systemic lupus erythematosus (FP)
+251: [P] Acute pancreatitis (7Pe, 0Era, 365W)
+253: [P] Drug Induced Acute pancreatitis (7Pe, 365W)
+254: [P] Drug Resistant Epilepsy
+255: [P] Alzheimer's disease (based on Imfeld, 2013)
+256: [P] Facial Palsy lower motor neuron including Bells Palsy (180Pe, 0Era, 183W)
+257: [P] Emergency room visits or code (0Pe, 0Era)

Deprecated Cohorts: No cohorts were added in this release.

Modified Cohorts: 136 were modified. Several cohorts were changed from [P] to [W] i.e. were withdrawn from peer review consideration. Some of the cohorts in [P] pending peer review status were modified by the contributor. The changes includes cohort name changes and cohort specification changes. No accepted cohorts were modified.

-
2: [W] COVID-19 diagnosis or SARS-CoV-2 test (1pos) (3Ps, 7Era)
-3: [P] Cough (3Ps, 30Era)
-4: [P] Diarrhea (7Ps, 30Era)
-5: [P] Dyspnea (14Pe, 30Era)
-6: [P] Fever (3Pe, 30Era)
-7: [P] Headache, Migraine or related Neurologic pain (7Pe, 30Era)
-8: [P] Anosmia OR Hyposmia OR Dysgeusia (7Ps, 180Era)
-9: [P] Sore throat (7Pe, 30Era)
-10: [P] Nausea or Vomiting (3Pe, 30Era)
-11: [P] Malaise or fatigue (3P, 30Era)
-12: [P] Rhinitis or common cold (7P, 30Era)
-13: [P] Myalgia (not explained by injury, ischemia or systemic inflammation) (3Pe, 30Era)
-14: [P] Myalgia (3Pe, 30Era)
-15: [W] Exposure to Viral Disease (7Pe, 30Era)
-16: [W] Exposure to SARS-Cov 2 and coronavirus (7Pe, 30Era)
-17: [W] Exposure to SARS-Cov 2 (7Pe, 30Era)
-18: [P] Multiple Inflammatory Syndrome (30Pe, 30Era)
-19: [P] Acute Typical Pneumonia (14Pe, 30Era)
-20: [P] Bronchitis (14Pe, 90Era)
-21: [P] Acute respiratory distress syndrome (ARDS) or Acute Respiratory Failure (3Pe, 30Era)
-22: [W] SARS-CoV-2 testing (1Ps, 0Era)
-26: [P] Asthma or Chronic obstructive pulmonary disease (COPD) (FP)
-27: [P] Asthma without COPD (FP)
-28: [P] Chronic obstructive pulmonary disease (COPD) without asthma (FP)
-29: [W] Autoimmune condition (FP)
-30: [P] Tuberculosis (FP)
-31: [P] Malignant neoplasm excluding non-melanoma skin cancer (FP)
-32: [P] Obesity (FP)
-33: [P] Dementia (FP)
-34: [P] Hypertensive disorder or hypertensive complications (FP)
-35: [W] Chronic kidney disease (FP)
-36: [P] Human immunodeficiency virus (not HIV2) infection (FP)
-37: [P] Hepatitis C (FP)
-38: [P] Heart disease (FP)
-39: [W] End stage renal disease (FP)
-40: [P] Diabetes Mellitus Type 2 (FP)
-41: [W] Chronic kidney disease broad (FP)
-42: [W] End stage renal disease broad (FP)
-43: [P] Respiratory or pulmonary tuberculosis (FP)
-44: [W] COVID-19 diagnosis (3Pe, 7Era)
-45: [W] COVID-19 diagnosis with SARS-Cov-2 test (-3d to 3d) (3Pe, 21Era)
-46: [W] COVID-19 diagnosis and SARS-CoV-2 test (1pos) within 3d (3Pe, 21Era)
-47: [W] COVID-19 diagnosis and SARS-CoV-2 test (1pos) (0neg) within 3d (3Pe, 21Era)
-48: [W] COVID-19 diagnosis and SARS-CoV-2 test (0pos upto 3d, 1neg within 3d) (3Pe, 7Era)
-51: [W] SARS-CoV-2 test positive result (0Ps, 0Era)
-52: [W] SARS-CoV-2 test negative result (0Ps, 0Era)
-53: [W] SARS-CoV-2 test positive or negative result - keep persons with positive (0Ps, 0Era)
-54: [P] Febrile seizure (1Pe, 0Era, 42W)
-55: [W] COVID-19 diagnosis or SARS-CoV-2 test (1pos) (3Ps, 21Era)
-56: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (0 neg -3d to 3d) (3Ps, 21Era)
-57: [P] Bleeding (1Pe, 0Era, 30W)
-58: [W] SARS-CoV-2 test positive result (3Ps, 21Era)
-59: [W] COVID-19 diagnosis with no SARS-CoV-2 test (3Ps, 21Era)
-60: [W] SARS-CoV-2 test positive and negative result (0Ps, 0Era)
-61: [P] Bradycardia or heart block with inpatient admission (1Pe, 30Era)
-62: [P] Generalized Seizure (1Pe, 0Era, 42W)
-63: [P] Transverse myelitis or symptoms (1Ps, 0Era, 365W)
-64: [W] Flu-like symptoms fever, cough, malaise, fatigue, dyspnea, myalgia (3P, 30Era)
-65: [W] Acute pancreatitis with inpatient admission (3Pe, 30Era)
-66: [W] Acute renal failure with inpatient admission (3Pe, 30Era)
-67: [W] Hepatic failure with inpatient admission (3Pe, 30Era)
-68: [W] Heart failure with inpatient admission (3Pe, 30Era)
-69: [W] Angioedema with inpatient admission (7Ps, 30Era)
-70: [P] Stroke (ischemic or hemorrhagic) with inpatient admission (7Ps, 30Era)
-71: [P] Acute myocardial infarction with inpatient admission (7Ps, 180Era)
-72: [P] Influenza diagnosis or positive test result (7Pe, 90Era)
-73: [W] Pregnancy (270P, 0Era)
-74: [P] Hemorrhagic stroke (intracerebral bleeding) with inpatient admission (7Ps, 180Era)
-75: [P] Ischemic stroke with inpatient admission (7Ps, 180Era)
-76: [P] Transient ischemic attack with inpatient admission (7Ps, 30Era)
-77: [P] Gastrointestinal bleeding with inpatient admission (7Ps, 30Era)
-78: [P] Cardiac arrhythmia with inpatient admission (1Pe, 30Era)
-79: [P] Dialysis with inpatient admission (1Ps, 7Era)
-80: [P] Extracorporeal Membrane Oxygenation with inpatient admission (1Pe, 30Era)
-81: [P] Cesarean section (7Pe, 180Era)
-82: [P] Intensive services during hospitalization (1Ps, 30Era)
-84: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (1pos or 0 neg 0d to 3d) (3Ps, 180Era)
-85: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (1pos or 0 neg 0d to 3d) (3Ps, 21Era)
-86: [W] SARS-CoV-2 test positive or negative result (0Ps, 0Era)
-87: [W] SARS-CoV-2 test (1Ps, 0Era)
-95: [P] Delirium (FP)
-123: [W] First event of Suicide attempt, including injuries and poisonings with undetermined, 365 days
-189: [P] Right Upper Quadrant Pain (Pe1, 0Era, 14W)
-190: [P] Abdominal Distension (Pe1, 0Era, 14W)
-191: [P] Fatigue, Malaise, Lethargy, Anorexia (Pe1, 0Era, 14W)
-192: [P] Nausea or Vomiting (Pe1, 0Era, 7W)
-193: [P] Jaundice or Itching (Pe1, 0Era, 14W)
-194: [P] Encephalopathy or its presentations (Pe1, 0Era, 30W)
-195: [P] Urothelial bladder cancer (FP)
-197: [P] Coronary Artery Disease from vessel disease to ischemic injury (FP)
-205: [W] Acute pancreatitis (7Pe, 0Era, 365W)
-206: [W] Drug Induced Acute pancreatitis (7Pe, 365W)
-207: [P] Acquired Pure Red Cell Aplasia
-208: [P] Neutropenic Fever (3Pe, 30Era)
-209: [P] Hemolytic Anemia, Extra corpuscular Acquired - G6PD deficiency excluded (7Pe, 0Era, 365W)
-210: [P] Hemolytic Anemia, Extra corpuscular Acquired (7Pe, 0Era, 365W)
-211: [P] Pancytopenia, Acquired
-213: [P] Acquired Neutropenia or unspecified leukopenia (21Pe, 365Era)
-214: [P] Acquired Isolated Neutropenia or unspecified leukopenia (21Pe, 365Era)
-215: [P] Isolated Immune Thrombocytopenia (180Pe, 365Era)
-216: [P] Isolated Immune Thrombocytopenia in absence of common thrombocytopenia causes (180Pe, 365Era)
-217: [P] Thrombotic microangiopathy (TMA) or Microangiopathic hemolytic anemia (MAHA)
-218: [P] Rhabdomyolysis (3Pe, 0Era, 180W)
-219: [P] Sudden Cardiac arrest or cardiac death
-220: [P] Angioedema (3Pe, 0Era, 180W)
-221: [P] Anaphylaxis Non Environmental exposure related (1Pe, 0Era, 180W)
-222: [P] Stevens-Johnson syndrome, toxic epidermal necrolysis spectrum
-223: [P] Posterior reversible encephalopathy syndrome PRES (FP)
-224: [P] Long QT Syndrome or QT prolonged (Acquired)
-225: [P] Drug-induced Lupus (180Pe, 0Era, 365W)
-226: [P] Drug Rash with Eosinophilia and Systemic Symptoms DRESS (1Pe, 0Era, 365W)
-227: [P] Severe Cutaneous Adverse Reaction SCAR (SJS+TEN+DRESS+EM) (3Pe, 0Era, 365W)
-228: [P] Severe Cutaneous Adverse Reaction SCAR (SJS+TEN+DRESS) (3Pe, 0Era, 365W)
-229: [P] Progressive multifocal leukoencephalopathy
-230: [P] Autoimmune hepatitis (1Pe, 0Era, 365W)
-231: [P] Erythema multiforme (3Pe, 0Era, 365W)
-232: [P] Paresthesia (3Pe, 0Era, 365W)
-233: [P] Hemorrhagic stroke (1Pe, 0Era, 180W)
-234: [P] Appendicitis (1Pe, 0Era, 365W)
-235: [P] Guillain Barre syndrome (180Pe, FP)
-236: [P] Idiopathic Peripheral Neuropathy (1Pe, 0Era, 365W)
-237: [P] Kawasaki disease (1Pe, 0Era, 365W)
-238: [P] Optic Neuritis (7Pe, 0Era, 365W)
-239: [P] Narcolepsy events (1Pe, 0Era, 365W)
-240: [P] Muscle weakness or monoplegia (1Pe, 0Era, 365W)
-241: [P] Urticaria (1Pe, 0Era, 30W)
-243: [P] Tinnitus (1Pe, 0Era, 365W)
-244: [P] Dizziness (1Pe, 0Era, 180W)
-245: [P] Hepatic Thrombosis (90Pe, 0Era)
-246: [P] Portal vein thrombosis (90Pe, 0Era)
-247: [P] Deep Vein Thrombosis DVT (90Pe, 0Era)
-248: [P] Disseminated intravascular coagulation DIC (1Pe, 0Era, 365W)
-249: [P] Ischemic (Non-hemorrhagic) Stroke (1Pe, 0Era, 365W)
-
-
- -

New Cohorts: 43 were added. 205: [P] Acute pancreatitis (7Pe, 0Era, 365W) 206: [P] Drug Induced Acute pancreatitis (7Pe, 365W) 207: [P] Acquired Pure Red Cell Aplasia 208: [P] Neutropenic Fever (3Pe, 30Era) 209: [P] Hemolytic Anemia, Extra corpuscular Acquired - G6PD deficiency excluded (7Pe, 0Era, 365W) 210: [P] Hemolytic Anemia, Extra corpuscular Acquired (7Pe, 0Era, 365W) 211: [P] Pancytopenia, Acquired 213: [P] Acquired Neutropenia or unspecified leukopenia (21Pe, 365Era) 214: [P] Acquired Isolated Neutropenia or unspecified leukopenia (21Pe, 365Era) 215: [P] Isolated Immune Thrombocytopenia (180Pe, 365Era) 216: [P] Isolated Immune Thrombocytopenia in absence of common thrombocytopenia causes (180Pe, 365Era) 217: [P] Thrombotic microangiopathy or Microangiopathic hemolytic anemia 218: [P] Rhabdomyolysis (3Pe, 0Era, 180W) 219: [P] Sudden Cardiac arrest or cardiac death 220: [P] Angioedema (3Pe, 0Era, 180W) 221: [P] Anaphylaxis Non Environmental exposure related (1Pe, 0Era, 180W) 222: [P] Stevens-Johnson syndrome, toxic epidermal necrolysis spectrum 223: [P] Posterior reversible encephalopathy syndrome (PRES) 224: [P] Long QT Syndrome or QT prolonged (Acquired) 225: [P] Drug-induced Lupus (7Pe, 0Era, 365W) 226: [P] Drug Rash with Eosinophilia and Systemic Symptoms DRESS (1Pe, 0Era, 365W) 227: [P] Severe Cutaneous Adverse Reaction SCAR (SJS+TEN+DRESS+EM) (3Pe, 0Era, 365W) 228: [P] Severe Cutaneous Adverse Reaction SCAR (SJS+TEN+DRESS) (3Pe, 0Era, 365W) 229: [P] Progressive multifocal leukoencephalopathy 230: [P] Autoimmune hepatitis (1Pe, 0Era, 365W) 231: [P] Erythema multiforme (3Pe, 0Era, 365W) 232: [P] Paresthesia (3Pe, 0Era, 365W) 233: [P] Hemorrhagic stroke (1Pe, 0Era, 180W) 234: [P] Appendicitis (1Pe, 0Era, 365W) 235: [P] Guillain Barre syndrome (1Pe, 0Era, 365W) 236: [P] Idiopathic Peripheral Neuropathy (1Pe, 0Era, 365W) 237: [P] Kawasaki disease (1Pe, 0Era, 365W) 238: [P] Optic Neuritis (7Pe, 0Era, 365W) 239: [P] Narcolepsy events (1Pe, 0Era, 365W) 240: [P] Muscle weakness or monoplegia (1Pe, 0Era, 365W) 241: [P] Urticaria (1Pe, 0Era, 365W) 243: [P] Tinnitus (1Pe, 0Era, 365W) 244: [P] Dizziness (1Pe, 0Era, 365W) 245: [P] Hepatic Thrombosis (1Pe, 0Era, 365W) 246: [P] Portal vein thrombosis (1Pe, 0Era, 365W) 247: [P] Deep Vein Thrombosis DVT (1Pe, 0Era, 365W) 248: [P] Disseminated intravascular coagulation DIC (1Pe, 0Era, 365W) 249: [P] Ischemic (Non-hemorrhagic) Stroke (1Pe, 0Era, 365W) Deprecated Cohorts: No new cohorts were added in this release. Modified Cohorts: No cohorts were modified in this release.

-
-
- -

New Cohorts: No new cohorts were added in this release.

-

Modified Cohorts: 85 were modified. These are only name modifications. These cohorts have not undergone Peer review process. They are not considered accepted. However, because of grandfathered status (i.e. these cohorts existed in Phenotype Library prior to version 3.0, results for these cohorts are computed as part of PhenotypeLibraryDiagnostics study package - unless withdrawn). The Cohort JSON specifications were not changed.

-
2: [P] COVID-19 diagnosis or SARS-CoV-2 test (1pos) (3Ps, 7Era)
+
2: [W] COVID-19 diagnosis or SARS-CoV-2 test (1pos) (3Ps, 7Era)
 3: [P] Cough (3Ps, 30Era)
 4: [P] Diarrhea (7Ps, 30Era)
 5: [P] Dyspnea (14Pe, 30Era)
 6: [P] Fever (3Pe, 30Era)
-7: [P]Headache, Migraine, Neurologic pain (7Pe, 30Era)
+7: [P] Headache, Migraine or related Neurologic pain (7Pe, 30Era)
 8: [P] Anosmia OR Hyposmia OR Dysgeusia (7Ps, 180Era)
 9: [P] Sore throat (7Pe, 30Era)
 10: [P] Nausea or Vomiting (3Pe, 30Era)
 11: [P] Malaise or fatigue (3P, 30Era)
 12: [P] Rhinitis or common cold (7P, 30Era)
-13: [P] Myalgia (not including secondary causes) (3Pe, 30Era)
+13: [P] Myalgia (not explained by injury, ischemia or systemic inflammation) (3Pe, 30Era)
 14: [P] Myalgia (3Pe, 30Era)
-15: [P] Exposure to Viral Disease (7Pe, 30Era)
-16: [P] Exposure to SARS-Cov 2 and coronavirus (7Pe, 30Era)
-17: [P] Exposure to SARS-Cov 2 (7Pe, 30Era)
+15: [W] Exposure to Viral Disease (7Pe, 30Era)
+16: [W] Exposure to SARS-Cov 2 and coronavirus (7Pe, 30Era)
+17: [W] Exposure to SARS-Cov 2 (7Pe, 30Era)
 18: [P] Multiple Inflammatory Syndrome (30Pe, 30Era)
-19: [P] Pneumonia (14Pe, 30Era)
+19: [P] Acute Typical Pneumonia (14Pe, 30Era)
 20: [P] Bronchitis (14Pe, 90Era)
 21: [P] Acute respiratory distress syndrome (ARDS) or Acute Respiratory Failure (3Pe, 30Era)
-22: [P] SARS-CoV-2 testing (1Ps, 0Era)
-23: [P] Hospitalization (1Pe, 30Era)
-24: [P] Emergency room visits (0Pe, 0Era)
-25: [P] All cause mortality
-26: [P] Asthma or Chronic obstructive pulmonary disease (COPD) (FP)
-27: [P] Asthma without COPD (FP)
-28: [P] Chronic obstructive pulmonary disease (COPD) without asthma (FP)
-30: [P] Tuberculosis (FP)
-31: [P] Malignant neoplasm excluding non-melanoma skin cancer (FP)
-32: [P] Obesity (FP)
-33: [P] Dementia (FP)
-34: [P] Hypertension (FP)
-36: [P] Human immunodeficiency virus infection (FP)
-37: [P] Hepatitis C (FP)
-38: [P] Heart disease (FP)
+22: [W] SARS-CoV-2 testing (1Ps, 0Era)
+26: [P] Asthma or Chronic obstructive pulmonary disease (COPD) (FP)
+27: [P] Asthma without COPD (FP)
+28: [P] Chronic obstructive pulmonary disease (COPD) without asthma (FP)
+29: [W] Autoimmune condition (FP)
+30: [P] Tuberculosis (FP)
+31: [P] Malignant neoplasm excluding non-melanoma skin cancer (FP)
+32: [P] Obesity (FP)
+33: [P] Dementia (FP)
+34: [P] Hypertensive disorder or hypertensive complications (FP)
+35: [W] Chronic kidney disease (FP)
+36: [P] Human immunodeficiency virus (not HIV2) infection (FP)
+37: [P] Hepatitis C (FP)
+38: [P] Heart disease (FP)
+39: [W] End stage renal disease (FP)
 40: [P] Diabetes Mellitus Type 2 (FP)
-43: [P] Tuberculosis broad (FP)
-45: [P] COVID-19 diagnosis with SARS-Cov-2 test (-3d to 3d) (3Pe, 21Era)
-46: [P] COVID-19 diagnosis and SARS-CoV-2 test (1pos) within 3d (3Pe, 21Era)
-47: [P] COVID-19 diagnosis and SARS-CoV-2 test (1pos) (0neg) within 3d (3Pe, 21Era)
-48: [P] COVID-19 diagnosis and SARS-CoV-2 test (0pos upto 3d, 1neg within 3d) (3Pe, 7Era)
-51: [P] SARS-CoV-2 test positive result (0Ps, 0Era)
-52: [P] SARS-CoV-2 test negative result (0Ps, 0Era)
-53: [P] SARS-CoV-2 test positive or negative result - keep persons with positive (0Ps, 0Era)
-54: [P] Febrile seizure (1Ps, 0Era)
-55: [P] COVID-19 diagnosis or SARS-CoV-2 test (1pos) (3Ps, 21Era)
-56: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (0 neg -3d to 3d) (3Ps, 21Era)
-57: [P] Bleeding (1Ps, 30Era)
-58: [P] SARS-CoV-2 test positive result (3Ps, 21Era)
-59: [P] COVID-19 diagnosis with no SARS-CoV-2 test (3Ps, 21Era)
-60: [P] SARS-CoV-2 test positive and negative result (0Ps, 0Era)
-61: [P] Bradycardia or heart block with inpatient admission (1Pe, 30Era)
-62: [P] Generalized Seizure (1Ps, 0Era)
-63: [P] Transverse myelitis (or symptoms with transverse myelitis) 365dWO (1Ps, 0Era)
-64: [P] Flu-like symptoms (3P, 30Era)
-65: [P] Acute pancreatitis with inpatient admission (3Pe, 30Era)
-66: [P] Acute renal failure with inpatient admission (3Pe, 30Era)
-67: [P] Hepatic failure with inpatient admission (3Pe, 30Era)
-68: [P] Heart failure with inpatient admission (3Pe, 30Era)
-69: [P] Angioedema with inpatient admission (7Ps, 30Era)
-70: [P] Stroke (ischemic or hemorrhagic) with inpatient admission (7Ps, 30Era)
-71: [P] Acute myocardial infarction with inpatient admission (7Ps, 180Era)
-72: [P] Influenza (narrow) (7Pe, 90Era)
-74: [P] Hemorrhagic stroke (intracerebral bleeding) with inpatient admission (7Ps, 180Era)
-75: [P] Ischemic stroke with inpatient admission (7Ps, 180Era)
-76: [P] Transient ischemic attack with inpatient admission (7Ps, 30Era)
-77: [P] Gastrointestinal bleeding with inpatient admission (7Ps, 30Era)
-78: [P] Cardiac arrhythmia with inpatient admission (1Pe, 30Era)
-79: [P] Dialysis with inpatient admission (1Ps, 7Era)
-80: [P] Extracorporeal Membrane Oxygenation with inpatient admission (1Ps, 30Era)
-81: [P] Cesarean section (7Pe, 180Era)
-82: [P] Intensive services during hospitalization (1Ps, 30Era)
-84: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (1pos or 0 neg 0d to 3d) (3Ps, 180Era)
-85: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (1pos or 0 neg 0d to 3d) (3Ps, 21Era)
-86: [P] SARS-CoV-2 test positive or negative result (0Ps, 0Era)
-87: [P] SARS-CoV-2 test (1Ps, 0Era)
-95: [P] Delirium (FP)
-189: [P] Right Upper Quadrant Pain (Pe1, 3Era)
-190: [P] Abdominal Distension (Pe1, 7Era)
-191: [P] Fatigue, Malaise, Lethargy, Anorexia (Pe1, 1Era)
-192: [P] Nausea or Vomiting (Pe1, 7Era)
-193: [P] Jaundice or Itching (Pe1, 7Era)
-194: [P] Encephalopathy or its presentations (Pe1, 7Era)
-195: [P] Urothelial bladder cancer (FP)
-197: [P] Coronary Artery Disease from vessel disease to ischemic injury (FP)
+41: [W] Chronic kidney disease broad (FP) +42: [W] End stage renal disease broad (FP) +43: [P] Respiratory or pulmonary tuberculosis (FP) +44: [W] COVID-19 diagnosis (3Pe, 7Era) +45: [W] COVID-19 diagnosis with SARS-Cov-2 test (-3d to 3d) (3Pe, 21Era) +46: [W] COVID-19 diagnosis and SARS-CoV-2 test (1pos) within 3d (3Pe, 21Era) +47: [W] COVID-19 diagnosis and SARS-CoV-2 test (1pos) (0neg) within 3d (3Pe, 21Era) +48: [W] COVID-19 diagnosis and SARS-CoV-2 test (0pos upto 3d, 1neg within 3d) (3Pe, 7Era) +51: [W] SARS-CoV-2 test positive result (0Ps, 0Era) +52: [W] SARS-CoV-2 test negative result (0Ps, 0Era) +53: [W] SARS-CoV-2 test positive or negative result - keep persons with positive (0Ps, 0Era) +54: [P] Febrile seizure (1Pe, 0Era, 42W) +55: [W] COVID-19 diagnosis or SARS-CoV-2 test (1pos) (3Ps, 21Era) +56: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (0 neg -3d to 3d) (3Ps, 21Era) +57: [P] Bleeding (1Pe, 0Era, 30W) +58: [W] SARS-CoV-2 test positive result (3Ps, 21Era) +59: [W] COVID-19 diagnosis with no SARS-CoV-2 test (3Ps, 21Era) +60: [W] SARS-CoV-2 test positive and negative result (0Ps, 0Era) +61: [P] Bradycardia or heart block with inpatient admission (1Pe, 30Era) +62: [P] Generalized Seizure (1Pe, 0Era, 42W) +63: [P] Transverse myelitis or symptoms (1Ps, 0Era, 365W) +64: [W] Flu-like symptoms fever, cough, malaise, fatigue, dyspnea, myalgia (3P, 30Era) +65: [W] Acute pancreatitis with inpatient admission (3Pe, 30Era) +66: [W] Acute renal failure with inpatient admission (3Pe, 30Era) +67: [W] Hepatic failure with inpatient admission (3Pe, 30Era) +68: [W] Heart failure with inpatient admission (3Pe, 30Era) +69: [W] Angioedema with inpatient admission (7Ps, 30Era) +70: [P] Stroke (ischemic or hemorrhagic) with inpatient admission (7Ps, 30Era) +71: [P] Acute myocardial infarction with inpatient admission (7Ps, 180Era) +72: [P] Influenza diagnosis or positive test result (7Pe, 90Era) +73: [W] Pregnancy (270P, 0Era) +74: [P] Hemorrhagic stroke (intracerebral bleeding) with inpatient admission (7Ps, 180Era) +75: [P] Ischemic stroke with inpatient admission (7Ps, 180Era) +76: [P] Transient ischemic attack with inpatient admission (7Ps, 30Era) +77: [P] Gastrointestinal bleeding with inpatient admission (7Ps, 30Era) +78: [P] Cardiac arrhythmia with inpatient admission (1Pe, 30Era) +79: [P] Dialysis with inpatient admission (1Ps, 7Era) +80: [P] Extracorporeal Membrane Oxygenation with inpatient admission (1Pe, 30Era) +81: [P] Cesarean section (7Pe, 180Era) +82: [P] Intensive services during hospitalization (1Ps, 30Era) +84: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (1pos or 0 neg 0d to 3d) (3Ps, 180Era) +85: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (1pos or 0 neg 0d to 3d) (3Ps, 21Era) +86: [W] SARS-CoV-2 test positive or negative result (0Ps, 0Era) +87: [W] SARS-CoV-2 test (1Ps, 0Era) +95: [P] Delirium (FP) +123: [W] First event of Suicide attempt, including injuries and poisonings with undetermined, 365 days +189: [P] Right Upper Quadrant Pain (Pe1, 0Era, 14W) +190: [P] Abdominal Distension (Pe1, 0Era, 14W) +191: [P] Fatigue, Malaise, Lethargy, Anorexia (Pe1, 0Era, 14W) +192: [P] Nausea or Vomiting (Pe1, 0Era, 7W) +193: [P] Jaundice or Itching (Pe1, 0Era, 14W) +194: [P] Encephalopathy or its presentations (Pe1, 0Era, 30W) +195: [P] Urothelial bladder cancer (FP) +197: [P] Coronary Artery Disease from vessel disease to ischemic injury (FP) +205: [W] Acute pancreatitis (7Pe, 0Era, 365W) +206: [W] Drug Induced Acute pancreatitis (7Pe, 365W) +207: [P] Acquired Pure Red Cell Aplasia +208: [P] Neutropenic Fever (3Pe, 30Era) +209: [P] Hemolytic Anemia, Extra corpuscular Acquired - G6PD deficiency excluded (7Pe, 0Era, 365W) +210: [P] Hemolytic Anemia, Extra corpuscular Acquired (7Pe, 0Era, 365W) +211: [P] Pancytopenia, Acquired +213: [P] Acquired Neutropenia or unspecified leukopenia (21Pe, 365Era) +214: [P] Acquired Isolated Neutropenia or unspecified leukopenia (21Pe, 365Era) +215: [P] Isolated Immune Thrombocytopenia (180Pe, 365Era) +216: [P] Isolated Immune Thrombocytopenia in absence of common thrombocytopenia causes (180Pe, 365Era) +217: [P] Thrombotic microangiopathy (TMA) or Microangiopathic hemolytic anemia (MAHA) +218: [P] Rhabdomyolysis (3Pe, 0Era, 180W) +219: [P] Sudden Cardiac arrest or cardiac death +220: [P] Angioedema (3Pe, 0Era, 180W) +221: [P] Anaphylaxis Non Environmental exposure related (1Pe, 0Era, 180W) +222: [P] Stevens-Johnson syndrome, toxic epidermal necrolysis spectrum +223: [P] Posterior reversible encephalopathy syndrome PRES (FP) +224: [P] Long QT Syndrome or QT prolonged (Acquired) +225: [P] Drug-induced Lupus (180Pe, 0Era, 365W) +226: [P] Drug Rash with Eosinophilia and Systemic Symptoms DRESS (1Pe, 0Era, 365W) +227: [P] Severe Cutaneous Adverse Reaction SCAR (SJS+TEN+DRESS+EM) (3Pe, 0Era, 365W) +228: [P] Severe Cutaneous Adverse Reaction SCAR (SJS+TEN+DRESS) (3Pe, 0Era, 365W) +229: [P] Progressive multifocal leukoencephalopathy +230: [P] Autoimmune hepatitis (1Pe, 0Era, 365W) +231: [P] Erythema multiforme (3Pe, 0Era, 365W) +232: [P] Paresthesia (3Pe, 0Era, 365W) +233: [P] Hemorrhagic stroke (1Pe, 0Era, 180W) +234: [P] Appendicitis (1Pe, 0Era, 365W) +235: [P] Guillain Barre syndrome (180Pe, FP) +236: [P] Idiopathic Peripheral Neuropathy (1Pe, 0Era, 365W) +237: [P] Kawasaki disease (1Pe, 0Era, 365W) +238: [P] Optic Neuritis (7Pe, 0Era, 365W) +239: [P] Narcolepsy events (1Pe, 0Era, 365W) +240: [P] Muscle weakness or monoplegia (1Pe, 0Era, 365W) +241: [P] Urticaria (1Pe, 0Era, 30W) +243: [P] Tinnitus (1Pe, 0Era, 365W) +244: [P] Dizziness (1Pe, 0Era, 180W) +245: [P] Hepatic Thrombosis (90Pe, 0Era) +246: [P] Portal vein thrombosis (90Pe, 0Era) +247: [P] Deep Vein Thrombosis DVT (90Pe, 0Era) +248: [P] Disseminated intravascular coagulation DIC (1Pe, 0Era, 365W) +249: [P] Ischemic (Non-hemorrhagic) Stroke (1Pe, 0Era, 365W)
+
+
+ +

New Cohorts: 43 were added. 205: [P] Acute pancreatitis (7Pe, 0Era, 365W) 206: [P] Drug Induced Acute pancreatitis (7Pe, 365W) 207: [P] Acquired Pure Red Cell Aplasia 208: [P] Neutropenic Fever (3Pe, 30Era) 209: [P] Hemolytic Anemia, Extra corpuscular Acquired - G6PD deficiency excluded (7Pe, 0Era, 365W) 210: [P] Hemolytic Anemia, Extra corpuscular Acquired (7Pe, 0Era, 365W) 211: [P] Pancytopenia, Acquired 213: [P] Acquired Neutropenia or unspecified leukopenia (21Pe, 365Era) 214: [P] Acquired Isolated Neutropenia or unspecified leukopenia (21Pe, 365Era) 215: [P] Isolated Immune Thrombocytopenia (180Pe, 365Era) 216: [P] Isolated Immune Thrombocytopenia in absence of common thrombocytopenia causes (180Pe, 365Era) 217: [P] Thrombotic microangiopathy or Microangiopathic hemolytic anemia 218: [P] Rhabdomyolysis (3Pe, 0Era, 180W) 219: [P] Sudden Cardiac arrest or cardiac death 220: [P] Angioedema (3Pe, 0Era, 180W) 221: [P] Anaphylaxis Non Environmental exposure related (1Pe, 0Era, 180W) 222: [P] Stevens-Johnson syndrome, toxic epidermal necrolysis spectrum 223: [P] Posterior reversible encephalopathy syndrome (PRES) 224: [P] Long QT Syndrome or QT prolonged (Acquired) 225: [P] Drug-induced Lupus (7Pe, 0Era, 365W) 226: [P] Drug Rash with Eosinophilia and Systemic Symptoms DRESS (1Pe, 0Era, 365W) 227: [P] Severe Cutaneous Adverse Reaction SCAR (SJS+TEN+DRESS+EM) (3Pe, 0Era, 365W) 228: [P] Severe Cutaneous Adverse Reaction SCAR (SJS+TEN+DRESS) (3Pe, 0Era, 365W) 229: [P] Progressive multifocal leukoencephalopathy 230: [P] Autoimmune hepatitis (1Pe, 0Era, 365W) 231: [P] Erythema multiforme (3Pe, 0Era, 365W) 232: [P] Paresthesia (3Pe, 0Era, 365W) 233: [P] Hemorrhagic stroke (1Pe, 0Era, 180W) 234: [P] Appendicitis (1Pe, 0Era, 365W) 235: [P] Guillain Barre syndrome (1Pe, 0Era, 365W) 236: [P] Idiopathic Peripheral Neuropathy (1Pe, 0Era, 365W) 237: [P] Kawasaki disease (1Pe, 0Era, 365W) 238: [P] Optic Neuritis (7Pe, 0Era, 365W) 239: [P] Narcolepsy events (1Pe, 0Era, 365W) 240: [P] Muscle weakness or monoplegia (1Pe, 0Era, 365W) 241: [P] Urticaria (1Pe, 0Era, 365W) 243: [P] Tinnitus (1Pe, 0Era, 365W) 244: [P] Dizziness (1Pe, 0Era, 365W) 245: [P] Hepatic Thrombosis (1Pe, 0Era, 365W) 246: [P] Portal vein thrombosis (1Pe, 0Era, 365W) 247: [P] Deep Vein Thrombosis DVT (1Pe, 0Era, 365W) 248: [P] Disseminated intravascular coagulation DIC (1Pe, 0Era, 365W) 249: [P] Ischemic (Non-hemorrhagic) Stroke (1Pe, 0Era, 365W) Deprecated Cohorts: No new cohorts were added in this release. Modified Cohorts: No cohorts were modified in this release.

+
+
+ +

New Cohorts: No new cohorts were added in this release.

+

Modified Cohorts: 85 were modified. These are only name modifications. These cohorts have not undergone Peer review process. They are not considered accepted. However, because of grandfathered status (i.e. these cohorts existed in Phenotype Library prior to version 3.0, results for these cohorts are computed as part of PhenotypeLibraryDiagnostics study package - unless withdrawn). The Cohort JSON specifications were not changed.

+
2: [P] COVID-19 diagnosis or SARS-CoV-2 test (1pos) (3Ps, 7Era)
+3: [P] Cough (3Ps, 30Era)
+4: [P] Diarrhea (7Ps, 30Era)
+5: [P] Dyspnea (14Pe, 30Era)
+6: [P] Fever (3Pe, 30Era)
+7: [P]Headache, Migraine, Neurologic pain (7Pe, 30Era)
+8: [P] Anosmia OR Hyposmia OR Dysgeusia (7Ps, 180Era)
+9: [P] Sore throat (7Pe, 30Era)
+10: [P] Nausea or Vomiting (3Pe, 30Era)
+11: [P] Malaise or fatigue (3P, 30Era)
+12: [P] Rhinitis or common cold (7P, 30Era)
+13: [P] Myalgia (not including secondary causes) (3Pe, 30Era)
+14: [P] Myalgia (3Pe, 30Era)
+15: [P] Exposure to Viral Disease (7Pe, 30Era)
+16: [P] Exposure to SARS-Cov 2 and coronavirus (7Pe, 30Era)
+17: [P] Exposure to SARS-Cov 2 (7Pe, 30Era)
+18: [P] Multiple Inflammatory Syndrome (30Pe, 30Era)
+19: [P] Pneumonia (14Pe, 30Era)
+20: [P] Bronchitis (14Pe, 90Era)
+21: [P] Acute respiratory distress syndrome (ARDS) or Acute Respiratory Failure (3Pe, 30Era)
+22: [P] SARS-CoV-2 testing (1Ps, 0Era)
+23: [P] Hospitalization (1Pe, 30Era)
+24: [P] Emergency room visits (0Pe, 0Era)
+25: [P] All cause mortality
+26: [P] Asthma or Chronic obstructive pulmonary disease (COPD) (FP)
+27: [P] Asthma without COPD (FP)
+28: [P] Chronic obstructive pulmonary disease (COPD) without asthma (FP)
+30: [P] Tuberculosis (FP)
+31: [P] Malignant neoplasm excluding non-melanoma skin cancer (FP)
+32: [P] Obesity (FP)
+33: [P] Dementia (FP)
+34: [P] Hypertension (FP)
+36: [P] Human immunodeficiency virus infection (FP)
+37: [P] Hepatitis C (FP)
+38: [P] Heart disease (FP)
+40: [P] Diabetes Mellitus Type 2 (FP)
+43: [P] Tuberculosis broad (FP)
+45: [P] COVID-19 diagnosis with SARS-Cov-2 test (-3d to 3d) (3Pe, 21Era)
+46: [P] COVID-19 diagnosis and SARS-CoV-2 test (1pos) within 3d (3Pe, 21Era)
+47: [P] COVID-19 diagnosis and SARS-CoV-2 test (1pos) (0neg) within 3d (3Pe, 21Era)
+48: [P] COVID-19 diagnosis and SARS-CoV-2 test (0pos upto 3d, 1neg within 3d) (3Pe, 7Era)
+51: [P] SARS-CoV-2 test positive result (0Ps, 0Era)
+52: [P] SARS-CoV-2 test negative result (0Ps, 0Era)
+53: [P] SARS-CoV-2 test positive or negative result - keep persons with positive (0Ps, 0Era)
+54: [P] Febrile seizure (1Ps, 0Era)
+55: [P] COVID-19 diagnosis or SARS-CoV-2 test (1pos) (3Ps, 21Era)
+56: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (0 neg -3d to 3d) (3Ps, 21Era)
+57: [P] Bleeding (1Ps, 30Era)
+58: [P] SARS-CoV-2 test positive result (3Ps, 21Era)
+59: [P] COVID-19 diagnosis with no SARS-CoV-2 test (3Ps, 21Era)
+60: [P] SARS-CoV-2 test positive and negative result (0Ps, 0Era)
+61: [P] Bradycardia or heart block with inpatient admission (1Pe, 30Era)
+62: [P] Generalized Seizure (1Ps, 0Era)
+63: [P] Transverse myelitis (or symptoms with transverse myelitis) 365dWO (1Ps, 0Era)
+64: [P] Flu-like symptoms (3P, 30Era)
+65: [P] Acute pancreatitis with inpatient admission (3Pe, 30Era)
+66: [P] Acute renal failure with inpatient admission (3Pe, 30Era)
+67: [P] Hepatic failure with inpatient admission (3Pe, 30Era)
+68: [P] Heart failure with inpatient admission (3Pe, 30Era)
+69: [P] Angioedema with inpatient admission (7Ps, 30Era)
+70: [P] Stroke (ischemic or hemorrhagic) with inpatient admission (7Ps, 30Era)
+71: [P] Acute myocardial infarction with inpatient admission (7Ps, 180Era)
+72: [P] Influenza (narrow) (7Pe, 90Era)
+74: [P] Hemorrhagic stroke (intracerebral bleeding) with inpatient admission (7Ps, 180Era)
+75: [P] Ischemic stroke with inpatient admission (7Ps, 180Era)
+76: [P] Transient ischemic attack with inpatient admission (7Ps, 30Era)
+77: [P] Gastrointestinal bleeding with inpatient admission (7Ps, 30Era)
+78: [P] Cardiac arrhythmia with inpatient admission (1Pe, 30Era)
+79: [P] Dialysis with inpatient admission (1Ps, 7Era)
+80: [P] Extracorporeal Membrane Oxygenation with inpatient admission (1Ps, 30Era)
+81: [P] Cesarean section (7Pe, 180Era)
+82: [P] Intensive services during hospitalization (1Ps, 30Era)
+84: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (1pos or 0 neg 0d to 3d) (3Ps, 180Era)
+85: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (1pos or 0 neg 0d to 3d) (3Ps, 21Era)
+86: [P] SARS-CoV-2 test positive or negative result (0Ps, 0Era)
+87: [P] SARS-CoV-2 test (1Ps, 0Era)
+95: [P] Delirium (FP)
+189: [P] Right Upper Quadrant Pain (Pe1, 3Era)
+190: [P] Abdominal Distension (Pe1, 7Era)
+191: [P] Fatigue, Malaise, Lethargy, Anorexia (Pe1, 1Era)
+192: [P] Nausea or Vomiting (Pe1, 7Era)
+193: [P] Jaundice or Itching (Pe1, 7Era)
+194: [P] Encephalopathy or its presentations (Pe1, 7Era)
+195: [P] Urothelial bladder cancer (FP)
+197: [P] Coronary Artery Disease from vessel disease to ischemic injury (FP)

Withdrawn Cohorts: 13 were withdrawn prior to peer review. These cohorts have not undergone Peer review process. They are not considered accepted. It has been withdrawn prior to peer review. The Cohort JSON specifications were not changed. 29: [W] Autoimmune condition (FP) 35: [W] Chronic kidney disease (FP) 39: [W] End stage renal disease (FP) 41: [W] Chronic kidney disease broad (FP) 42: [W] End stage renal disease broad (FP) 44: [W] COVID-19 diagnosis (3Pe, 7Era) 73: [W] Pregnancy (270P, 0Era) 123: [W] First event of Suicide attempt, including injuries and poisonings with undetermined, 365 days 196: [W] Rheumatoid arthritis (FP) 198: [W] Crohns disease (FP) 199: [W] Major Depressive Disorder (FP) 200: [W] Plaque psoriasis (FP) 201: [W] Ulcerative colitis (FP)

diff --git a/docs/pkgdown.yml b/docs/pkgdown.yml index bb6bc216..69be0642 100644 --- a/docs/pkgdown.yml +++ b/docs/pkgdown.yml @@ -15,5 +15,5 @@ articles: ReservedWordsWithSpecialMeaningToPhenotypers: ReservedWordsWithSpecialMeaningToPhenotypers.html SubmittedCohortDefinitions: SubmittedCohortDefinitions.html ValidityChecksForCohortDefinitions: ValidityChecksForCohortDefinitions.html -last_built: 2023-10-16T14:15Z +last_built: 2023-10-19T20:58Z diff --git a/docs/reference/PhenotypeLibrary-package.html b/docs/reference/PhenotypeLibrary-package.html index ef39cfc1..3e267ffb 100644 --- a/docs/reference/PhenotypeLibrary-package.html +++ b/docs/reference/PhenotypeLibrary-package.html @@ -17,7 +17,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0
diff --git a/docs/reference/getPhenotypeLog.html b/docs/reference/getPhenotypeLog.html index e64a4e0c..0b79e16e 100644 --- a/docs/reference/getPhenotypeLog.html +++ b/docs/reference/getPhenotypeLog.html @@ -17,7 +17,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 diff --git a/docs/reference/getPlCohortDefinitionSet.html b/docs/reference/getPlCohortDefinitionSet.html index 20b2a37a..36abf8c4 100644 --- a/docs/reference/getPlCohortDefinitionSet.html +++ b/docs/reference/getPlCohortDefinitionSet.html @@ -17,7 +17,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 diff --git a/docs/reference/getPlConceptDefinitionSet.html b/docs/reference/getPlConceptDefinitionSet.html index 0031566f..4421d89a 100644 --- a/docs/reference/getPlConceptDefinitionSet.html +++ b/docs/reference/getPlConceptDefinitionSet.html @@ -17,7 +17,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 diff --git a/docs/reference/index.html b/docs/reference/index.html index 204a7b3b..f2eb2129 100644 --- a/docs/reference/index.html +++ b/docs/reference/index.html @@ -17,7 +17,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 diff --git a/docs/reference/listPhenotypes.html b/docs/reference/listPhenotypes.html index de5ca314..64ad67b9 100644 --- a/docs/reference/listPhenotypes.html +++ b/docs/reference/listPhenotypes.html @@ -17,7 +17,7 @@ PhenotypeLibrary - 3.29.0 + 3.30.0 @@ -117,7 +117,7 @@

Value

Examples

listPhenotypes()
 #> Warning: listPhenotypes is deprecated. use getPhenotypeLog
-#> # A tibble: 563 x 81
+#> # A tibble: 571 x 81
 #>    cohortId cohortName        cohortNameAtlas cohortNameFormatted cohortNameLong
 #>       <dbl> <chr>             <chr>           <chr>               <chr>         
 #>  1        3 Cough or Sputum   [P] Cough or S~ Cough or Sputum     Cough or Sput~
@@ -130,7 +130,7 @@ 

Examples

#> 8 10 Nausea or Vomiti~ [P] Nausea or ~ Nausea or Vomiting Nausea or Vom~ #> 9 11 Malaise and or f~ [P] Malaise an~ Malaise and or fat~ Malaise and o~ #> 10 12 Rhinitis or comm~ [P] Rhinitis o~ Rhinitis or common~ Rhinitis or c~ -#> # i 553 more rows +#> # i 561 more rows #> # i 76 more variables: librarian <chr>, status <chr>, addedVersion <chr>, #> # logicDescription <chr>, hashTag <chr>, isCirceJson <dbl>, #> # contributors <chr>, contributorOrcIds <chr>, diff --git a/extras/PhenotypeLibrary.pdf b/extras/PhenotypeLibrary.pdf index 281b5512bb7795c4c73559f502ec5ce0048e4516..b07648f0406c70b3bbe339247a17abc193a6f9a1 100644 GIT binary patch delta 18949 zcmV(uK5R?bA?*WMuBxn){8Y2<2U{(Zoqc3BEM_K-mm2wmoOZerj#3(gG(tS(M$_k9t9#iPEhIfP3yLZ06b!&Ns8W;) zDms5fArTRRL$HVujbo#0HjbkaK-iTeTauKcgfZCZ{ouVHK66$oBpk)D=&g}tROyA^ zT!dm8_vU7EOV{U*7dKaCIS^+aEq#78MyZ4554aILl1*Ew+6Rcmh@?Fph8RZJYs;KB zrYy}DnLgxmk`6w1R~ZrK8RH+6t+r zeCN*t!XOX0i}XUac~hBv-@(4FKmnpK0;paEJ8Q>>vJq3h?9ZNsWJK$bNudSvyKo!82%t$>sF0J z?bULn8tt{tQbg0C!sK(AKP(|*PCFS;79o~&E^Vr!In&6jXv{u#cUs+4b-919SS=p+ z?=*|7E)Qi}ies19n{`>rR{sNL0e63{v-`#1n?Pctbqk9Il@R`VFVKg&(#`Qe?HycK zxvX1xpvvK7$ilN#md}U!x>tC&=5^8zJ5%-Jv6S^E<*$7Lyo;0GF!Uzm?_>776yl(PN4uPMnw*9}1;S*gA#<%)?VHKO^n|j~^YuNd)MR(& zns~c1?uzNa->Er!3>Zkkr(AzBSWLcCf)S&{&FRU+0?gHNvgrZOaJqaP%KVN?n}p}< zaw?w};G?|YFnjJ2dJyTPYTLDZRuZG2E8~%%rb~62L&jia=rh<3zj*r`bm}zXJp`>* zRo!l%w8SsDA{X}W{^yG#X zd{DB93%i842<}3{7`$Wb4a40Q)iJ&JRly9ZFXUH@DHH*it8OHWJ)F_k!|#7YY@N&1 zb7tZ7=6_1JC}l@c+RXt&S%BKYgm|?@;a@2c?5Iu!<6^>-t{p<5wq5_KF60j@z1Kp7 z1&W_WxacKI#Oa9`-q;ko$&_+<>mx?go#-xSCw~Js_zUH;2MBtj12{4{l5i9SF*PmS{&W=_f_rDPT*Nz%iRseTfD}Xi7!3rRu zqN*pSECZmGQPu*;Sb?lu%^U!#9_9`}3xFcf!V2VOMF+5Uas@d2`v9g49`X5k8Sb_e{8swye{?>yaY&D{Tq?FRg-1~^&& zwX}4y@c5^sf9d|h{MEXf0YPp6cPnrAe}7_`TLCPAZq5#7K7V8X1#@-<{woa+Hz3I7 zKQmwixLVnmxmr3{xw-v?`HTHecmA_Z!2eRcnX|Kl&%eB#{$=$)a{#)#SvgoUBe1dm zjcMWjH?|EBguwF8tjK|^od9gC|CU>NIRA&v)5`T<4Wj*LX6XJVVP@$Ba_|9IT7Ow1 zuqZpZ{|yPC{l8jf0u%|If$F5$NFafAadT);d=IPWS%+Cg*PUw=H5Io4?es zGPC|$2y~MMdRtkl0^Kca0oG;?e}8-SFS!=T(#q8V2(tRi?Z4UzU}9rs{VzIATcCwK z=pPce{;jeCS^n1w{?hfY{8`j>BqTM}82&d4_Fsmoe+R)`)5rO5ZvUeiB`3@OdH4rL zT-?bU;K#(q%?n^+=VkkQ|NbV#$Ij{hzX|y-Ah!QJE19{w0=)qSf9qyt`+ryU|KsvixUsG~CTVmVc-1e+vFlTX?v-{w4We3*c|n|8f4;+*?_BTUj8iuQ*u< zgxFH9)@4vSd7b&GtYHm{H~W2ccJvTS+#%dO{=LJ zm%YOf|LEp$g}Z*D3#9NY3dEv(bVdoVNN!#zm7be};Yb8ebd` z@u($wMJ9uyglp#yx;Cw-?8s8KepsTVtTrnzTBe$wcC^qe4`(BR2$hsDO0;N0;PAs{4EEZdP+)V+%!tEi}+T^Rj&%p>fpdL?I^ z$i5%}MA~)>j(F9KUCqMSIy9_EMr&LzdcBvz)d3a9D}Fe-?6zYIDSwPyKGp9pzf+Cd z`we>gGNib^Auo!U&K?i7D3tBN`81E|$@X1>RVcs<$0-*CaDS%ipMRh%nb(iDv@jY( zpBVnECd}y)Ps{F);@(dYAkGFnUUTB?Q+tYN6{bxhhj~ZYqb$aaHekqq2Y)bOv0-&M zm9Nuqp}mST{WvMoBqB#G9|}eN}v)*@BgLgV6p8ky7ooRnX}iO-NNv zunLnMAh@MEo=HgF zzM3cugk^#9MgUYt{pDkl3R6Mti{#-ICy2w%1mq3G;oOT6^SO)Pv=JV(V}KXFP%AM* zWBuG)8Z49o3D-gsf`3;w$~#pIHT+H3@k{b3{BFN8e=SUZNx73w0%b94Aj4SRke3;! ziU~9Hhp8{)?wGsCzq4R<8mXE?l7nDGrTuhT-QKdr@TwezX9bz+R8)u3p67 zIe(7ys!oH@7xC-wX~YTnb`5RZeKwOaa^DnW&ExOpCMu`)bnKyCZ*6O&3MDDVeuyUT z-&Wv`cGPb_`MD$2&2Jyg3YkH+4zUzy()gUR!P$M*MG`_Ol1==GRrZimVWPgFG!z>AdiW6$m*-; z7X7hvoFTcA^|aXN;yOpe1s|3lB-H)ZurmCYt!w;}(>l`0V7PSNVnqm1_-}BOqX}E) zYuNguPwQKyEXMmiVu#pM7gEwO{q@r%taH1a7IC@Xk4!w`QAa*}khVFE8PN^v%YR~N zHDZ+LVeg*#ehxWX~O(b1vP<&hj*BgM7zKZw<&6IEPtA?znGuRjLE(kDI;ak;X|=ZG5hR~5WYTC)ZSepMB*?k z={&(eX+g*hVEI&+Fl`N(OgXI!`Z0kI3Fr*_)Z0sXE#)lzjoVB^4L>swTfiYJ1Vehb zzVLWXWOKada3+02QpapAR6_6;2+W?Vm;)F0K}bbUdmjHq)nO0&yML=*d*0l!cWvfA z^_wi%7KK@Z4Gq@sE0i|UMt#LoLr9uJrYBxCTP44xKJRxnZ&1H;V z9Yh8Pg3-A$y0+v%ot5lc^$r&}Z4u9asT{Y+Iazp_4U&<7Ro*M7z5S0|?VxV)VBM@P$++NiZpx>4@ zg(&2GN*+aK>Z2FnJa;kn#RHaEBK8W3AQ_0C8I1M(a%kFa>wo+sT;?p15vC!PG%uWl zTC1syABpr3zB!*K?0rac&_|ALxYYNP$>7QuSLF-P{bFHwWSwjp%b_+}t}#APj3k5N z7~m45u)qy4$p!SEy0jy1FiZ&wQEX=BNNZEot&gq_l{87h-zD%PbiP1xyx)QhcL%8m zv5n9g!%IwQM}JE)vBL|cbxNqRQUn`OnzjHonbogCn0BpNJ3nzbj(+YhZFq+5w9>i4>T=QG28O~U{1TJ7MB>Q-U z#yKPcQJIuni{L64FX4^9f5ir-8PWkhJ=rxFe~++>7=MmzaOKkUgUmLo%r?7^jvGgN zEE1!S+dZqqBa0W90;*U}qjK4?D9W?UBFF*j%cmI1@dcXM-QGM<)e*h#xo}nIm6yga zNTRZ#Et9@Ohs`QPZ#S4QNKCTvY0TgkIAx`r!8?e1PKTeIo|Uano`A_ES3GJe+c7t@ zK0q^4wtt9d#5|;SwteRGDH|QFVP82CqG!3fkt>#vd_BBe$C63p^!7PcnUokPK!S|s z@DrlZ;x5ZbmM130alloh2>!0p-6rZ9#xL=akvd*oX$p7b6iPGoqvn;+AL)jq5_kmx z4JD0Ih~YMmKxV&g1~$hZj?Cp~oyrXj@%rmIr+KZ);Q??vTEU}efP?Bz~w?ke2qN! z4(?BxM$;<6=cv1G>;(y4FyH=dx9k>MH6`8+@KRM#F#ar5hke_B!fv~;TRbOAw#q{E z4u8R$#A@Vv?+TO4BdpHGZ>N?=DF!H<~ti z8~r_7%I%OgvFLz|fKmPj2Di^6prtZV%|VCf*^fHNSEJmM-4vD~-f+gj?p#(%{p z8D@m~LZ<`6Q^58(ZL*zqjy5G@^c7tdQ zRYEhQsoxzQvt;HhvLxBFxye^YG2X)MWxxaXo74!g8E1f*CPI{W$YobN$bXb(9mx;B zM}t=VFgtWVw?#XywH8N{N&l>atGQsaCntdd)wysy+rS`kFQr4Z9di=tXIgwO4qm)L zGJFw;n-|gY$3!ac&`~`JObHm$Y_bW60UQaOj(Y$j+bi1gD|%Q^^Nwqx1P`h z-S2?w14v2{Us2B-Xjo4scz;nH%09ZGK~tXfCWi>7bQ^x>o{-YN*D}Bi-vXO2@xxBP zuv@aNcS^)O4PkSj-4QAq*Ue!)rVD3)In|b%EdkFzy1lG)IAfC%y(d>yuqTOaQlL+M z=}Gm~;I|*=A0jJU!H4izAj* zSjEYYrg>J(esV|}i+_1`G6dtrup^?{jv<)a81hY+K$?L36^wDuIyav)Difo*x8VF^ zLq3Wogd*>z-?)W;2;}l2Xq8xoF9b1TeB&8>Q@sVh>e2yIXCO0%jnyJdlm%cL`6~Hd z=W)VYM8@QM#$^LT?_e~7yY{g7dz=K>BQ~KB9A%z*RAh#3w14mk7QB88VgjBKcA}6M zHYU{VRm1hTP63liUsE%Z*HqF>b*%%4<^} z^7t1*9qT>cJ5umQekpuR>NGNMUBh~@9Qx@%x3iWmvwzyQ2;N+4MdQZ9(rBOGebPrt zLt6(?>%gzl7uGu9IO^`P6e?s;RuXqZCaYt7<5XNuo#$iGlMsY$-UL@roi4W_T_d%Q%_5g#Opypxk1dlz(X#gXB0O;Ii3ALyG0dzC|Eo z7dJAQW3wMq!*!H&!YSc7J+mD%AfBa1KE@Rj< zP;6{>%sN9^4GXwuMeP}XBx|Lz=f{!qaH;8ypj+uWla~?8a^(oRO>VCiVdrT*u5Ph+ z_oZJ@DaZodgg`;@l4wMsEq96d7xdKE^Nn@#zJEHld5Uy=PlpxNdZuh#jmGVtK^US_ z?7l`z@@*+{04V?VYoCr&-OD{HfP3G#7a3EwSBC*wyQP%*Qicll zQ${7k z@PBCtZxs)Tl;#dQfBcuf7~_L|zR)@Lj~4u7K$1e&nhJ;83|Uc8ChO;=z=ixRQOn%+Ar z%`~^4h)^MBC*43GTDBcE9`I~#N^jGCZ9LcQP>WM5u zgu&3iZS%n4AB8bR=rYa!D41y(Mm~eo9H>my>P4;VICtV$A}m?iuYT){!XtdooqyXP z>_Ss^L-mc?wfjbJ?Jq^#BEUS?#1HOCfj{&eUWvdrA4Thg|GpS>h?eEoP-7l&;Gg-=uAPL%wPR>O*Srb^#|cf^O0?T&i+mZ)?k*uXYJVhXT5W_+ z6#Wt0%Z@RqT`@UBY-rjGddib?qO0Z12?0;iTD$G))xrWYb<@TKb#wF(DkG6Pbo)T%I5sB)~ij7lD z9-?b!n}_0@vdUQF!H$K7d0%9Xm{!Q(3mm)K+Da!&SbDwfe|*Yq1<=BLj5H?ATCuY0`j`n)VDurDE2|f3GSGZeqQ(j#qN50C29Gs_ zKa0p(uu!TURHA9zkc>0#$c%n0LT4o8l;6dHg^qN!d({u)x*xT`TO3HqHG{_Im1YWd! zb107YzLC#s91Lt6*4h@&(jo>iA#Iqkw#*-G+*Iad${G2&nN(vK!1lGtK}hrV)7__Nf6 zZ!-j)I-0(HxhUa`(|c5-b0wpsR!mpd?mhB{zE-N_#y6kwLtu-HI0?kYd`5{o#sTzl zm#UOQC9zA@7k|ko!DM#hrC0my4C0|@RS78*zU)HncBNj5K5HyEzX-H@K@S^l`YHdw7uAq>;ogW(@vd7BjgAPN7W1eXwg~Q&2)X(DEFC0q!&T%tyyxt-fkdGkS`NKq} z)dAhI6f@$gAq6;Q@uSWN?3FN7G0^y2)f|0F**_;}T=U*>pYU+$B^Gt$Wn^%Xp==O_ zu_Q?0x_|hS3ri)3s@vS|;7`jf%^Xu-6m8kP_lCNOGUG}nrbCo_AS|N#jb?jJ^y@-t zlhebBuP%BJGmXNu#|Mhysp=z%hdQyyTInB?C3sI?S}4&exayjZa0tx^w_d>Obu=47*0W4rnG&3B zGu(~8&(s+7u*^SUq94UtfW8m|-^Qpb;+-$y#`OAN4jjBsnkp;~ytm$t&EIzzRwf}< zC4bdE9%Q&dUx8{Ze171QufE-z=RTpZGVP33?!aDSv=<6!M1*0ZA za?^I$4l+=tXo~6YA`Og#)VPSP+C$rFf0$_8Ka74l-645^eFeMjqDg@y##?SKX`zm@ zS-IrK7$q!1EC3#L(O#`gA{{YW;0$Zk@PAeT^w#|44&6G(Q{2lqv5VTVIl=T=a&ww2 z(&Q6r3C5FqY2T@)L_|?MBd$am{BQuH&@Bob;0)9C(UnmRxN{}qn?GIedXZ=G(ekxa z3L+^UB6l2eNMki#y{oknzRYg#fa||2tJ{M*G-&wJ)NNqW_Bx4tvGgNrUnYpX3x7n{ zg|s^e3dEeF&~b%azWhSr-W}IREELHGwR+~s_Gvxr zRo>JPN4n+6&cCXzazvsV#u&XMRk&S%q7^I22CLpthW8bD`yDM$hx97?uQjfJPL@Hj zzl9D`;iEi>6hl)hf?zzjXH^I<(L}B*B#Js-sA2nXxoFl~=zMqFwR5mVyMGbA^Ti;} zqO#bQ^fmJOBwEp-^YbI*wjI}?)SAb=er{9yFs`(Mz&$iuKezM6?CE7v`!vg2fk?D@ zw8MOmxz<&0SGGEC{igfk38~zc47}4K;Z>Ak{b}n+9$%bK3r8C4OmZXx@%iI6eRW}; z(36Y?*_84@lzT>~7mU2F(to6C*U@shFD*}5z_4;e1B6|JpD^=u9&h8s9wyLN19J7N zOsF~0Q`AU|=WQb*r&fVyYV=i6Vi14a8yJL;?6V8Dpl|FWyZjHN)jFifZVmAqpw)S5 z8l0LocFtnNlKV+Qe@uhLA+3n?>9Py@x$09FhQm`9Rms7%V&azWK7Yf$8yQ@D${QT> z{kaNZUxIA@qAq2=^;=f2rI<36>B0!JUV2!)9+362fBh+uFu1j&P{&43>90vUo~MMn zO!JZhCsx|$AYq4Hpn22vowDZx5B1Uz6(_5@G3C9Z_%U&-iL*z~0K}cx^I@Y(QedVH z8@l)f(Ho(FAyIm|(tpj=)$y#Rqv1;1!d5j<<>2~;#i+-75IrHN`1buv=A#C?=I-$L zxn|{lY(^`gOya<9a^}f3woQ z5>7q1?s0?wFmuzGK(Vpk&dKJ^$8)SFRmwF&?X6a01oA>*27l3GHxSN3U~-D|c{pDu z++f6s#8)kI$oGht zl+~o;UcgD(7K6+W?G%}%G3|lMgG))yM@r=^)e#>PIEAc5^%hV;n%|_pIv(gmP>Lfg z_NJsupFPL1iQ?oK0&BnCbtJUaWREPrts*Y9wbnPYjep()AtayZkohMS8Lgn>_E1gcS9UT%9D@KjgAe00HGQmh{-VCgn}h#-IMdI9ZlNXpR$zY3SmQH0%nz8d z-$gATbAMG^%lIJo`78PZ)vK&_^IPh7$hjbmNu9WQEb$^1$%|Y>=wnBsEGJDTfXk@o z;X1Mnyi?Sh`tyA#*FY~G`%oqY)z?fvYTyHhDVTr+3WEx$%~Z7NRT~rTZt0tiYF?Pb zDGrL)m_;?pjYU>*LYgER>W+evBN^m-M7f!u^nd)`*O42ZNnB#lMzk#u{&I5Y26J5f z>$ePCJK;a2q%yGY>Y0%8J}4&`tVy$d?MO)YpUx+(e*M=*`psRvGZ|$9@!YD<1iFLKtc>aOBCcg=UWG=r^jO6P zet+wScwd2UK=v|;Dl`A#=Gf>S^5NfHRE+2INXeYZ5aMpgAGkwLV4exF-L{! zw4itf5nW!lq!3J5La={g$8Sqh7m5qzO@FruYrxiton#dy?tQ)<>vA!+ zFSwMREy{xR8&wOfmZeV2nRc2JSU~A}_(y$(SGE1~l}8ciJg)Zv92X6)UqWAKduZhX zbB_XNj5!?>=uXgysQiYQRRV$y^y=B5gSQqK%#B?xDXDjuvr#)#cmp9xeNVo{iGSi! z)>K^+nnji{#rVbjl2$o&W-jLfrAMPx$6G!g&*C?kM=((9$~6)<&Ku$P{}V)#M<1<&539hVz*KK%^&d*wLVLxgp_<)qfPZm z1UuZ_1)Xx+cl`<_EFx%!-6JNW#uP|I# zVDt88G*SjD$j3JLcyVbhnX5r#q%#2UwzeU<=l<5Hf4cYEHv3Low0Slz6iTjuSklNf z9S+|t#&dosQx;E<7Yilo>wixl8V8?=&J%b{wTO?sNeGa8cg5K2=D~bX!VjVRge{oA z6i_XEU&y876=}0!!@Fhjv>Ii4W0*zb|E`h4xFQCG4}{c^Z9BrmhLWZe;b-6y6wHs^ zbyI^tk$?)2nf}>3EM7_T`OL#4M~^F6c-9Z0`S!5R!$a;p6Dh7gR)0xXM5i_W%QhCJ zujW&Za(}0jpLo7bO+lO-<((>uQ_!`-Urm%o@moGcZbnW{d1DBgO+g#poIY0WtF*3v znO`}WiO$d$IeN+Vdtq_>@JzP8qE15(v@^EcpYh*9F<4!37m7HBouS|iit7%1sPi+H z5AWC*meAj_OUB4tm4BU+D|?>$77Ffv9>h|zA>Zv8(#PFq%Dxinj{7^$74MKu^2UiJ z2CPuWIAP-V=JlhiJL@lVy0Y9N3?Z||678;!TI;5%v-Pr&^1TbML`9LW-kEWMz>0U$ z9xxuLsK)u_I*W=0y#;eVq>zKz{z=+YNWanwTeW-Gd)4mh{$4?~|{~kT_$Y@S7S7 zyH-;zgnvP0`X1wmonhWkZMJ2(FsxpLiE8Y#B&o$1e*Gcq;$1I3+`q;rD_MHfes&wS zc1oVS=?SbyBDK4G6v+Qd@lHqbar0YX!x_omEYvwx%1j)^hVp}$SGTvQI#)KD=~(4sDy z6XR*DqBwA;sTANf4dln(fMP#9YBb6F!WiOJZ9t??^&NU4u~?d*bY4o|8a%=sN4Lwa z;a)_Y$LNVY7qSeot)w>`w zFMnelvzi-~y@mu;J6pI-+z2K$D;Qt7Y$<>bH3(Nk*>=dJ&fEC#V308b11*zjo!J$> zX?k~b9KE<){p}eEEVmwaZr!r1jXUk2Hd3L^l7&j+5`X0!=UyNzsO*7bEY~tUeo-hFs&Y5GW*tuL zmnzSLAOx&UYgMoFvVNosx6vIakpdCF8`;-o1i~RP={8G*0fj0+mQnTtOS_wQWiN^- zuYNz-jpSI$u&ba+wmyOob2dQ}ES6ZFpy8YhMQld3+L^QS>OUS~+OPN?w76fQh<`WW z^d9l?CeZEO+<@h$J)EYyGV1W16Wy!VU1r(Be?4;W0fU)Xmm1|GgBZVLpy> zU&~~qF2N&K03M?`;E99HLGmj35P!X?7QO**75RtA?iOk*b-S0ebPTbGTxB?)tHy*> z!jy3OE8j`}>hkI3u&|tZ{=;Q%82d;s=KgTfOCW7s4~1CBRcp$g zYOkyE@ETA4mTY+VGwHq*9<}icDX!$q;_x@3*=L0o|IL8>_#91^GF4nK$=2dfp0m^q zbIzKO&#CK$rVel(FoE59dHa5pTOVS#|L-ts^!Qlcr9PraXCpDeq*pL{P_uZ%tis-ughe;!~0oHOh{8Mda2E z%xSjsZ7-+BABV_fizl&1$-QCoWsF@*tiR2$Wvqgoy&z(pkQW1Rp?^$(GCH3y?TXoL zb%`Z~t6x~()JrMK@G0#H4mf2<+HW`Rm3P~8+H78t+Rp&zB;LuP#(~nL*_9jM}6#%wim6~n;Xt5hFtkt z^ctsp_Z|H__mIlXpMTWE0PbA#OG!;f_laZj#5-VmP9PH$Ku6y*!}o0~4kw??E%A$S z#U;z2%i`RZP9xDgqz-+>`q{+lM5aeQnh`0`(ZD@#TpLrXID6XZ)fuOLzsd0n?FXKR zGtq9zA$-?rvf?iHz}3*ALkOwMHmJq%7Q_&|+O)j?ayHAlYk$%hSIE#ZWC~V9U|Rlc zQGF!>A}7N6z~B#Jfb!+!{rtH5rId^-@`c5BaInv>Ee7JMK?74Rqik0Wx+;FR(#s4H zhN7#=3%;Hq6B%;EE4}GufD|6fGFI+!QF7n*5s_uKqB7xx@Z{?m4PZWvIW(OnzO;F% z{8Ts*ccj+PWALaO4VcSFQsY?;qcF@M$2%J{!>Y|avon>r?@;i&tA7`Ebd~klvG0&sEWfBqebBG#`21d+rDkN{I?7RR+;jLkTLuHp_OPO?JR1l* z(xq@cG)b>;BD{O$`G+Ie89`6ps=4ArQCz)m4y{1}9iAziTbOy<(+?QgZkMQ`NVUhS zxJD0UD|V~!YZy~$k1#vzyoe3IV42#iOzvbm0)N$6P9gEo-_Ypl#Sy)uvE>9&II#vH zwyYMP;fA@On3aW(IEhy1X;;~KUc5|j))r1MG?v@Ad)X5|W8l0890H; zOMi`@u!%9Ibt>B5Y$W zCHve8vF3>53IKF4k>`rr7ion$+p-}u97)x>xHw$k0HUwl!98^T|3It zK`sr1r7vbzaN6)3#^ajo$Z>tu+^xR1q&C++^i z`{(utK3(9^L^BlhlJSdX7@766iU3IQegCInE#a4cUb=r znUDOPY9^xVRh#rq1&M-l-@EY5e|5eRQpH}~TX#|H6l{B^8E&@XB7jfv>fj0?z#Dp5 z@wRiBGWtiNGTRI!L zauz?A+rx)Hryc5ENn6_*Tc&JroR z6Wxa+z{~nQa#vJM4DAQ3%W4(1vENDKJj;-EhaR6WneXg*(|>4QF=}fPr`ZR-@3r3* zHBQrlv&Tvfw7koPRawtiD7K*H(x9rtXNs3DKYFx1G8W=7S0W+`;{OU3u7de_U|T^cekEHuzWuIaU&PO2!cZ9eAeF9$XHTH2R} zh67Jqat&d#l7GSdFQloh3g^u*_lr}ghCg*crSd80xr527H^?dwqO}Zbz;|h_TQQMH zmSpVvrx&|h7M|3^n^e5Os?v7>7ZH$HW4!=j31^uJQd!JX>^birL8@zUGk(i?i_~>a zpXOeCQ5QqJUlYPlPXh3`a(_8;vc{$T{j=i(w0KcPyOLs@ zpzZ_d3_*WA+?&_piRIYD{D2@x-Y8?y)U5MEGfrj}IJJGks~S5YR21DLr!-9puiqUx z)VtnX!ykTYyjMtG0VsK1o64>d<*jE_sSd3WvEjuB2@)Q1AmOD{#a00^KqMEE2>@P& zAd{W6O@A(4cYyoaP zq_C(KNGDaUCK4c5F)6{VW}%fIXJ}Q^ULvbvU0&&LhzJ%g)Ep#KfxIPy_d14Dg(=i( zdcCIST1R0MxA!&*BRK#2l_Z428;G6)&y5-;27mdZh}cKsr)olr??CRCWbck-+RSs^ z6{c>Iz;mFeJXi$TbDB$8caVzjytl!GWaD^8DXi+9L=0hM~%GQ*WDkFg-wY)qmY9<2{H1k z{_LgV#;!z}5F2Xy-;O?=WC}{s^-eGQ3wbU)wXaVp$%fU!3lqv&Xx4rBvB}kgN4sM) zde5TCXER-6yEfXCeeX1Gs+=Yyg&-A31 zpHK^z2w?P+MZ}<9HC@JVq(P6v2-?0&BX#VI=`A#Fy`)d{Gk>I(&QCIpq_f1T-haTS zSP*{+7G=x0`VM2nPcoAnE&#`s=LR*tHQ-go7%NKdxED_HsG&p32rp+cfNqmNuqZG( zU)bpyfcC@R>5S+xwp4;&qDIy(*dNpN8ArohX(Li_p+&IhryUe^1R)+z5Eq!;c(=e? znn92M%L`J+AR^x$4IuiR>z1VYc7LI{*0-q>=@PrUewM^3Z-+goD%gEKZQa_ZUv4(X z(v_>icC7%@jy>B5E+P@Wq<_U*2d{}27NXpC-6z@6kd)h9<3a1qRVk%9s0s$=QDH(W zN>;y@)x2Yt?*f4?M6{%UefGV|Fs@SJ0|?O(`5@A;Ym1NEMwHR%5O&Q?%zw585qy6v zqj}hfbG=mRLV6}7)zJDu%Dbd7D_yx-DP5=_O><2XZh;uZNu{%z&S9oTw5!9`d3=$8 zOSQ+uoMvdk!Dn8TkPdp*dG#pj8mvIDHI7$apFBqgBAignL_m(UYBT1TCfwUse zOD#L>ZYHLCip9XXz@dO2Sdm@f!Bk_E}^}j?D6PMUStVC)lYuYp$+}bO=^F zSI$Ac!jx>S>k8cA#}fQt>DjR61r4Z0B*7*3*eI;RVNM-{@PA7zew*%^al!-K`WeU# zpGNZc?Cg_nbVu9~=Qmfa@kS4rWO&ffiv~+M?@)Dm+LDO1@K=>6%P`jyWDJrBq-#~U z{huCPM&sCXiGjoui@Hd;U%Rkk)FmaRnoS7(h4fPGKnpB#j*ubeHn(jP=B20g!li2) zzgMcpUA!s)CV%m(WKxFE$aer8Oy+6KDaAr|@$l?ZxzBC?k)`{{GoP>Oq;gMC5 z^&7Z7&OX9GRO#E1!pn^;HT5X73V~K8!9SYe;@?noSzKw=Dh*<%e$E|{MS!1a^p*SM zzv(Z0xPxPGnNgtHIR$vRC|Tip)h>Aj+35{hk!7a zwXau9#(y{#Egazw-Z&F*KW{9HJvvyh43I$72e#Ho4`S64t5^h+ZkNxi)2Jz$k}k&u zvGhunGjwk1)F-Da63rmJIwIDlsa$wmhNteL8p_pnrPznSMNm)BdIi>vBFQ2gByMFeK z_fFutfZurTt<1D)Bds)JTFmkETFob`6IQU3>Wa0T9xu(u#Nj6I6=-w9q}-# zw2m9aKeZy-=B4IMZ7QpDHxVBZ%3C3{txCyZ)CgJV$(>F~3Ru00g!U!~Be9e*@<^&t zuz&h?=xD{w6hAnKy(#Tt$9=a`{gINQ`a<6x-SRnKkaYQS9XEcUay0+v2KgYEr`{I- z1D~uUA@wGNtZ>(x4dJOvsPHlnJ{HV_u4!1qnsOA1qnPE(?;tgb)&Q znu_RjZkm&n4oC>+uyy}>@9%l;^YMFr&vXBK&5eI_ymPH4=HM^axNBzC;YIeetg0ff zbei0M#iM`ITMb{Pp0s}u{Q_EE-x`=_iCMYLZ?NXnCSFy3;pZGL_8UfLHn zur&XNvFNh2zDsX(4OD*Ly>{Kzb1S`g=kBg&ot-~Ae$mzDxm!z)PqkN!9O}vFNgFS& zwKVn)c6Jt(1xs>jke|>dQ5I57adUZVdYHIK-*Ax5UG(Q)}zbdt&gklh>XhoLwHA ze8I0aXGzq+a9yE!i_g$^`pw+IB6Q+zv)M9XOZ)X~d%ey7#Mh3oE!%kaQ0(m+55C!T z_v7INzmVo*TT7j^%KFefu)Do9*Z=UwA6@pC;}<8InsSPN^DP)F$f$Pj+IRHz@>Nm0 zI!d_b0wy2kzO1mOWLss=Dek7SxLF zuU_%A5oRyVJ6mG^t34}pB!mBfg1W*v#qR#>>=&Y+r$ zQ5j>vKyoSu2v9Hx)gE<%X5v}q)Xx6{XE6qJLZt#3L}KFe=MFH!vLB!#i|oe{p5L%V z1R{_tj#xKjnE(RLzy5ppo}pFb(RHy305&`-5IU9SSVFZ z49Rr@5mo7t0Js1~RSYVV1`LvEQ3?JY)k&ct%LEXls*fUFA%h~OVi+udk-1pPv=As+ zARt*FAT^X#pbV%Ox9*G;Jf(A+95Q-zEV1&!e zh}&pU_DE+$(KZrg%bG<{NAj2qgptgQftWHT%n5#2VEQ9%69AM7iP(KPvFJm&Vw598 z_7hi(0qf;x&D+9s@hlO-bfoMx)3NdoB8F|q#EJK!D19Fmq)I!rEBdEbc3BX}tk&#@d5#iyYs!)WDh&4of3-%2BUzfK%gM&>w@-w#Q U7jDnoY+{H5Wb*Neh>tY=3&DHwi2wiq delta 19092 zcmV(nK=Qxbq6PP(1+bk10Wp&S>nH;4Sd+*DG=D=7m@;|J`Oe34lW|Z6IQVdaU-&$q zolM>f98ipepgfp;4@jIKL6bnx7>Sq#vm&?~eHjxx%JPS-l;ePvdX1-#`}$2tg_5w9}Pvl+qxi5#lK~nm*@R-OI*kA>!05D5k7aFaX=2N>M7P z=zkQ2L_`Pjtr5Ap4 z5sGQto14uoU7tT*++3OEK%9BB^!d>kr4E`u;70IBHf^P9A0QSZlJ>!odc;u_59U6oG3BGb^gLS{LZ_KB zi@R*CZFuF4{O0%C=ycHho>jGmf9XZT86u2$(QFcf@hu^N5ssr?=xvj!U(~#4E2Nt8 zoj(r<+#%*J(hJ$w?iYh^0*Q^*Ei4*TLip>wKp*N#H^&3DcW_3#G(3_CIkJTxD`HFk#%@`Jf=t_Lu)x4 zt@eCKQW$U&OULxuk-?}_h=T?m?Q+^_avA~^2$P|P%(Y&%ZzdDd6Us`@*Y~JWliitX z;_b?~E2aZ~r{?T2U?2sba(~HSG5JmjMvM|SrzaB&FjvdTrUyL3>GE+X^E)nW5}vQi zseE35kMe@U?72(mL8OzaZP)TyNsNN7j7Nf+F4buc8H16b&tNz<*cw5vA$VlN(y_ zhmuWP*d@e8a2FEB;2mRc81A;Hj_Jj(3T9A!A-`fwp$NcSbt7Ty;f%f>e*Yt4>s+p$ zGYhXb|5Lg}DLabNZVnjA0@M~J#H%d||4NBqM|CO~7ZaXz?GOsJ?fO@BA%9ruy%r)Y zQ2aE)MK4(*PEW)P-V+|k=JyDSi4k=ty35(g-&BPQ=d%b1dZPn5H#L(1a1;eGH8?Rf zlOYf%f33S!R2+H{FCLcmj!q7iAh%D5|7%BeOG|*8jU~VeXm1IS zP*%~EQ<4GD$|z|9WGq3JE~fSX6?ZdxpgBMhXl@B|wWI@BIl2Js|9t?MJAy2L|CHv+ zfBcCh<_a(cxH?&y13%p?z0570{!uXkoGe`&fUd5e-vK~ZfVGP$$nCQSZjJyT$lTuD z;-3UQBZcf921jEiJAir^4{RS+M^yRQVhPHw|y6&)oh;HD4Sp{^#Kz7;$k& zFMux-8#gb2iJh12^ZtD%#K+F*|Gx?OFCe!6Jby8Da{+n*^grunW&2n4fB)n2pC`lr z0wV=7ceMCtbkyBUK^C9W_CE#xsLkD7Ts}$u*8=#g`ajP9ntMx2FH3WTl|@H$fl%9w z>`b?M-29OVN&O%FY>*>iPUTG+B}GBCj(vd{kz0IKCa-m2%*~Vh?;YL?Cr)pB^7Q*Z z`*G}P`qC{g3W@wF=mv_=f7hwIco_D-vKW;kXP#=u`d-c}ZbIpCvuf>cPpGOHmA%3c zPj+#*z+FDj1yOhu1z}O%JD~)ae``#@?nY|{!>BJlIi*fHdbp<<`ZYQ-+;sce>2|=d4kfKf^A2nJ*rQc+ecP zD3d`^!nN^^u0<;3dk_1pR>2uBvLi?U zk-pxHBVPI2wt9AC1sYZ)qb0rvz0OnNVwZ~J89xGDcHNCaHi>oMeif!`UkShLz6%h&3_ zHv$B@^kVSztr{N-qoo`m63mvj0~KF?ufa;ZKxhR*q*i&Z6?8boP*XYW!uxr6WG^HZ zf4qgd_qX__f#d4Vlo~iSWjd`*dBEhXrYG8znA!a_uO-$_hXTjc_$}O{ z+9FR_;g#>=WNpkOk6U5%@T&n;UYUv9|#2w9hWM zTO!73e1hc|j_G5gCZiB^0NijF#Em1!DWuaBW6wJb}QC@(I_fg#; zX4@XB=fnLe+xfo8=AsR@S|!L}_5v+f@y94fO@4!`b}Mx2mu)4-wN15Dp(Mq~q-e^{^>^Ii z_PX^4UpJ)MnLkNH0RZ2gjr8LhUeKVD$@uYbZBv?RBwP0A(-7xl0l&rWoE?c-rIH|1f7wqMnT6P63*T4WC!~)gko(V9$f}E&X1$S9 zoF8%}E9r4D#kCFwv)(L|B-DLYurmDTEzA6p6WY=#V7PQ%Vnqni_%Cpj!-;EV%h-Cu z4=Zb>EJi!sVtd%*XHwF!eRUHgtkatv=JC0|4vgIsP>0^Uk=8kl7|{*t%Hn9%e`CMU z!`?jd$5R(1etjMkYPQfm5Nvb-tfBr2UK_X62Yt}#R`90s{$MI63b`NB7?V6-8D(^4H9VQ|y2GhYjY8wpu`m*Vap^8;) zz4K9pi8Dv)8S10ob!`gmexCfXj@?;*e`J^&ARfic z5ft`7jRy)O*wapLJr zA-klOK~`Y^N^VYb_lBuEK@zw?)vUQ!E>$|GRCkvM^Us28l|a{BySYdUxR@7(yZ+{u z8IQM@noK*(4Yw+4ekhu_e>0b#&5X&u8YLrT-tJAYKr!{`j}Wo)qo}Q`M2N(GP}1oq z1Eo13H-P0sO~RxlU@Y~xHhA(UJ|v(c{6lv;`MH#{^e=7`4K@7l{8J@QTznCJ)!v)8WNE$j+u=oE?HRm;=(Sg8d~0B ztAaBlKmR^;V~tMKe=pNPUe~!FE*`-&>UB(V>E{s$!`vm8tB_y>Q<^PvgSvf28xY1v0_}J~ zDx-TMU4*Yrr-|Ed(j4?r!+)IX`p9H(WsEBG1?cu!817le8b@-d4Hv47b`_(@pg8)u z1S!mM1B`P4eaFsih<_Ny1%)V9GjpW1sA^Y+mwuEqO2XeH@*{LSL2|ragA6tYs0gtQ z(HbI3OlXHoe=@Nn3Z=D6sIpQ88&De80M?mR&qA2CEt(r!xEu#tI}12Nnos21;U)Kn zXKBwKSmaB$%S0~;Pz3&07Jg#x6)!>oq#TAbn7@L#sza*(YBs?cX_deQOowJ4F48!K zMj|Sal4}xNgy1E<@b@iR!!$wK!+%S03Blhc>?DRGe;ZglH+dto$tttS?xo|#(He=u z=;e0HDsj)^1*U?&FQijBZ2^mRpphJ#xh8v zvY{=IzCwpjDa5ST8#73ZvGJ+@#xHQpNE@NSV9uGcfNuplf>!eeW*Mp(O-ZB8N=Z# zM5D=FmXRV)OpIfXt4a~_OS!96)Fqr>;w>X>w5q}c?!YmOW_+^xnb05UilhQ~0Rasq zjZ%o=I)gxFw_*x5%^!ix(^BKR0~(}_DH!3*Krx$cr(W2>UXy8@o8C<-Q=glV&{`~S3EFYFS}$&#%!7rjC7 zf1>f|&Qq+UTLIQ{@&7(+`8#`g_(o$(%&={0)^(-wXmPN>M2_ZIZznEaWFAb=|IO9Y z1kovazO2e{L$IA8WWkjG!lMVu(&f;j+kb_ug-BIvApTzGwgHSEkAC#3yi%&?2~&~j zs?`Bpm?&7xp-H{uOgJKxFK6qg-GyX~e;|R6i*Qo1tXpd1zS1(kX^mH>B$g{ptGu<| zwhiTaXscLEKt{kY{~d$t#{tkniKu$F-Q#4k7V_CJ_b8Q;^<*6PwfMTG8n03De^G`h zp`Orj|KRu-EUnj75;T-6Rm~DH>6s8Wl4Oyvt!mr))>$S;8YlU~EK?Bsz`6%UZOqRb z&r7ix7N-@uGG7#oQI(TlW^Ex&&X|Q-+(HX_W-R#|b%N|!{rOH76j0{e70qw0V{!dp0-u(lEwLgq;j{&`zT&AvWW0V5YGUB_49w1rIW%e`$Nl-QVHh zC11>TosV_V_DjvV;S|#M6>wE&Z1$97P>>oIjz=pPB<{I%n3h9M68-OHpR?U3FOUph zWYUnVQC0*t8x~tA@e$s01{se)b}KSkl8%JSv<6d_gN?(vYViQfH9=j2UGB99G(p!Z z;Bps|Qp88pBL^DRg9%<#f19$G?#F-$&q||xB-1x*ey8rx($8xdV2W>!&6o6Mt5?`1 z+1fKMVwR4u+TZ2?m5u9azY^Pt)6bk{!_Ah6=O5EnRyvrmN{QZ`t0LH)%r+*_D?k6B z@~r>Ym-C&-5?AnUW^iw}foE4qZu#!WXz6MAVM6fUQ(ZEm?3vn}e|NjXsfpfvT6b8Y zJS%;`lRt{jlM=ec*B;ZP3N-r-QQje+qRtGW9H5C(QRwKf2mKHe^=tJFlX?B2nS9U# zJ6w>5_$x#$8#z&pDS~`#yTBiFDKe4XzdUzZ1ZOIO+K{9Z7R1)}Gt`(}G5vEx7L{1V zDfcFMmdw6#Na}NWf3`9Nqs6d8qFN52nClqwjhH~1fc!;_QIA?z?-MFx!|9ih{6hmi zibjMYug1T)h3^D%d6BeVSO(7oF=Kra7<|&a1Os*GfN8%WGX{-RBaM{=U>o=<_?~BQ zBAP`; zRI^iw(B(P?j3t99I5?4@{*qITL8n1KblYFFz0Z;-L~0lak@Xz-oylS%l}pT!wjx^& zj7a}40I30hj68IVGVn3q>?o7c8_oMl7+jdLYN$H}&-it#rEZiXF(mm~ z@Q=kPu(2K|ZMKl14oWZu=!<$&vYxdhdNird4^7*TS=<+9U`j7HG&aJx2G=03MZL%4 zUkG)m`*`a>!5igQc%R&1Xx6ff^aZbV{4I-!=aDnQEOzu<4+< zxUSe0hO%lFaF6dbC;U;Y6-pj&2TFsbCRc*4r7KLHhAayeL+IAIJ(`3a$91?m#a>U!*Wc%-C=Ao#sgPji< zZOnSLETZA+5{YES=jIhkCrGjpE1GRy7&L9_8>@(2{vwbbF?Hcdt^&8=wn=Kc{Iwy+ zf1$it0z7~ZaM~Yvf%$3z$YE4pdm2uG&NrtMNa`{9GBO7bE%S>&ol5rH4g0FZrgz@G zeD^arekiSbB)X~?u>dBMbUTKm1U<^rQ1vw_)io$_+VESl88(ScC{e zp#R$Bfy3VmV~Wsan!PKSY8pg6f>iCPOjPSct!gI@Fs$((R}Kha;uwM>~Q)f66f31&U=Lmm15#l*%l;J)5w%U1q?dGBtGX+(*?45 z;`%S4hc1_hz#r*NC}gRb z!{-@nw1L*YlIScID&+BRPJNB=+a2dq$U=)lhq*G2v#(mOt7V?PY<S|PcG)6+!`WRW1P2WSe~n8G@JXVR zAwBFE16lK0~5ins$|61+(IL#Dj|sFQ77C}n{)xkdG;0}5*yx^iH$!U}Cg@4m16 zW@3G(f$DC5)`Vbzbivz-e^i*IQezpN*V6SD0gQ9((Yuy-X5JUlBtsIFjYVt6*gQm+ zj#hWYX(i>6hTRQwb+g{695Kz%fhRb2*X6|ymhf-+){ypeyc>0mla4#?Rp4uIe|k49&@ISPi9dfh z{FN=p6?gJOZY_Wo=544UdCHQNUB}y0kOHF@v0O>5P=kTy>lbRQP$D{tfF|%b1Nf83 ztXXq~OBCOEy|Dd zD;gEc$-0+J<*_Y~e_-|ktP|qpBW51l!|mBKVo0V7-1-tuhOWx3K7J2wy4OXAZ*M>l=wp&Ko57R zaye8oyHs6~e|$1bW*6SKD&LI(JoIdQ(z(FlZ-6N+fguPfp}q}1G$w56lnv`~f5H4% z@O_}bc$rlF?FLh6;IjsW*6O@v{rY!Gx}t~d>A3Sn-FIux#a*{%)MN-FD2V+c;*-r$ z2xn~Gkk~H7ox!-U-Y7BBjFDevJPcjnE-uiA5pr(Le^Wgw2Se^@Jx%haz|zuvVvej_ zgCHG2Av;@NHb7LjrS}^hhBn6x(@-jhoiVAe`PY3MO1+LzQ!~7tA{LOhAlvEP&rHi* zx&>d@2Bz#K!_01RVE zu)<~We+L(qat>9OneFa-^EJ&hQ*ShF*{#LK5RGG?g?{$6GI+ zb7Kq>79kb@4?1Zt7RQhd7|n48HLH0me*wD7{&IV+9iypkWt`YWZP=V(y3M&cjppg{ zi8TbHDLu5WRO2F|C?1g)BK5vFfMMung?4a;iMp7I=z84g67kh7mzy5sDSWhiP33|p zio2){`yA3Z^=Gdt%|ySc^$l>nS0yz&P`f$}U%Hw#O!{^Qkq?$$RL#>*Vy^?5gh)gsrC4A33X;2@({bTYy{&PMWDq`o{Hl)*%maF| z;Q-s0d=TZfA?g_;uZuLPf9hq7T<%lzLl!W+98n)(Q-2F)hR*$El-S)E`l4U1Zixvs zCuW=)iSe{`NaWZu=tPyiGFlAc-L0NM2+1zHU=8}pE~?XiS6a1Qn(W#D&mLNhr@G#; z@z2IdtXN7PN!a8BSUl3ANUsjNps$M_bzuZNWl^OZTni>{>EaE& zDEmBQlb@QD+1g)O-R5G-G^R5{%sS~owK_o7)6V6GMB>2OhC(eHJ*B?}?P%T?+y$Da z95}JkUV8~!>;jFe&R>+>Z+NKZ2Bh}5zEpr={Am!c5D;C3UuL1PL;Nt67zs!4ec8$%!(Nm3z z5kprYiAdBh;C(W?Qgii7NT8CCk4!ogOl_rh2yupG+s=JP`fr!@%ML4jEc{JhcD~@$ zf$JPb3IH=#jR+JQ`fMGoZ@fK5y3?dwB2`~%)Q2F?6n-PRe{TlCnG1}KlRggSYe(o0 zIg2mz)&`{`tX330cUH#iKmCB{75UfL!>km5J=N_Z#G_h zxXI2Z-sX=HV%@~@@Nns|xj&zMi&;saA*sSR<<)n!|Mf}1_4p#T_jO2l3)iM!%)4P* zZlFNO zrhlYChU3bPC5mGZ0Dt4dIF3&os-8Znt@7sJ{~FBnHK&_x{&p=evuvdPksa;}Ox@|E z7Ld89f2m=-ll$0@c|-Lqt6BY;_6u@4Sba=8z79*gh(+=&7ZLiq${Rh*bEiH5qN@Wp`)@-?#DR8V?me>-sKif0U$ShN9c4TQgt6848VzV7*J z2Cl8}dnu_5?5kQPq`WuE5e94WRBsy+68?wNQHyWirJ-I^XV349GJyncl}FoSSgM&_ z$s{pa%xa@lt?WAPmMEuVq>=YA@yG!NN`(Yw;b|P5U4Q_iadf_?gujPmj3#8291d9)qW3CZ?*Wt|3VcN|o z9>GNCm(8gJ;}#I?AJ_@&($t0GLU|Ldf5PgpwPHtEMM>Kq&xg7mh*O5DYP8a0+Uv8< zr6+T;V10&FLQ7?7Kc`JP%m~b(^xXZU1L0L{-UE3Qfli~kZ@^K}kh*#F+19%jE-<%f zaK_l<5rM8m?Z}F+h*>2d*dWjDKXmX`0t2~m3ne9W_S4p?dkQZgB&lC1*ErE!e@YrE z%R*Dg5=NL-=RF2-o8$KprZ=fvqvHCU7Re!E4m@~nS>55%Q%&ZSUm34|9!V09Ds3$4 zj8p}r71HXCg@?nE-WuOV3GTjpKAjHv9Vg^zH*cZSZ>?0+t8 z92r*%>8Ral2t5Yvmew9C7EW%cfBmI8(B}ytz$nBW4Sc{ivlh-{7SGx}C3d*a{UJA% zM76?Thgk!&Fy!C*;zI( ze?~(ku!4MS{kJFQmXhgeG)6jo0B=hxqFe4?^}2^!-*wYp#6_zoqe5Zi3Wy~QToV!S zO=3K!dopDS1bJ~#qCWoge_`?Pndm%0hg5U;*sFv9xmOpA?Jge7r!V-SlpnAKGv@*- zg|D-@bi5+1)@*p!OdgiQOfL*mX#Bs_a~K!Jfbc<(>awi|nAlL#bRzr=T!Mo6ahtBH z5GWE*0WuR?J%i#EG#`&VOmg(Nl7%OI5E?IcD?B{pUcaNn^+qb_e~RcdNB3>wP1)$x&XZqB#X!zWb|+(kOn-r^wC7$tiCLMYAqw#hcc{%6*pB@h|f& z2Q$|G;U`Bg*>)=|jvtZ9)?3tJ;Er~}mb;bkH4KB*1$VZHW6%i-PQSQz*PA*&V`1-x zjbR@BCA(yV%tgs5f2E@Pp?9|6c563|k`4K0+kig)I#c$UP-oQNX}WlWY>YQvEGb}- zI@S>rzbCH`UCl{vfzyTM8sP^rYaG$$%CMDAx*An|~L@M3f{`O=Lk7YM9)BmEBJ zj#^Gp+P{X)pb~hy%J$_4XrUECZ5^8#0sGP?0k(vfwVh%Ye-l$gC#ZmCI5BEfQ1oJV z!v28mEIcEBsB7PzKl7DEB=qz-QQ%js&C?l_&3*$B~N-CuHzr zn6`^0t|QVpe&TI_f^D(>OXwL5eb|#fg-*j7X6?80e<*^I1P3`UXFte*eD0ZAJ~Hu# zmDiaS(e~r-;h776SLT?D$%`@#ZHSIwGb6m3x7@z{;YFw94@WnWA{JiRC=4cnG5f}R z1v<_CJ>H)HVO^7)8z$~sk9N1DWOYr-Pq0KIwhAYPk2+X2WH54F2K$8)b9L5td?fr* zRizLHf0gN1tOIt2S$&o1n#Js(S`j9yk@vi$CS%0qo2;`}o%mqiGM}tu=|S7cb@=iz zdCIB>unvjT_WWKTKak>;j^yp?ufU%djsO;Ey~Uk|Sj20W0ZGf*F*t>MEC`TjqSe@p zvDiZ;!ubGpopu>JQUd39aPJt*BjN2AB@XM2e=lvA7~}1F>tqW>;m67 zu{k`7UR6IiXyrip}im6*$#> z6`ngm2w3Zu${wc$y(njH!y8Z%1tNYIvXAo+gnd%-b(RPN3RQqCqwE`&Ru}K$b~I65 z-A;-t$)S`%XF;QET_hpqRH6o09I-q>{V5rW*l(38C(e$G|9FIHJ>$F6;`&7sfB%7( z=NKd%H^rRC9?(L@%pIB_A1)YSgjE(~sZY^D3_NbCJkzauy*=p1f)Fie`iNjnXTU$S z_4K&mz6!r73)10PX!i*aNnxI{$K-@iCtK6(?|itr*(l0w z4U?go1dmt&c&tXh2M#s|$+P5Lf6S_C#2L<-vTeYGYCf z6T*o=zN7r5h2!%!X=CsUr_< zyX+r78A37O1dJ(~=&b|@?RqFbHqi!7ctek2Z(&;)UKa&6>qQ;%*{J+)@<37%lao@Is|ZPAqm={0)wtzK?b7k zc_Z0&0o;|#j)GAjsbQL_{fa=!{E%1O$+l>&8@Gp8tS=@nv7@+uqBLBlRlf?E#3pFMhY8NIpaet&Wssk4gHl>lmNwz^$=F=g@=}Q;*6!>5Uu?~2%K3RrT+gXPp|YaC zLOBeqnSHPQBj`D|c`9!`UVH6r?ozHil|M9r@$Kq&_pNo34VW~t4t2hk(qe$pFCDmS z<%@s>upQF-u2{Nyf4s6US&H+k8Qb_kffO)sdHbupT|v&|y_St*X za^C5Xz*i-I-BPsLVnncNyC|?SSQ58LsNzyTTJhf3rXZIUd3Zzljgy7+CU$ z)~vnywC}6$6eU@|g|7rJHZ9?*$MI#PB4b_e$(>fRbaP8Q(4TsJVK0o@!HIcXrZ3?!DBw}$faqN0RO48rea3j|0ccrmFov>&nZMN3D-KbbU~ zmHoM8E;ghF@jWoHOW-D}9>@ta5x3e_%P3re;WZQGzll}3SKWC;Xm&Ga7govumkz@y z%pS9voU(e;jKtRso2n70YO}-~*`gd@IU`hit*w%Ve*s5d>LAvh2(QHILhD9NDERRp z{91H*WOu*A2u{((bB?O^fGB+5iap5`{rBnDb!K}th)2JHpMIPDj)N^B*Z6kU$Nu&T z%#fLWuM~v*sFxXdOA&{y{1I34@@v+*^Q9lRa7vskx|iMX{{7dI!!~33+~q&YMP=r&%BwO0RX| z5O`jQnx%8SB;IyvWfWoe?YXkyO%plCkCfv;$R#1UK{yp03t^EA_wzz+4Vj6*UAFsN zP}15}Ad_c8ifFqW`qxT1F^0PxHr+@T0`W(~e|(AMr_Eg>+1;*ODeNQm2pXA2!5Ezj zf7zpkht7SEh`+|Y7w$18FpW3ti^25K8hSpqub{EBvm~Bl$~rTKL|IWjx(mq4`sDDk zkLAo@BzQ&q=$KKHn+Ig^OhhlIS7K)R@IfL_HxnOo)k|MSi34pyA_1Zb7DgmNN>bSt zf0DO>PaXhr+!WZ&sz64~SiG@jX<1{-L*))@yf?aJQYGn@$w$osUWL`h0tg-A31+%r z8bFVbz9@`)Xb)i#rvKWhMPex|(?8jx;wnW339%nJJdh6GW1#4MB>vVsYp?g%>F>rR zMICP&nQ64r=Uupbz07)Ztvz`AWMd18e>piGaeym*fe96b95J+6^0|(2;eK8EY@ zm?uIrCNTE+h{F6sFdyXO5%P;qiEDA>n==nv3K?d$lixNa)?<=IykTn<@Ru8XW~Q&z z7jNBiT8QOTA8~fM9B#-6-#|F|TGz6qPBC$-O5?634cq9=3U_3UuZ)Jb=8q&Ce<#X` zPKvDe>EX@rKe)^sW&1HMcciJ0>meTRzP;tzWd|XC$;Fq1r)|JDKKrYhatt-y2DU)U zgRQV@^^Ko4cUtHXhgCkoYfgC#2CayQH;SxO@~*z!g9G?e+>0>pROou}3I@^dFTbxY zv>3g)8CNsLTYq+;%;aF_i8C5ve?*YYpPt~+fZgEUL@~tT{*g1qlZ-vL=ago&dVSHd z=|P*6Ks+Cll)C8y<{ms*Dey{5zQ18q=8juy*?&B!vJ$Mn;#CAOvOFF&aZr@b@3AHJ%w1Ay~&EkZ~qtbHf=_= zR@BF>o@?Y+3j;HjpUfkm_OQL9EdvzAjau~wPxZBL!d~2-1;*7%EG`pWyMip*n8kKO z6P*%p(x#?!#&e4$x=4m;f60vAn+~)WR-=%R2+69IU0(*`SzGzO&Ht=X*JWrnCZi@D zS04GRXXVWHwpaJm;)6sRRTT=(;L4S`#t%ElW`KxH#n%0#-Av*mV})YC+^nV#G=NrR z&i)Fq_MkE~JMu#Km}ix`(LKb8IL;U$Bp6+W{LZx#W;c*4w2?0We+8biC8JF@=oqyA z0}W7jg0RKd%S3dbGD%>)9Jf*X-joM5 z8=kA{iIFj!@rChmg9^9aA+U2_zs8dzeTHqSLcer+iy%OOKX~CoY`9ET2PiZq3^e<_E_#VK9uXO`~@M<|M>qaB}E0!OOSnYD%=yu!X6T?rYQn zR6D)Oc#6tXkYmqiusc-1$y?Ff(=QRk&NKYoIVgopE$u^ze`=A+z=~Y6H7oVA-V8ZJ zOw&|_1;{IaVS%`X>Im~+m4nrvbSw}Zu&37XU$Iym(@txR7m1?D8IZrI&f5mN_tuVGX_s*(^f}?CUKm~efqRb(hEjx|2|uGhQNa_b zuxZRLUpfDTW`qakpC-@J!iBWkaG#30)Do{?zrA1+nW@axtHzDo{<_Q=!bz;cn6~x9 zZ>$&vnNH!3z;({Nwr_g5SUpzvYgS*i{attRzCTKke|_7GK(Ib{O1x___XAn@*+Ivv z27zoIp5&$x;;*$~x1f?`f3hNJ&aMjlpr^kf3AAQW2o!nGA6ebOGY32lat6rijPJZv z&b`jjGTSzrYpw!0l$d1wW(I=tNn?HXSXXc2P4<~!RdY+PcB8J^;q~?A;0;6$qllB` zd~iqQe_LQdtf&aJuG(}Sz&e`QuxGtox_2M z^iB$d{qHmnNb5H)jIO z5`pYPlmOkH4w?kc=u;bu_~oT+-J#^oO>s1HJaa7+$=U67+b~M0RdqS+(}GK$cl6DN zLme8i^ZuDLX~!eu|BdbMS)#4P0apiUq`L>5FZ}EqHSDki<2MsVwJ~;EsMz3CpX(_| zvHU?4i~^i2dW_2ZpoNvT_E!4NIQKZUCwJsY%zwnZcYEg~tS8_lq_}a?-Og~#t zQG!9cR}}kHJnnm7EkdRdPXxb`S`!@r1>Jg;_(hH-uOZ2IBE2uA_q`pAoQcjpe^9fW z7k}ek*dw5h%RTQ`sP8U@>?x$*_I^fKvYea$JmtYiJQfoZ23>jL&-s>S=E^?kZ0F;= z_KBQzc*1Yl{_38}LYRL$op8sJ-Ts`aF9a7A9E>7+j-|EUYeJyVWo*)$sagDHCdT7! z8N}dlm}X!-J8b4q|59G$Z=4lLe^cPqEjg#PMu%4Jsp-wnKJHT%{z8cvD*7lo82jw0 zvqN>;TaW(yS*st!zkXlLG=_Ra*!`9YhMzY{_|}?;YO69G9p3`8I#k=h$q(2xJ}Rt#YcEl-EIMQ2_NvGdny^r$O>Qs^B{~Wfq&L}@S`ZS`wy~JnP4RfWY16Oo zDdk;dS4t!A8tfSgZmm~Zf5pqyjQi@ZQ*E$#MaflUj8GwF$i;gv4JUqm7r{ah!O+83 zVgix6IfpiNB|q>jgh4A0#Z}7Lv*L-W9bhRSE_4NtU(=g@@nv^m$*|HvyllV0C)Gx0 zAO@TYa^eovNPsO4{5nUc)<985ld=Y^U!kz{yvHZC6AWu-*4yAle^fFmL}E3rdBP%D z;m6>K-qC8BzynFA>oY5y)swi$Jn<_jA)&vx66BLWm^SS&O3b99m|tN9!{YJ=t`N)A z1`cXjp91~s)*5X<+S)=NT%qn{QL}+nF9%zYeTX*3ilHD=dl_mv^Zbbr8WF9%4h}wkm-3e>gvQlGut%G+yJ&pe5JZ zSv#sSdJRSmnX$H^;4a6BVd8RP#-KJWi+ReBNc|3Mq2jNsIl-Uws5@Kok0y{X1-Fdc z!NW!bvz9P)5lg0k>@SiPzp^^hNT!z4pnx@i zdC^u&AEKt)fAH((}TL@(f|odNya$7N$tn<@Mbj@N3-$WXr>=bKl>C7*%y(xXk* z(^i;TB&of6ff1R%bz4F~6A)7=rs(g71pCMSgpbqw4xLuq8ZrT0J@-slHP`&Lh%pX5 zLGa-#^#cX^kZ!pXigB@}+q_m2=N}1-te=Z|2b~CNf1N(p;M}e5`7w_c{y#&$DG+Of zWZk%m9|aQ~m89{R8(^kuZdTRBQd%qDtpI?97LnPa7{M%J8(m|VGJIF<55{?W#jb%s z>l4aSoB4SB6~2W0Ut$a(M?y-fgatH@WX& zXsux1e~{{=)2!V!#T3)-r4IihXq-V^VOe`r|HeX`IzS4BKO?g`g+g z6wSEkkvIjT$oxyR@LJ7g!f((`uk_g5V?h*?f6N5VufzSX!?oj#3NQU%&>vl-dBJ=s zoHs|*)5haTQXX#Zhv;A#WJ*h=CXdsnf ze-aS$T)hQQ)wg6D!u?`=YPF#s5u752^g5^f_YV^CUMxFnZ}s_nkj$oo7)DIr`L-AR zC`}|fy?jOgAB~`6GRix&bjBFHc-+cfRv|zwh@g_rJSkXH@sAEv{1wZ^o8eXG|QDHa$3RL2GtF!KqA#is+Q} zmKcw^3rma5H=xy0^00IA;-NKP+g3JCXe2Ob{KW6()jjXME|#rz^WIk(QjnE4$+3%@ z`{pcDzdO-%!B_F)@7KnKQ2yva^r`H^3vSLHXD9z=DXrdfg?_qj*Qn<3zU9GD z*x&v18gln+TFcnItNcc1=LZ%I3hSD*Irq`|AEUf4y_de@t>5>p7!}j7Ff@=I12$@( zXsvbcvww+K@SYl{fSG5?Kg;#)o$4evEOKrl0B#*Qj@grDR>t_oZgi--mRX;3&st_V zF{J6i_hm8NPQP6maIVkuOCA}GC2I|2@R&#`Vt(1`#Ii4~!@%9akNf=WaDT_L;-+{a zx#w)Sdw73BviHVM;)6c2mv+l_iQiUl+vIVlN6i^upUTMfeM`nX^s!i%S8w$)=FPMx znC&htj{SBIFT9XfWqcezKR#mRk$E3)c$zqCLdLe`3CYaP3!YO5XU8E9{aoeBW&+j+>o9L0-y-zlmG|rh?o7MXFvBeJa%+h4P%APZp)Qp*Y{EtrKhL4!_ z`QDSGZx4!F#)_v;y1rtPv!UXEYl`+x{eT0t2?IAb%BxuCbSE-;!R^*oss4D&lN_nQ znB#cMr|URNa6&{}k>9OI>8&Z5MT>45qq`^{&Y6-~tWjxhr}p#Wo_>;N_bvnisAvIU z();bN$zjr_Uf2ZM9@7^l!;2RNRYlf%giC%B(jLT09@>m>$)^_-%qW$$y}DU1ARG~< z9$%gLGL4RQVtP%Zk8SfdFwq7}QQg>&3+iMCfh3-2mUL2+D{rlY%hfl~E8A z%7j&B69%0CS>Z41oP~)bDr5Zmrm7-Lxc-+E#H+w$(5|5EKlzy~t9*_1uZEDFUUtw? z!nST@vMMOU5D>|rH>^s1iBQ2IQiO~d!V1ui#7X8PrUok^7Klh_NC;NU42A?-08>JV q1)4)Fme2r`|NojKngRk0b25@=XJpP!OE)k@|IQdZJwszHhJOH7z3PAf diff --git a/inst/doc/HowToUsePhenotypeLibraryRPackage.pdf b/inst/doc/HowToUsePhenotypeLibraryRPackage.pdf index 5bf2a9997451cb3e343accb5133af8e0510c7f62..f0a54229e9669f725d2f087e466bf3b2df9dc501 100644 GIT binary patch delta 27094 zcmV(pK=8k)f(*og43H)PGm~KrD1XgYOLN;c5WeeIaFPpkAVL5HNP0Y-x^W!4len(z z<`QQ*kVuJ~Qld&yc74fjFTh<&BrP!$SMBs7fQx;6`vl}#3(K|MkKAvpKi!SqTySbp zpD-#s>uzpQNr~?YOUi)IP?I9-vwfM5nY16r4tJSd<*@!%#<00b#?+2id4FY?p4MYW zFY$+TTBza)I3~zw7}U)C{-GA}_{-hT+B~x;C7}?^m=8n3UC(m3M*90hQMu7!;7i}P9OjcC6d=T0#vST9Gz2rkwWvq9Cu=hfb0v|1v>Y!WfnIBw zxA|(!sa?gelqgB9kc5&+BY)_k6_lW3CuG9DT9uW`GF7EogF&Rt5au(@j%dtD=Hk zJ~yjpU!I-6yWJOP9WNe`knwH2DBTmVZAEH%)`CeHp}wr0^+PO&dw)jVo=nFzE#vE& zM(6L626eNl6<|&g!!$GH3$%%|HuV`meb(%{>?$~1syZ@2oXsw1Af8d6q%# zmM4Iiggz6(>aWGZI&?I7|3ayEccVW?CJZ_smJEqYsl|m)sNmLYIWlz5=bAsTs37{V zh^_hP*Oy{!PZVuomwygjV_er77uYgIyv(b(#CQZ6A>mU0xGtFJP$qRncrA5Y_bug3 zc27<^mEaO{L|CYQG>BSXhobdqDNNVzi?m8M(|-N6!3Vsa5@_w-6S^6H)2og}&`bYGeeAGzha6?b^H4XtM}H`j+j&#B;CA3J960}G z4`QEWY1tbbvpmV0VG_mnF85Zc8469WnvQ!I3t_9&bSmmO+=&HxWhfDt=yhZ8zv)IM z^kt{Z{XgzTCOskouRZa1wfWMv>^92F+Hw(BJ2?4burKwULOXqVq#o+8=6+ z%bIHMT77zpQoxQl2~CKZ9VMKcb}4XKI>c^0d+Ktnj>m~ z=$^{;s(%J2+iB^Nw_h@7f7N=9k688)duT}l_k~tbV7Rt;+eF;gHIDnb#*ct>J{((t zNPXbGj8&v&=FY8k^hUxbcLO~8jy~l}{b)27U2X9I%kk>;df4Nz@faTfA62H(5~HtHeP{O{_oz|V zow=%p`Htu8$AeSSoSLkHvkVB6BsDMi^1$%ff83)M%`0ZP%vZxK$MbV?FsZGFUW#u! zi65z5Zo8_;AIqVCM2u4++^~K|Zlg#$68b;F-x71(kAq?bw_*hW#x@Z+FbXeBWo~D5 zXfhx&FgZCklTQ&A0x>t2(USowe|mLPTivrZ6nFOm!QI{6-HU5*2=4A)+`VXVcPZ}0 zwYY16;uQGk``(}4`|r21l9Q2VX7;mZ_Q^Uc6eP-O3?gPA6QCr>-i3jMk(n1Dub>LD zGqz`8Wl#lLxY`;!0azKCnc3kfD8!tA#x7PMdvRkIATNN+#S)-o>hg|#fA?T!=7FaG zNCEAEPVYuDfQctS0qA0^?&$zz0Z<$NB`AZOT^LM^o!`wsdkZUjAk8~O4CLVHWMyIL z@+Srx1H+$4f6$_g09j*G8<4xRjTOMy-V7kisK5wN1i8N}tpL;@dw>bh(%9A<05S)t z13v*Y)Ff2Z08*+-8p>)ke~j;e)m$AMKu-Tti(OTtrb_0sz#c2S{nCssH&@ z2im{aZ$S@GRDZYs$@A{`2d*HYE~2ijEWyI`XAJ-rfE&=s+3HW)|Ei7hy)wYRN_&Tz zJAv%}N&uj?ba8RuWnyx7cW1P4b#`F{Iax3|*#1?Yx}}vfz#Zgde*<{GIst8ge-Yzq zZ}v{7izV>y0DpD`Aa7*~w08#n0ZD@XHrl;Y`3`#5yZp1TcOqQ=#I*g}9pDTE{zn>1 zW9PrH^2*Bc06SwVdl#U+vAyZLql>YNt24mpFWvhaXh!vSfk1$mtCQ28918z1IsG%u zKS~z`y{}Bq*4x+EfBnCA%-G)5+3Vl9`OjsWg6y5GoL!v%jtB&pTiF8tRPX#}&#dhK z(kX~2%1BD6sWZsGH=aF%0_dF`dqx)zm%qIK#1j#h=LK*xa{^d+*a6J%O)6n;CI+&z zd#~CV{ttcPR_{EyfSf#;{&!>B*n`~dz5fq`xs|<{`5*4he_S1yH0-S$U4b&<|Kt9y zg8!G!0_Xx@1^^uaKo3((rauY)>X$!imOtuuB7D6aKn?(NV_RpSua!CQ{Q~dpZ0rUE zxH!22eZBwP@ShSq3m3r5%GBk()!)Yj{;%jV_U0e}&)@3zO8#N`pC+LGYgB38=hO^j zZ|ey#1DeA#e<^}o-dlqD|IeiTS1w6cTU$kAJ0SJ{;`F~AjqR*#J^$17zg)C{f2yTc z1UcCm+y0l$%30FN18AmfXa7&Ve*h+VRW%tc4Z8o`Hh=j^*qegP ztn4iStQ?#GV<#tLPk83{USQ?m0C=;!H?|qjBU@{uSZf8}x5xc1{431JKC|WcF`}cb&_>BEI8YES-S=!f-IZ zYurKq26zwZ{;!bS046V>)8F?0WLx>qiSySeG5?GH|2c~PlGR+CKsG=vE3^08(7(AT z7`r%GdFV2~&jHK3{{8ijZ~Fg{fZ|^x{BLMce^HQ!Hv>B>D}aHO`+e8g-VYTP7FI6b z|G=95eJcJngYSLv5BblL1ONg(fTr*(iy%|J5bLz&uyQ|%FVkP4D0mppDzODW$tFOq zWKMSy;ELz(kOGB@0$T&JD2qVy(!Bb9DS`GSpD04GY+pCplB>Son5hWw8v7~u5g<#5 ze~jm8GHL{6DJ%zk?Ixu;mdz{FE@hw1YENh<0%(k%i1BpxJjSw4y`f#FlIneJ|4{(t zUOdmzg6U+7?y-!D-$k%I-39LQ_K5j8#<)*pg?7%UFbsQK7TV!k55{4ofhD?7&eIGQ z$}5I;WFMUfooV+d#;UQndL9%e_AnmAe>N+Z2fqFiaxmKiQXaAlXLxcM9}{FQrW?_# zn0D|mZ2~LKNV2`cDQWo{(_*w*TjK{e9G9&_j8j>q(ZTR96rQwe{}Ix z#o0HA3Sx4af}d6is zPFiRL6O&COV@|o1cP}sL?V`saV@iADo>xJ%Vq09!tF{+yV;EX86m|gkf9qBJ;R)i1 znfsk*FFqFUX^T1x>#9(`#;(RUZHvg{<2`^Q(?^VmW2@fbDpr-2^(43na&+)>9MRzk zjrJf31=%39*9-M~<)cq0@ygmwnXOnt8_p!v%xDmAq;>r@C+uPM;EUU$xR8O@fst3m z`sZtOF&Wfy^G=wq1ns7{f5~|(J^qcr%ni|d>?&2ET$#(5XpnA^(AfmuVp787eUpOC zX*@-!MbX^Ftk!q47ScCaPob|c6yRhfWp*XW<5!o$&1lVd9lreC44=NEla1fzFJ%V$ zpgvQD`AIIc6A0FuZ)FZXtxZ25rI2|Ua;l@548xov|6W?lKQ?)>e?{%v*0AI>Pa!XI z=HYf;_%H^{$+&?W^X9h$!#Aq)o2{>sWjL-bgs6w(){R&>gncsBSzUA*>LwNVq|tll z$|>`+7v3$n{B&{?8?}B#G~Krb4&hd5{*YNXsE7SDA3L}I4iDCIVR-{;T+jBfkAzgE z=O{=voR`WM@n|r@e;EHJ-QNjfeJTkDl6qYI=PGt*DXZqUw@~`f3`^%xX;0`1ht=D? zH^vSbM^dpR|I?)fl`5|--9lVNV8*vSCt@wxSSu}XO z)S0=ZXIP==g_a^tke5<$evoucbgS@R&aoR=RK<5YB=9rpf6*=quO{KO;3{K&3$|w> zN;F1NH1f}jxZ->ViIVe^iDS6hmPDbT>md7lEV#oq5AA>Hb7dW6sf-RgBCaLn4Evx3 zvtN>J^J{v@9NE;)dR7;rNK7MCmkNFHLD95W#5qd{8#m$d^`0bP6-&}WXWNo|J*0Vz zOC!B`fT!>nf0?WYkU!>j$qt5)OS+%#YS{A_0~_L~_k3qD^#JL0 z|4QE=Kk>)Fd=@sB&_V>vfE+Zq{q2qgd;6=T5#`r;_fcZ_ko=Tdj};Q#*EVODHElYOlt|cRiB-lT=;t?_zLsQ zj+m%*f9ww6a+Ft9QYxO?M*JRl_=&sTaNf8HhVB*idK6g|Jsr;!c-Nz(AbwmD|L^q) zC*H)tWdgof1Mj&J%x&*2^vhrUpW)IOY|{JdXy#AmWIVJOm094vMJ5;^9+~!AWV92e zWZi1d_Q;_G7_cig3ur|9YmsPsK4~tBIDDkWf6vCTmAbD~LlDj`?07_9Yt)!FYmfpl zUT5HXY!h?8an4*V`oUu<(dNqivUXDN7m=1}77)pkljwlJ3@3})Ij?kLX)ncVqYArB zPtJ)E2-=oEcgx6t(0!v>l=7w*ydSIe3_|$f%OT=wtaVs|a%7C?0yZkg4=Bt^Ve!+` ze>4`F?ehZN&mkWIv~-mwJE+C47q@VaEM5xLda$;uI-o8kG1p7MDB@emRn^mIbEN`* zw--Zq<@oFxzp3)GY`SV?&&rSM_#9h6GvTr8X48`@8B^8XmLpJXH_;r~AV_MOAS8KG zQ3)>(e2SRQ{~mRKdI;`^b{KQJZN_Bfe?zgj98)cIpy?7(j!TJ^Vil43Ja)T4IsRI1 z^p^IWKzkUB|Ah7{7}XK2j?<2)_OaW+Gh5*E&oq+(dNIhgE(;;g3Bo=Cs){GIn`%ZA zrnU0t?~F`m_gb&MH-@-}I}@osDc87NEs}iLGK@piYX@_Su%+DyemjuEQ>W)8fBwNw zpD{>F0@B0@zo-y?K42Ht>G=E|WeL_3YZy$Kde=8&=PC1=FtMLXWrYtxu0k}Mh~BxyxMtzHBS&aykgqlBzH9ew82ibyTyPdKRA;^p_*R4Uto_m=q0!Gh^G zx^63<{n2zRv|{3?n7?4xl05}bf8?2PN-l%x^jMi75*i-EgW*%tiopByl6+}KA`FEr zN!rk%CPB#GT5qS22?dBXmGi~;mdt?6`oD)PwpLx5Z^^@H@V%hapn!etInVl{2K+YB zHg7sKrQz9_|BOr;Mb^`$;h3rwrFHu>>*x)0W-y4p#9B=^bxrWa^aIz}e-84n#Z|~S z>LwtC;z9&z`gw}`*63JT9)EQ^rV`BjP zrcRZmyoY7nlicSII8iV+e`WIeE0F_E5gYXz35Uf+Q)|ifYHJ;fw+01Z=Um#;n!7iM zT`VHNLuIwD>HSl5aW;Z&j2PqgFImWlHo+eg=XUcPiA}e4f^Oz3HF}y@$PCV=bX*n> z3c6XgJf`!}C_>QNT<3w~YKL`^HkS}zvF6>^VHUEN(5kT?!j zw<#GT;WET=;f6>df0#LsK<)GUPP9#;Ok2F%0_iQ+zpuni85vKi-%};oH~6#FGsf`s zEO*O!!Ig+tp9hN0jje_BVOXUExwG*Vouq$Nhb z+$C0&Pc7!fcod`8fB6jL@wbE1qUW=_ma-IYp&h)nBjP{luYE$jg5Zs|A}|@63W6IF z9rLWzw07CS6e?0iUVBE)a6;1!#UkoH(8M%Ez=NTU+IE>Qj^onGf#1R#X_>87c7Eu&uElxUHCO- zsuEIFG|}Q!1*a)>8VX4fm9)wH$?DTE%q2iiDBVfQlC55K13=YEN^9z%-WMh@#2f2>azRkN%;NkFRpI|{;Wf@s4)W!CD= zU*j(;!uC?;BSKM7RALvxodqsU6Y(@|c?I7v+M6r6m$$^wVy;;A`8WKqoe8%5iyZlZ zCP;7(KVRL=&%1oKtj+pHP;--;^)ph5hE`}hCN69S*aW~iOpC;ZB#?Uyyau0Wbn{C= zfA?a1@Hl_+snU-(Y@Ez)#57aRXDLbSmAPJqp=e`UNr1pXw zGjVaduc9yP7`DPV4NtLGnY?0T>s*m#o0DHBOM8fNrnAz0H!{tRJ1Q_PE@rxi!f}pu zUDK+3DpzT(6(eA~E^B_9BGJRnyhf`we~ZPl&d+o%FiF4%d=7Y|dvk+m=f4?h9Mz`W z1Z2!)iPNaI9jfcz0KXlZCkjjwMh#5QPQV@N^hN6u-i&%_;K=V7g?AR%756E-F{U$W zwDc<>V3O)wudE1CbessKOe4VA4XLTNTlG?DGm@MaK`X_RbAPT6ZJ~$3L&FJ-e|bS8 zV#Q>7#ztxurTr9wg)bpK+#0)4GFOxt9AQ^)1Z^P7Cu;w@EEEcZ%dB+{ir`S{8#|BJ z<7dihn`294qj?c9qaX#0`&89BybBG0x4^edZ760k^|}mSUZnGm*2-GhUxMZQ_@xS5 zV?USt5oJ<`ZQwSz_jI21v=b;+UBS-5Fji6i?M? zh@q`w1)1AO>aY187dRDc!&}zAQ)AtPBu3+^Ug=UM*Sjt>dgy@$o zWp6q5JNt>Z8QJeJ;{Oyw+_!PmFhJ6)+?g*9mdf#v!s$HNn{KwPq4QpS`tVX9I>@;8 z@n;{SctDgmXYk}5|HmN4C-YJR@RIOPFKL5`(e-tkCN-1bsY@qhe^ET06@p4GyToQ$ z0?PPdnx*mpn{5wPB=E*fOntjStdW>8<_$(TuVqudnft|Dq5gPeyiy9yIAb5qXQfT~ zk4RB%YabOi{qcg-@;a9Fwz@Ofv#$jx8@;oe8qIvFU}aU#uS=U|$dKQ1W9@s)U2IpU z&Nbe=6e%ZdM;U>Qe-vat_c0kX$XiMC&e8OT;j@g66~__bqhkw(LClqk0r4ba5s zZsh|GXnrwUs|0tN2qk<$(4aJcP&$=37S->*4UX{etV-%PfBE7CZj0ao@P}j{)y{#^ z_ps~JAgkg3u`$##p7y!4T7@$;4>P+iY{#8yr$3X9(B=e+QUqzzo2r6rPjPMeie@FW zK!~M{eP9fxEX;3%|}Y_Xy~j~CykVa^vaNk=!}($(q4v+ zK-ci`lK$-Lf2mQo>|}e7NzE4Pp@3>3*O>5XU7tjh&$)N;_n?!Zob z$VvX=4TqfW_0zc=*e?+M{*76}MVNYORAiiY-ZJp6^7H~sI-jh@9nHq!7&GyU%(=BC z6#Ybqio?u0>s#fAa{P^~`d3(oAC)paYTcqIGn$po1Igbyy6M6##02POAREXwE`?A_ z9BtQrfA<+T^t!-h!MAm_;*mNwdQ2g3W1)+!q)z2Bm0{`7$;&5X)gu^R zwv#DNemGPi^J!$%iuYq`9;g=b(^~hE`Ig$Y>}oL0@zYf`4D#s+ zBi`f6`SY4bcW!`vg0e00B51S&HdK)nLO_Y+e@p)?%x!fNLD(j+81{L(pZlyrZCGL8 zC^$ffspXmHLvO2~7oF5M#FV!;kcO&!q}kNRvQo&5VgLOarYNN(7(t zf2oZ}(kUk19$~lc&VA5T>MQXb&8TPt968x zm04mEd#KBpPa+79*wIJJzX7Y+6(&5}Ru`fOhP^?VsNbpCWU_`<&YLpL*8EkWe=WK) zkMLewxpt7o`beq|)d?ay2--?;VzNSv?Rk@<9r_5qq#GU#6YEzXncXM1iX#{FR4<7p z7f&Q7-=QGV&3nohY)0!9Rd}iu8zTRuut+q5CmRM-tWa60xW<4OEsYbnL}DmSNAPyV z>cB(zZR1+s5PcrW&R+59Urn(zf4O#`Yxn+g>O7(KAJI@GssPvtKVBY1>>7h1F^ES8 zImXG4&HGhs%j9OozKFf0%E7zVKW&USIm9j%_M7i)MNQwdNNl2e#{xERqv_*}t`$x=HU~!{t8St0_L~@M4L^PnI>_6?M^hA+Cx-L4ei}Bi{xS8M zU8t4RugegUt{gvxt#J8ue>20^#ER)vS-&oUO36Fa%Fqzt35GaSQqmrFbNG75jrxH{ zMS83HYFD59cKz9`ZAAh_f9lyW8P3f}84kSu6Z(Cj8jPBuN*63ESePGx`a&}~H$gXW z&~^bzZ|Rnd5pBDzoA`&Ll?W?qg4U7pq}bJ-QVA+%PW7xu#7q)w((Tqmmlt zR22-RJZJ)~+4a%n&~tixIq5MJITJ@O_`5?_{7l}S@3>-^1G48SyzY2Zs;f@$DT;kQ zKVi5Kyw_O%Y`PoOLWo2FhOV(0)D6|AuGx_Znq?noo)3+tfB4wu+PMzjdV-jx=rEtl#ttWTu82$A&{Gel0 zYnQ-Hgz9W?QUM3|ibi@f6oV+VyWuXhF315?ZD%6_mC*flpvj_Rx?ga0SexxTbgQR0 zC4Ob`4Ia&se?A}4vp08%YH1f`sfJ<0dTv63)-&9=|JtGz|Bu41t`09DibUFFDw9AbRhQ=4ogJ16f1dKzzyk?cX-hqbCMirOLtEVd z_&Xb(YzJ#U`uYmeqE`_%<~?!uc!(_QW3J4HokmMNnxzUJ%~I@@%?6!`yVu}dLK%V5 zyRA07NQmw|_&nkZ`du!4izQ#QHhSngk)2zkgyUe}&K@F-$v)s});@3aUBeF=e;x0W z+C>U0e|=Ng0` z9IGU}ri?6zb7KF;b27poqm3RlRz@)bFSlojKK7nzv@=MGQPP%Bz_6*|hjSkjK@A)y zkP$U?bj*XRt!jkuQ9qPZ74+gyZ{&H$wPakhe{E5td z^67&K8$2jX1Zx>%umOVv*h`v&aP&(h7}#_^RO$<*AAX;#X10zT#bq|AKMt7{pCU9~ zk5qrin!%wH1B+<#u=n~VN`SPMc@Q_Iuc~RP)3ZmI0ftfe&5_lP2!{m$(_)1V%WQln zfBmU+5eq`XIOdhZ^7fHv$CXpdD#8A$$D!AxNF!MvJ4|}1AObV@)7=QPWM0z@uR#Vu z2rBqid-NknH&xlQrvau1f~CW@G!PZV_n5RFG~?gdIiyv2+55q1xH~39-u85qka}uc z$MC_?VKghk)yU9_aO7d#$*(<5EkMf2e}otmk1g%P{{)Jp{RNs8$7sMgxQ~R4?&T5^ zc8H=)t*QFvK@!+R z8#v-*H||O~n84ME7ZYii1xuER$uCAT60dK@T&S$wG9Nk?yo!HN8+<__AmFk2fBy6v z#Zin;s!2_|N_al}^_)XJcK^$yq=?%7Iohi zMvt+ynfxp64ivlC7`+0%25esh2rq_r<);xHkmV1~Eh{6Du%0{ypSjp)FJ{G^u-}S@ z;=!yqDM`|;*96|+YZ_5@V$opwf8$NNvJYEo(kV_0*D5<8J>?{ z4vYMa7Err*W8#=)yyTvHK2xV$aMe{zg>SR-Ob z@J~@-U(Yu=#!{$&PZis&tB+s{AJ#OZbwHA0&-L~vE;i! zxNFGR3OtVQw~~A;+rBGTK(0|n)!Hq8^A^B|cC7k^_f`2)OH+dMYSEQ+$GK6gIvr5e z#LPdv%=5OHyX7yu(%3hJe?AqX19MTX;VYvvqrX8P-Y)<~mu@xw&ArPvW2>Uz^hUvx zwy~%1D^tpzrziyldsuXD*IcDBA8KPVJwX!%CVyx2Pyck5{H+46v(Xqk;3{2XdVnP* zltX=l6!*1M5HY!6?6`tLRLtE1W!FV+g!!Om>K481HlNrdw5^a6qKUe8U}Y3_%bI-lNnJk=&E2y!NqGog z{U#_p$K_LjX1DL1e;HGXF&DIGoz1>ugL{l>CI8{L5v6uG=0kwG&U;LA%kPR8_~&Ow5Vd{9miTGRcIJf4i48|MU-_C1yZd+ z0wl6;?1`V1Aw;o-y-B}7UY71`MWoFr7Q|1;Bdz}*e~)tV`hCHX<^^x&Z24_|vml7j zc8wZBV-3U(12g>V)64A&%jX{sHFh=T;W+eya#izn(H}&w7TaDZx%{|ZCn#CvDm$@~ zaFZA{`6H+%*x?5_kY?ZT1oqmgr`a7@7#>e(pQShBF-n$v+0rGkm93e+Um6Z!Oe2xS_8yZ29clS=I%T7MK&8RF2vpF_%$t^n0JO?8iLGn~JwK)wJ@J zqFg46c`{NwP*Ff!HFerQ(1D7-o*2j_3%8#cTZ<>&=39zk@02b-jIhzy?JFC&iCA6* zY^e*i=wr)Fmr^@3a)FoiIDC2M85}(v`ks(Cf19R}Mpt889%N!3XHLNlb-ZXo;?lKS z!Gpakms_L%b6BmMrD@M2;PGpqL_v^7PdnabD#s*ppGw@Ry528&tX-}{h4~Nm#h`K$ zk6`%`$f=(t&R^ad<~@G0)`!hF#~Jmy4E3%UTnAPjZ7$A7sjGp_pbZ6X22u{x!EkeW ze@#^0`I&-M5@JEmRAEzuCe;hcA`7_$^4fe=^0}VSDwBUMb<{ljeT_$fb?)}I1TK1H z-$$v!-u^~+4^`bVLkv=dC2kk=oTB+%Joup@CTw{DrV?uveb2v_kB!$K?r2us-!2w= zOjI?~`eM2RF83L3$~{2mz=T2_9vGEfe~^Px)4Fc+MOMt;5x<0!jHntoH+C8zjIc*E zwPt__QO(umH=g8sF9D-X91005gGvV@@rvMD$>!$m&l(jMr{*Gl#`UUkOy_R$xM#4Q zI^jgS#gt;U1%kXX5$|0sS=U!j9K+!(ri;!=sU|BQXu^A_hiUQ-K(iISnC`|}f1+Mm z=BVP~_TC=y&v}R9iOP`KO!5|ABen3~}oZJ^~*qgQbtjQ(` zT#R`$52qHO`{fjX9WvX`AvSm*Mlm-j9+q})*|1_l-fBrg;+1YK_aPgDx(#evUM>SD z*b9HXT>aS+$#ODaD*ik3=aVigf2s0*tRbx$z>+VR>h}dLL&8+-w5IlwBpSo?N|?>I zA?e!g`~zruO#zm}m+&^9us!C%KCPI6tXc^lZ1zl z#omKIPmL!$uP>Cv17^6F={c30ecr5#(M$@XU4k^Wt+@OXG{KTg?SbeZ?2cG*-w0dW zjJ$Y0XsLCnFM`G-I-a31fAgFK0d4r8{Zsc6?F!+3>v%2Y>=0dWtCLW4T3$iq^%+ch5gghKn)Xa$$`_UP ztezPCP{bBk4U4-fAvvy4Ec3<85}8N8hw|kKZ_DnJns^MrOVwNefBW(;#rBLIjH4Py znH-)eD2wXCFgSvf9BXl2{jl+D9!jLE*wxy09pPj<4FnIC!VB_Ty<<%A=IJ};6OOQq zk1({Pk4s{AL6}Zm6C?CSTqc}-=*EeqtmfF0;%ko>5As#v0pFtFTvpXl`IB9=)YBK& z6_^CIMN0I*F76B?a~NsWA1HkjDzz5aQP z^g5Kx$e8sAIhMNRjOM`_pML_&Ee-b_$V6ns=ucsZ@8Zs9f9$%2WWsrcVd14sSdu|& zl*TC|>-mqT!rOE;*t-dNG!JWryAxX#;24etzoguxl|OI~Ag}f+K}^+d&79fHq|H9} z!xI{r?WA~vVKMJEYiHMvExbm&c_6#eD=i<&tmVJekCh6QAN4JTjVrpgP0c{a*h0YZ z7`KvWyYG8Jf38OP?6ulrul`bq>ubN1MNGcsv+nG~bV|6n7qlF-jJ#59SI=9OO9>R*&A4t162-_Ze^URxr8FO>*Oel;fMuZKmWdZ*2?MRx`S~jvrhffRYDl{_ZwISB$ez zvc}!~_s*8N^U79@oKR|X!5D#qfPuM zc462eVT1`u5`gmj`-Y1S zowsS$LD#8~GuDj1WtpzXrOuT^M;+dbblo-9+o8SF@WoIJsdR@jnUG)3mNKpmtP?s4 zf2>7o@$pAtwK{At+PMdVCFAeq5#jkrYh0n5-IP-=s~_9e_nvEd{BFshdxnD5$nT)M zp2{z!9OvM8`MQb$%(Ja8t<>qJ7CQr%Uaeg;j7azQ|6aj`U4NTPQf4G7NlP70F-0y51cf{bD2K+&~NXEjn9Tgih z2NFE0R@McV>Bs9-d)ERz$59J8kL3J{W)ZV<6WNrY8AkLZKoj0VE%ql7z55UBrqD+L zR{28pnCHyCKT*Esb#nFUi5Au{UzBRC%KCahf>LpxEXNdrk(NA`EBAEhgzQ2Ff0<_u zTQZO3V|k)FjpHd{jdOC^y7paldm*u$&c0U*^)Yi8AOHbpudBMu!O*%0phHrLEQS8kv=ciMcz z#5gc2s2Fbxs?&*k8`#-wv8}$cf1NucfYj*J?eY-MYZv|=tH6s~4^M3S2dv0HhD zQXjWgm?MH|=TWbZm`r4S2xBW}3r3Jw+LicXpMIaVRHUWC!;|h^2aCSby1@pLr}2Lr z;zrdgT1ANrJHYadJ|M@sj^+{S{#qZIrp!Y)Z?ReKl2>xu8K%s0!L;knMYAX%K&E)oeSeShsR2Wx z>pm|~>{Bif8>_aLF)xkTaCncGWebd!DS(%`j^sz;YkXgFdLgU(8xh+I4@O@m%29Jj zOjin297^pezlo}Lf4|LR72~s>S&_=qRGiteiE48u^)BDIk|glbtCgyQ>HCAy3hKz5 zpZAZxUYEXKq|W|b+ug(ue)JK>4UkrLKYT_43o5h`{3Ho~Y5-O4@kn8d`ad5?=%H;8 za#>4C+7QFAbvs6j+5(!Wqo&zCEd$~ZS&Ad4-JQ12CstNpe~7_gEB#z=#Xq!SYk0GW z<>lht;AOCRX_YvCnDi9j-^*U!pfdTo!LBvq6X=3evjyfEMHL<>#x@9FJxmy(+pG!` z2+#ciOHcPMe-rL)K^2V|9U=xa%BT=H?oL)9AH0pPm`Y4M@$tj*8FvB_)c)7nN`Kk5 zDZXl=ROXzNe*qVKwdkvFI3?v&M! zu!RX&F9+ud+{JwGn4rCOZA_%9`3cHz7mQPs_@W3==T8Z?zF|du>c@mQP$7fl&5@7x zLMJLe(e<&9VK~IXl+`BCP3SQ`elI1Zw8rqI0UAjAf1R|L;nCjr*dF!+7o*JPl{RC5 zt#9mRju|9gpTF$P)f1Bqg4}jBgGr(Mu!orw(a%>{p}Mz; zrn!L#d7yNEw^WoLU}nx)abIg1Q8@VMI|T)R+Z7KWM|yK9yjOpnS*bcVf`x4HuqCID zcI`G4bUfr?OU!?jq1G^`rZF^}dOGWN1dwV#ulqRowS&PN5DF zf5g3H)el-?a9Vg~AZ9l+a6w zHog;gPd-@d1F)u;6K~wBciZh+)BlpG6u0&HcoJmTLRYGo>2d&lobyEMjlEReA7MS=V?ebV&2_ zy!MlIEfa?F9TqR9_8qnV{`Be%vzVviZH}WG#hOsK7g(+a3uoKLIodJgXOSf!f5lJR z`X&oabUfcVVX&13-BF?IpZ9BAEOR7_9NWu!t@GJuc?pFIReNa{N?7Wvb+4FQd#&Ts zy0v9bBj0Sluue<VKap4qH%ZG%*EP9;KHpdR4VRosKFO(S- zn$4b`_FqrFA+P;jl*=MRf9xbO{ecy%c)CuQB;v}^x;Ked$){_x8*{Y6FY9$u1@}$O9=WYz6IZ;OvZ;?a5M6{RA`vc0~ z-A4uC8S_-=#b)oje~xASj!+Rxn;sJWQk`>O__~NjqWIiNGUfBaMtKr5F+}n;61s}X zPMB>5XMc{`i}`OdGITmO87O`59@$=MazLuXK7+Gp)oA8j=*SCEEWx=hd8d6mwF5oJ zEB?%p9$wpF=r>ISf!hnim!RC!WL@n`;2gdzH>TC3^Ix2 zNZd2EHTEzae6)1h_}#U*jDh4NiV)f9bfq)3&sipz@c60@XLG9?9-a%YGf^Rxb2clN@dBucIMduGhM?@2v9K z?oF;Xdj$p)Q}l%0AysW4(hV-gfuKG>1vG7}pfY<1#k6Fe>inP15m}A`iZ#)8WdF=XC1OGs>D@FaIlr7fAvY5{N#w@!ZX)IRlon)k86+#CuKcn6lIYBIBLIDkm^yU#wVGN53@9&qgERw9}L6lXa1|lw(OQ)MR0`)e6lz7#&1zR#F(% z8OSFLe*wD|!49P);-UEzJslylZ$6MRZfVbRWIc9!qE89C40kyTne^~;SYt2DP^7rz z<+(vj!xVJNg(kl*vs#((*{k*pF@Ly;ZEVw*Hfp*bwJ>e3tZoN7t)7PByl_HK7;hZ5 zL>?0uwkJL^ObPCc|6Dw-9JCtQ)YRgQ!e}OVOW9G0LwbA$vf_560uiDY4%=251@;56h#~K5Wnr5RAvaK z-Dd_{t3R0m8!b0(7r(A8{_Qh1s-M*5MUQA%SO%7lWM&C1{qW<)D?OX+YZRC}FKF1! zIJWHfH&f|rh)*}TTzCzl(qz%%NS#mke`F*SnihQL)0%+BO27FMFtpaQo5bAV@y)7r z%v3hRGv?dlZR-)q@$>5=u>~}dmdGm|dyBGm+xtFInN^$ixT+RQh8x=`z~}zM7D7BE za#+q5=9FbTd>Fuy+8Z=PxI1b1$BlwDYCzrI5I~d5AMsIM?b!+guHV4QosE9Ne_mN# z5OGK4ar0xHv|#Dy!4WSBnBoGv!q_empKM;KHiEu};2^O{!w*!j5v*?hYTlhHj#+I$Xe2@9 zlwN9%#-ac58%{*T@TC!ap@5_e74jT@t}Z6}Rw+h)VYyyHBv ztwv4qq_J(=wr%TwH{beS&T(Ap*<3T{KxDdMv^_7wXz{N#{&G*tY=*CTcKI4SRQcsm ziUkXy3XiPMPxr3YtP5gpv4{q*{^z+Rm8dG^Hqey*7a*7+AYsQ>u}Sf4J2F{y&*R?)vUlolT#KP; z5E% z)%Y=FA`#mB$f|0wcs?2^U9#v;X|4S`TyIdn-;`YPLvMjjrl*f@Yx^;iwze>JST`m} zTf^lzMGJ#c;aAa5alDuhWE`SB(-8ypqZij9GmGq@9QLKeNjgzDlUqSKjOTjDR>Y{Q zSzZs(?27oxP?B+v;6k4a>^R-HZghVfWTqM&+*8Z?#mHe{Y?=D)Vc@qBz%w@>c?(|pgu0Q)pzXuDk!6L&N3>3#hsA?#0&%dUgrs6q%?j`T@ zL85prXcYkluSme?aU`1i=V0cc=c|PBzkaA;wwU^PqkL}8R2N8D`QbkJNurzEss2NB z^gummbX4f!E7zO?d^;N?&1tHp394=)Dz_glSQ=-5J5_Z~kp z?@bB}=nDMm4aA&A9B>FztddXD?i;4j!q=p#GMYaZC7j6mFn`RKa_3RF!D#G$B66*2 zC8Z&4W7AQl@>#qGOTxQj%7gc zW>xs3waM~G7VV`^65egw@iSw;Ec?TiFr!4vE@Q2}d*l~zqhqhJsknGyrR;&ZdfBZGTB`Sh?smJXU_8?ItDWZ53UfNH+ zDX-Ms-Z3pUI{dhqrm>L|?!!0#kp|AShhFJaeN}e*jO`>q{*JZzNv+b2XccrF;s4Rx0#{Mt)t#_tZwri3 zWwBB1SzO}C_P8qPhI{c#J_QrCvM5bvauQ5gh7Q)`jvS!qD^KwbvC*`vT=7=_AU$1E zVxk+*+gZ4Ehm4_IQtpuZ_1Xe&f>Jc~%%1z_p2e-4V+k^M?!niU9F42*dXV675;L3p zX5#C%M4nQBv^82R0=6Y;seWL>&k&%wVxP?zf^~7oAhU43^eD%z7;a4|{pP4vZz2Zn z-e}Z^fwyHk^-XF(+^=bqP9i!~Bs6f5oexgh1Qj7tRy{Cy(NpKxOB^ykB~+zaRZ8%_ zgHqncW7RwQwdTm2rT0C-)RqfmImBti`u=3jSes835iRJ5=OTSFRua7d)Z8i zX`7#>wVU&^<7E6p<`HhELDv60{#P}GzMw5jmZ%F9M@~C@&lNBDs>!GVzFmrU>1v5n z4GXkks8G9yX;SQ3t21l1T>;iTnrS$+T85ms{XS5_-5o$iCe0In2l&OVPb8)Rd&DOr z1#e_xOGk)e|MrFn_*88MunnfzNfHwC_?-7op*iLESi>(Zev&mwX{0%&} z4Ft!9-5~)E7UF>CzsN*SS#rBSnqNCFO&x2XkQr>P)nPw=Mbz!Ozyd+LNul+PTh`22 zx0g!0presDvbl~@sc-n7F=gt8tn52y4EvF3q6+>sj5IoxG+gEUOw^ep7-~ zl!UM`N}2Uvn#=P4<_sXjrINSLGs(;5+{bERw0D*2<9^4n;qyqXkXo6%!4J{mBEom? zJ*3qI;^~dx$O*!v84`{XO(`a6QJBiml;`kH5{VUTX2B~C z9uE^ntrF9;X23e2N)j&biau zO>wSz#K)?43197kc|9zcA}S+G4mGM0gv6z`i=c^IY0+~C?obiIy0_Hc z?lJ9ip;FhAX`s`(YTJWw&Er_mth*M81@z0CExnFl_b!LQUauuraz36iYk9fZ2w4e! z7klFoBTpg_Mw{*}|FcyVmPOrFfP}Lf@?=#_3;LYRdD<+@pUBJhgM=U=UjBiJU%hmR zsMBO@IGJLKdhO~7A`U#~sPEh}o`KQNW97WI=OSE(4y5YA&HvB>J66PTwcNPpEJ2BI z-KYya5`4Zf+(~)}%jT2(Mi$5D_dl10S5i^>JX=6KQu^M-S`nX&@yWM_fD)Iy3cobf zz*ZF#TF>=o41!9mu%q}zqFcV2(Mvlu<5Mu?An-iY|9bk4%SB*&crD@^L5#XxyP?_u zoHEc=23U`i8gWWO9LorME46jYznW@U1#4@7QE_<<^oP6XEA-G?wXS|@Zn>~^UwB0F zr{pPp6`B+;JQvs_*Xn!kD@llW5y8GePFK= z`^&lsZlqwe*POrq=>9I?P@b=KCwrgK8=jic1sJXM8JVfYDK;Or1=;^Y6ECK!|EJvPV(QgdL)nR_iPnO0>1 zc*4%S2WP9cv}NBO1d(Ib`3sX*V+Y-+>}9FDxcT=~!5D%ac4r9naH#LF0C81B;v=uk zO(f#w^N{%FX1iHXjh z8`}B^;O7iCzTOJ=B~zQ9)e3cAz#qNRG9!{i`}fFgHf-0^Dcno%l3kd()q^;_p8+&+Q#NWaZ7zH7bvpA4z_G_sA)naEqf^xY&eJCspKKvzY3(z#6pX6O7FQI{^6yTXqj zd9Y=ZTd3DHeGFa`g9euhPSL^uRN<(?r?BKDdLMn-q-D zY+f${7Tsore|p+hLl+eNHQiCxA1G%IB#0k_#0{*OraUt5nC!lTmFSZ9MKC0h0Wi2G z6@DHXWoPkC;{-i2-CNz;95VZ3PA!>HCq$pnrrj#k!|BX!{xe${`LO0DaUDzAcOkdAr1&8 zfHQN!av-2$#mmr!2*r=8X&)xe8qrt?^)s*cODzAWA`a%jbIge3+$>qAs>^ z;A0MF72MW5JO>jSk&Mf6F807W2xw@w95GrAlHour>AY$ z+fM+Ebak6snPnBCKh1;J6 zyY@J7)3qafxRQrxICldVR#5HL<<$ad4Ea{m#jx6ModlqwUb7+5s5+~D_QqH8NRC{` zAiaS=@1Li?uG96jWzby1u$`^fseG@?Bv&KhWgYvCAP2-6XJ-{TZocBvAP)Y%Z-o|d=osep)80xP zyCgQxvY0?ZRk|N$nxe>DBl-HN*z1R=Vb*d(dPxy<^M?F4Mc$;JCb)Hf6qHP>c&Ctp z3fxy2KDymwi<{w>&d(!*5nEtZKPdR@R2keElJ9-95BMIQl>2uG=3)#q`5MbG=FCTt z6b~e;96li#C=shC`TTw16k@H9|J-xQGw{PW&_>oTXgXX+*s$vtQnxj=vvfZLk9#)w7QCm?KVE=3RuV-&zfkHt91TK;ZYlI?lOLD6 zK^%|xwyVoSEcjO=$irCeR;UIG@+O6ck9S{Zw(~1Eh=s- zS-nSuCh80?ncQwqsUfg0&k<#E!#zmC$Q=X;Bx~wKI>T%JCOls7DAq19bZ<@GrIYBh z>JxocB8NR^b;>_|9im(Fy`!-;lnBHq1c%Mc$YL7cfFLwNa#BN5)exFnFtkz2wE+?T zuq28#RKk7J=jls6m_}?0sr^4g3Ow$t@qB2g7kDS7IYqi$0mXm28E&kw7d;-1smd4> z6>-xaWqhMAvsqqh5hc(}?ZYeXF_()lnkdlAvCzkqA17@snGVN}MW{aIyT+}lihQr? z#?8L*zW`RBw?qlrhWmD+N!a3g`nSyOn?t|9p&q*`@(Wni zFPf8wzwE3o-6aySBnBX-9{z^BuIF~TN*b>u@G5UT%3~3bp~9U7sbqFNhBfbNf%^zf z$aJ+Fe*SJF{9W`Md`PANbH=lmGj_rkYU1^Bn}+f$#E~K zkExdBYFJUxDaejJZ_zF4=RCdB8+)evUB9>YIL_$3R$`Lf@yomzTQw?>8s}BH5O78_ zSlok23m=qHL%@r$4FD*Ls{yKTUo31uLup)4hrR#YC`Um4ZT|94Oqx{(}mWV215`J)2mAjrgzVwWcPyVX_sonVE9eJK-rB*{81;k^t;c$qXm zmUDH!vuoU+JYW5vp{CH0B*Y!13BDN~Ex~sXpdRlIK`~=3RN(Z9>}nLPxe1g+8L-*o zWXOdZ8BLu9(sK4uKkC6QG(i(f9vulw;{`RKm{!k9ljUV%i%uM<4fm#)gIAai$+<0_ z+?3)D!TZ_%suc(&tGuJMT|zUQM^NZ-Hq6BqzCPMVx71@Tcz72f7z;bPH7sJbp?ZS0 z%=b;|yOITH03i**XP7g@vn#0Nt>c&qOerMkP~X*C^1Xj|;@=!oaCya*Wt-DVhuBNM z_H&W^`W>~J*jh_opNfQf$|j_W{pQ1ptwPH>vs)l*`{xAqy1^WY!e>O zR~z=V)hSAnf5iV@8uZjcsK07>?pOEg>ptWJD1nT2i^N=xE&ahXEddRJaE~~Cmt06+ z#37s;)y$DX3N7>993wu;XpW0Vx7y;S_H-enSrt_uVh*Nt-5XZa8hgj50y!i)L}{A+ zKKvhs0MN5rhib{r{S5iX8^dMr*-M<@q)|}MsDLEaUDTF3jF=w{l3qrMwbd8ms{C$z z|4Fz=hpYAnaelURLj|=qaJ|U}7{zd0ic1f*fY@7yo9Jn~+ahH{!;`K6rSe6SLkEAc zk$+x@aM37QY+|;!1a}50cHDwBR@!%SC-q+kz!G&VVw26bxn>dyGHy75T=_Ob=7`{V znykw`Zb9YQnc&=bC)Jqkc8N6pu*_>i#eQ{hB!c)*=kZwW8Q3u~-y3R8!h~wVDC6Z^ zheO=Lr2Jsw+eU<%`M27sZG2~^R!=J!;A{%Jm|mc%bBBo5L|ibOW@j&zZo3=3-2Np8 z*s4~vG?(L=FSA~_CkNkH_c7z^%w`!8HQ5Qp70B$LVoM7`rA*xMz63(~`;bMVV%@NE z^s?)qkg*K_xElyh36Gh~>`3JyY#4_13(y5be&=^rG*KBlYQ|abfjY`MY4l&G<>br@ znUf!{I%60$ldS})rW?6G=Q60#S_;&G4v{pitpV@=EcQacrN01YdQxDg_#dbyoMv() zD2XA_N+`VX5ia;$vnsXFhP-{Q2$Wa84{JRSU5x1mHyBa%$4^^zZ_dyqh<%0rvvW+h z;PB}yIzzV)*5s8HT)cq6*Y&|lt@`=ouLQ{5l;E|m-xJUh1jD8FOU85D8hk7OdkSgp zP8%^tn>YNf1Q)#G53&;FVE^>#ksDn>tpelg>MoI;2)m~h)R+M1=uVZWphw7?^SeEL zwxGPN*e3#X(?fcrUoo(2@PzV1N&3jSl> zf`h-3XT8ELSy%R^9-io~`UnD;?mCSc*-XWPZiRM`1k;OJ>#muWb2sjdgrsM4m7M$} z9K{&g#PJ|=X8nj0BSQ7LVo?fvPT-N5oP}dNcFV7_nnt!TMtQJg&Hvas7%|=E|7A?J zMMzKm;S&2oJ{Tt=2W1-tMLA>D5lcxY`tcU#u=waeN*L>B z?Y1ual=O&4KhX$Bm}wLcXT<}zu%Ms&<8Id(tPfB@e7 z^4lFrtyE9Ch>^SJvDiUP+K z1-!PWaf7K9S5Q^X4R)}yhy}8`gSEGJ_^)WIa&YA%9>~{$QUFj4A0($h9J*YC0M@2N zK)*0^^m)qqayWbn8p2jhy6)2X_3#&BI)v)(U5;%l`C#xzD^@L*kDO_eQ+CFoeirT( z8^-xs&2Diemg{2li2}jzaxU|R86~@3&ybAHLlW@AOz8a z+;KCbl}dkeKY^$Ydj%#FXHz%gA!$f4EZnHA1Bd?H4g-?o_hB5k$gGl3JQgix^$1;W zeKu_Eksd8mjp<3leDKQNBe8$*rJ-r`AT^euLsE_lSIjyyb~&Z`7V0!G%HHmezV>yjwXyKh zxu^5I9)h;mjUO`A(6w9}Gb)01?Zd2S4usQ9D;b@HMAw;9wN(9Aq5&7+j(yyMsjPi9 znXUr8!uonVO-w zS&cV8zg{QDseOgS&;BsB7ER=*zl(@35?1584|qPXH@p8b+3suD&B2ZpZ3a*X_apWQfdY<^2kC_z^ z!+=DHMj#Qg&H#pog_DDug+2A>4J7{mM5F!3L98h z$lU{R#5L$j2c0`DqnnRVgdNe@(FU0+YjN$eRFi~i1@XddE3{S2C;}(f4Z6yp}b5!Jl z7%`z6ucVK|2o0;y4Qf0vFucl0390;ugLs1ui(c*O$bHViQQhKd4{nz#O0aB0E$XsX za@J%nX`URN_biMEI@V8pV&~9r{Pyh|COYk3HFh<`(jQC_+xZ2B`4MDpoQ$N4*gSvp z0WCRIrh^E(+|*z8IqKz;UM)iU|Ds=EIe)v2Jqa&oO%G8iLcfhSW(HmtY@4%edCwQp zP>y5Riw8pa>B*I8^V3d|s*H~An7Ql-mfSm2j5BO*{Y0>Vt6m$8)5w41z0CT?{ z#aP3s%W3u5HM!63XY*yf@rhbx*KtF^O+nA@*a~=|?zG;UHo}EXw+=ioEN7yWlJh^b z&=IG1`+xKE{dHqHedhhS$V?G5mtW5MHeZoH3k%_30zAnx#|Cz5vt$!fRWHCXm*{G%Nr(`HD}fuRQ7ezVZ?S}Iq6F?9Z`FT90WmK2zcp=!nLqm!qB z4G9{Q#pSJbsdegguHvhby0N|Fxfh!I_r*g(YF~fI0x^eM=;X zNTNjUVd)#D&*p@E1Td-a6+^s3G!+py7=0v)+sjR8(S_}Ac5^;m-)ask5jxLa9v@#y z^zW6+iFOKP#qarRW}wA+;TbU7b@O7OuRpLqvfuY{o&>8e@ZU0)xF~DslL=cpY-EFA z*ri#e%Ha2FIOcbrnu8w!Z7bP?qkHjVwc?J~4>L=oMhzP?6&?rS8%J&>$i%2}4T!M* z?TH;6`Gnxb^vK^HgkwkHQRFjL2oix+cEBpuU_ruOS}(E|p|4%GoNwxm|dVg-+ZL-ufLIQ;!Ke_(|w(3?^1hQ3LxfDHGp zMMwp7Wmgj2Rja;GCk{c8 zoEVjAjrm9XI(@L*_}$nixC0^gIb(R&vkt4=bu9Dqr*5C+seX0T7C!Ry?Yzu@5QF@ zHJo13`8pCb-#&%!4rpVNSayl=zAio#KhF%g*-N8Z-I>@Y^eFB%>#wD4=_aeLB-|Dj zwTMlT>)=3E0VTsiDTWV{A*Pwa68G0RA6QXjSSqE8)4g0WkeMf=9k5sf#5zX5Ul7Oy z+IoA%Kmo9pc}aM$rO|p6Gf5|Du?Hii_SP;5a^}oQ_ALwpDv*g8f#kpAY~n-6<8{~} z*BWk5))*J0T*Hm7`P13KcCp&D_1tF$CISt-mPyK80M(9Yp#ACkMxi2j@aCU0^> zKNf=d{qKY@Gd%b6SGfE{1_b!+{BN(@qq`?w+^EmH>oz_R0oPY(lKbS%c#6ZZ^^IrM zhgo$54FJW>b9i{~c&9rZ6{$GhW-#mX zhL3D2-Ye;&7JXe91+#NX()lGa_o+C+@P^Ls{`>%(=06WyZ+4yC2d?7zi6Z+sO=!uo zZD6=+>x&%}?{43L2S1~L1H&iHk8(?xXB1w1!rV3w_Z6p})^lQtXOc4^rmrt_V3Y99X9ZjZI&m<4Q21TpA;9) z7jN8RRw94{mJD6SNa~Q4*r3?u@wqOE9&z^2LR~Kn#*T+sud9AG@5eq9o!j)TZhgGL znFF-t!Mz6;X146!|9)@UuhP1>OnQ^xIAFH`vfG?T3K({dUn689`U-voNq=G(V`ztm zdD4%kr(G}a<(Cu}fEgD=_JloOp08iu6MIuq%F{<+uSk!QM1UiN*1i6_N9x(tg2JTD z#7Z}ZVJ)WBtYp>&8enuYpmy6uEk&NEgZil|4?nannHAo=DnD~{;daGKB+|p<`qdWT zju}2@qgNic`LSEW7%H#)=)9g58+pv0K^=N!=H`pEo0R$}3v}LYTB@t+WyPve(hHbw zSU=w{WGz*DXA(XW{R;11uhD(y#!<)K-$S#Y5%i_~68KU1O3i=QtLztU98M_tPdC6+ z(r(yB+6q(J15R!(;|tYMe4CW18XYZ=#vS7${(>qKJ|N~T%l;c*`wq*n%eZwHsndl3 zve@|};M+8p=Oo3!z+iKoC=Eiz_pV5VD_5>sJgr}ZfwCXi3K9-0yb~U7Oz5!YtL^u; z{5HHy8zrcyHN06^*OgPzgQEsjvzd2Ksb|94ig@r$e^Fh+dLJZ|bo?|8*fmuFFB&58 zL!o0kFIx}QYz3J*%sZyL^5uPnEWC+8-z<$aqT=NkRetAp8_!>L9)z-B>tvd)xKXV5#ZcMPtPK=W2w4$|oaTls*R?BGGJ2Ix} zN+3R)+tL^fFdHjZW+F?H#ooLYqN{`QRZR6C5M?s$l6l2vPesk*XgWTue!tj(XRN5{31@X1J~I+&Z?2=H`j# zJR5uJbJCT$eVx?kuHOW`F;uKhtUiZI-0Oa^5QlaYLvY|^a69U4z$9MB%pZdk{rw|1 z)Y~%^y4}gq8TLuHp|G8q#HySTW|#~6^5PJwkzHeMnOQ{t;{u6_ax$~9aB>TCh_mr@af-5Wa0n3d z3IBg5`v05bAZBIbO07Qr&x;7AMj4@mFv6~HiNN;r8mE4x`But}DyjJk8(nyyz8TZG z9*G@0zJRJYkPAt5oD{i9^z+0)DpNWe+b|2;D}qHgMu)D1c^*XI7aneZq@!S`rLeCq z!e}jdFkX4cFC5>Y5pYIJGLW+gdr?H0<6=L ziWJ^m;K54%I9frZV?Fp|qHtJd%Qc(&N&0*3DQ1tU2Ii&lx8VQKCza;MhbzCtxBng0 zgRflhG~e_h+xWy*4&%8NKK!tsOC$w|d_9nnwqaxP;HcmY&$%C8Z9Wr3h((e=p@`tw OSUBM+D8v;d;QtSGh7HRA delta 27244 zcmV(jK=!}HfefgE43H)PF_(ef0w{mY7fo}UM)a;N9y=Pu zAJS=|iYK6$AfX{pGxPmJE#mQ)yPvgsW>HE)A(&AghJ?GG<#3M#G6e1KwRYcrtP-`< zay0W90XR{)kzvf2zHd3qCqXEHiMfnB)ODx?HNv&1N4O_zH4bwnk%6=vFCc-2HP738 zHRjZ=VgMy_QY$2(WYRFYs0DvH=-3IFu&-8SrLs&_sg__Y(rO6vnI=avgLE2f*H92K ziK`-wAI8$NRrb9yILI&=*~7^&&~D3*og5v!kaM8CNg#~@q%mlxk#jpO0j^b1!785{ z=-HQN=kIR!1zN|82P9;C8!t-t1Z-Q8nxD1Iq>NBs*3SANmcu=xZjXPbho3!hNIt=V#9@Se{#ePB^R^kETO z^U<#_wXr=>w1!SzSH^qSp%{WpaNzZ|WA@4jhI9=ilr> z?2{}ldxK+^CwVhWqWIqB-YPXiq3KoAaSvl5Y?Yc$MLCB%u|Tg3CIS_`ZVdi6-N=N# z>~y*R$KA-JM?~PYC;qNBU)q-4MtNCVF5+ruPQDoIOMR!%PG26Whx*Xmk4(3+s|zE1gthFM@3N_eTs|H+{QqhFVfk0 zT+WJgy?xZ|F`Y|a*r(An!+4y|l46U7weWXqKWO2Zb_;*kOzwDVcX918w^<)Bpr)os zi2;9`Zx#tG^8(=QSAd^yzI>Br-_d$gZI)=~fpg?8RQ_Y0L?v!-;#HL5`tuBp?55L<=-r3fAus=18Rmn^wGl*$4Xvcu&boV&2LD@!~Mt4v9*6i&(ZZ*I6~HLhkXjLJ@kXICcjpj z(sXe<>iyge(Cj<D3NK7$ZfA68 zG9WTBFgZ4pQ4tmcGB_}ovC{%4f3$gJR2*BkEgmem6QFT-cZcBaBxvK%NaODA4#71z z1lQp1?!n!HgrJX{b3eWJ?;Ab3tJhpwbFa0lMinKgvKphPDaaTo1+oJ(vNEyo0pt}_ zLAFMAtZa;`KyzmsBS!!m6AKFmA|<7`BhUzJ39^$g0t5K~++YiUk_q_DfA`ITg@qT9 z5+Dt<13JDbO##O400kh}NZs8Y$O@n_`b$s-Ie{6Cjhx=pKs$3wJ0R_wi#W*M-OW9k)0_(mPvsLpa^n(11$kGAUl9D(89>Z3;;3% zr~|bD8fucNY5-|fB@JaYe_E!uz-rF+_8`aqsYP5(T|=4yAR(%#E(ri?G61AC)YSj{ zssrub>NjTqD5}5d|Kxcy{Nt`5sV=Inqb$kF{O241tN<6Fqm$*IwEtBb)mvqNf0g#; zYUT*C{VM^0#sUns=VNAeb#-MjcXk3ZfgH`5>}~$4Pu;@O3E&EHf3ya?9UXx-z`uxb zwljUB6KnzeJHVe+0mxgL0PUQBf1IR1e=BX@sC;vJ!@>V7?2QQUpO`j(n**GH!2d{N zVdV6eue`FdJiyk-(hdx?GqN*zGXxufot*%Ne_?N5pegm=1p)!$&W?_Mawz;m<@nDu z|0rDy^mbW@#1oZ}=L7JtZ~<6(IRGqgO)6<;Dh{%> zeXH6D@eh3xmTx?PL5}Xs|GTlR?Le+}p8to!%+k)(><{;*f6n&I8g`Zr&OjN7|1p1q z5dVdl1Hk|m0MG#dbThGF{*&;pe)$8l{(;|!@boOUl{CM$yO?Nb|oq{cl4fTT2`F|1|wC6D{DMYH1Wf zjAeqjgu4L$@lz7+x%&PyCc)0=0M*oypSvUa97XK7E-ojY8+gkwb{>_3Hz-;?3 zk@YP$f9PKhZ%U9I@Lw_)fY~1CXbCd?C&c-d!O7C?-y*!(fd8d_iwCxF1pX@qC(9e+ z3i>yPw%|yWn z>}ctx$MQA?tZ(?+=O6z*{YL`Ie@*bed5ejGf80D7IoQ|$jBGq_i^l%8r?9fJaeM!V zugTw=;$I{9)+Yau|LjNrAkYnHg1Ec@GT{%hN^K1J>LXb&RR&AR%XC_SBcv@G53`&x z)lP^fk-JR>6fX2{_RFLy1j&Eo`{a}CZ&$2M8H8=~veA-MIeBBMBC=!Tqu@h`A}KnW zf1}By5s;~{llgM|7EP)-XQ=XH*u>zPk(apyIOyhH%!yG&brB zrcQVdy(qm&=P>4qk%W2zpa`M4y{F0uf|- zIXB^Hvf`MrF&LDoP|oS4e~4G+&QlC3IvA&ms!_u`rv&8_By8uQ4Lzt+1J^Jle^wM{ zUZKlT+_Z~Qa^JuZ67}S}`V~o1xGoQ_=;6^S;UQBXHo7@iQD5KJgGMmLm;FGhm zCZEmJ%7l78sd?xF+ln<442Nwge|^T8HLae0`K))4nS3WRwF4!nqRY0(RVy@Klw@R2 zc%Hc+sSvZ4qbiJ=z0^a)tNnV&>fFA-=QiI^=Aok#Ncj!>?jmNsCrQBA%6zbz9 zTA_p_W2vYU9_5|OO9tD>QJAQb?=g=nAUg3M+)gVt=Pe_cS~8Tj0K}gwe*}YLBw^FP zwjVwCSv{xBYcZ`VgZb+_>R)xt!;_A70S?R`FvE^4zYkWjsWh!8B8*XBK%U`>4UTEF z21qK%2B5#3tN&6y)IN?=)@jIS#unaiBCTRUhkhli?X5oM2&scy*b>8o@&D-`epU48 zY?VGLokniX5zCpd)dVjoe`mSNw;q_WA@&QWQdKxx<}xZ0q*o|>I)=ZH7(f22LBaYY zjxyN1aQ1vgYtpod>{ZrXxa=JzBzbYEZE@1*)ul)ydLw?Dw?HSO_9O=R=xy#|hQAlu zBXx+6)O;(UP@UP2jQ)q!sr&cIgdLU?@myj7FTnRjGt}Le|okwEV#^)DGHr< zd7S23&ljpaXLb6Pw_7nXS9?k_IEDUoTe&I z**H!0e$4nhcDf(we`RlleVlmv;0A$9-d~Y+`VcZ(?8>xfX79P<7WQzi761ICu}} z+rQ#GQ>aF83^QN$y&G&^nCRm=XEW88%-G;vOUz#&-bb*9oDiHaru%(y7?wJ5J=3t6 z!f`H|GZ^ZCe>uKKb~Xv2#gdrpUc92OuVs-+se?zvy0x25&RjtD_0@a0mvMxh>(EX& zzw&KG>$$-1HvghqQTY43_A_RxS1F+~)!^2J()z3MAwACM&KzXfgF-5=%LO^J%kb29 zcdnp?*drC%UMdSRo{6+~-}D$5klAi9s42R2%07s$eQNfU zkMQIKrl#g`#v7#;MoV&`e^kg%EGuqg{yaK7%RCn_D61A~oDChWua{(mTgE}^Ip|6J zPFJoaUh-IDa(bGfcIJSJt4b|^t(({E$?jc{kkVl3BXw8(Bg}K(3o~|-_W}KeTGn7T z)0(Gmf2)ZfB6s6i!(NPkd%ig-v!ID^hs2d5eR0hy#C3VLA^CeZf$&$9{IM{W^erg{yu3dkNt#>h&52_?bj0xeQpK%G;cOeXH28znEvn^A-uu|AtU@fTzCMbn|q(t z+=tNv#=xR`60>ibF=yiFD`+%9)@fk%$El+Hi0=h1~X`Hy)>+uTf$$@5^+PqF<;)poW=R0;Voe!Y%tx!585kXwY#w%xUr#+rA445N^WuwS6}w2==JqnpBf&N z7B$+2i$Lc&?4%~|V7>t~J-vq;DT0B2kiof^W zu__@FMIRNFz3I(+CCas4Z&LKbf78q{9|CSmJd(9!i=~EnX+t5PkR)9vYe5V%)N{^` z!Nt{drVykb(+B^2!V`plTf6jtKV@w)sIHCBSPSjHE0R>LmuUfSjjPY^n*c_oRnF1BPuHP^k^T zpZ6|F)-v-t_a8sTDS)|`r-?N>DveAy2!BLmcbF@cC>ONSFYc+~f0+)WLV5Lan-}?M zO{x<9zAR&})5J6XdSqTCyCSSOym~4E94&BOfX?w@@8uV=ZtF+mWhd&}$u|O<7CMz^ zdFI7Fp(_s87tf+>M7;b|+LZtBKB8sygW{$yet=p|+mimio@$I8!@HwOX>t`<)Fei6 z@}e{J`Mqy)zBwCMf2zzW3gcD(UlCUGw^)lW+?Nok z`f;$v`pPZcL(0)Rn|D{EsE?rnRDF+AfQC8YVbXxqHWy8Jf8u!nh=v-UP<|uo*%>kY zU@SB$WXa^G(P2t9wN}Ef-dKz3>3*4eO|6yApgECO^~)`2(#e93Y=_ITbvf@9N&TuU zBHb^&;RJ~a!EZNR!td$D%xWk%k^S80*>sTv?u74p3p9b084^%sALa0cNN$-=z1+r? zGDW^KPv1msf5&otMZ3-0i}6d{uu`aY7ey4KPh-6i?~9(=tEuaw?^L~sOb+(L7dtG(*W7mW$ zwkU5wRiX;j0aK_o3_mxC^ZjnSNULkG(cF`J__^C_f896Fxly43-+N*o(1Ak@|5z6l z7GvFm!Qd>G7=lyEi)wA*95U_uo>V)(LAbNzlsRYh&}X#^{eCulPa{0PA7b? zi1o7De>XvV2dfI}IMFVuk6yjj7;(=HkJmVG+bn z!W!p6zVLi(j9T@IoBqyPgwD#?-~@;0;{-v_>avr(7+(8DKA%3yOk-K-=nGeds!t@< z5t`pfNv@noSS_0liYJC`5AwF{s1fEIcDE+VfA?D@lpkr+S}i)d|MBr=#BN?UxV z!S@x`u#By%`w>%ZX=|DGwlf&CDqg1oDKYIZg*g|Odu|mS>P%^_-Uk);WWBgQ7iD=V zfA*^gH}g~SUY%xh#J$c53f6dF(v^7qew{hc%GzuMF?S*0Clvo>>ULM|A zAqS#o__;!}Mx*gc?Y%t8XC5hES1Q6YtTv#l6Y^71Tm5R+7C-k(ui$l^@L< zY)yomw2BZ()Ec#kMpR;jL*YQt`BQn8f$KhG=R$Ikg)E^-C`g)9ocK!UhAi_gf2CHZ z8k&ff>I^v}fmJzh)#<5PwFfZ+zuS763P8^{=SOOftU=*x;wB849je5@o(-O;E~_vM z{+(3Cu5fRrnR}-EjrPoO^A!to-!QLyv?a7F%HP4n;s;SY%Pb`7C_qqoc_v1J_;PJk zx$jcB)oF^fH=E2)Tg!eY*PEEhf7$WGLzQZ~xhgXIb-$(dizsc^(O#R<0B*b=| z*>-K=IhjFg;gaB#aIgiCK16_cki(>?cy%Rp0Rn=RgD~s2*a6!uJA;w2e{h+;Y&Vhv z4P~K~#fe*)AOmbrSWotWwoO6c>Qz;w#KyW;!UK2csVXN&P-FtlsTXCX`7-T9{o*qHzFE01J3+*$yT`yW9$(-F~@-5yB2NM)UUfwaW?;sed*g`%zOAPob*%`bjALTp5ewKtyE! z;2?D?;?`Ys{nrM-v9elo&~JU&iyL!h#+kT%)mkA@ImkJCbuy?1b50~xCy;PIv9Ets z1$IVCAe+N}@l}T8f6}WBu3*GVn3Rle@rNT(COyfQCwehi*0=J zO3%d%@;678syK|!m~`YqB9wN`bXoql(RP#RwGiG<>l@BQUxt8G*H;o0*Iv0J|Any{ z2MeXmdl+;kUzBpOjS1l)+xct#i;i0P0}l~ujvjS_<{>1@e!=w4eQ!Z3rke*gt#ZM58X)V3+n@fJ~HPY7QETZw*pF2PnE334}X-jWsIW zB7zQZl_Hbf`Q?F_3*u@a^9AQwxQqVAjumySx~x}_GJ@`?dT)De>3hkqmE-@Ok2fev z_Vfl;V>o+3f5`r;AXlW+MzU$hu%%cfkUl=_=WCvfdSYq-DVq9sblhD7nd-XPBd&&z z<8EbEph*-1co0BzG|+=2D?iR%Lmv$axWw=U&ncSRi=F3ezz!?d08E>bt>}?h2B{C` z#QUwMI4?sRfSnZXm@%1XaVhARVLF>sr?%R*aQitAf8vZ=XG(MD2DyXVcWRWB`DdDd z@B>PmWI2=&j8C~ZkV+zD1b&r{y}>^{pg>-x0P`gQ9q27H^B}l7A!2ADcS%fWEPf)> zE)}2`SkjXKb&akv;m9LXGSV~SKzxs80ZiQMZzP#tBQlwz74=8 zx15WMf83pHk^3WRpOc{}g?3cq8>=6vYDU)*^}z#-QH;OatNW{q_0DSFOx8X*g?CJ` zSFZ5bpyTDiW>6jJ+k8dt$5t+X&Q%En%8^#s<~)8zmT5Vc`XDs(+(x`9U97AJDQ)j! z&k_g&t#Ry)+x5ANJHEEW_mZi67swCZ)2{$+f2{u##Y9DD>1pKBWYG8OVB|;_qki`6 zepDA)URY+_kb7VJ0lG`v@TD-$^!W%Q6%5Vy?kLyRf)i~bZ#=x%bHo5{C}l9G2{VA% zL^h>=I)NK)RW7Z@#z!{dn z20sdXovHS68bv32?N+lkqkQ?;ZE#-Qe^IQwfgmOMb9^y9w*3-c8X61kg{*ln6tQW2 zm9$$h~-^*2zD9mqwn{IIl$GM*IyijfBTPc zphgf$G@#4OKYZNu6!{!Keh$fqZ68`uh&AIcjoVJ^`x8gzqKISnTNS~mPb_Vq*}4oN zsMc*@q4~bFY8*M|IRlVk6cYMEkgr|4YD7>YTq~|M^^40s!0(_PI``qhw50!K3BR+p zY@>m%wnlPNS6kiTnUZES&A)WPe^^UVIyi0NXwuDi;tJ_O zqQ@_xF7qV>q4Rb~CT&6@{7m=V2lnYNf_QA*uOUgavG+yQN3w7xB0mw`s9jpg5V_Px zoGziiobiZ%o-!f^?7(E>bW$WU;}&DrK8vZYdOPsyFwxm+>z|2*f5{nLiR%Tz(I9NS z=c?Alp6fQ|^wKXy%3riiYCqb(1j!WN>Aw;vMds?gtR;RXoPTh1^zj|Y;I#m<1(G>aONn}!8QKA>`x)@) z*Jcf^*bbRl+@6XtQ?oS{?G<3NC(vDzgM^nSqpeeTKyuB$BOm#)4%UkkAa|BF7*LP2 zG6H@uwA%hf`DX6{UO_1YqU~4n(Ag!kkaewre>af*cv!^Nw+g%)vHsm+ z2k)pcm2tmi=n^~@8J8tTIk1N--v?upKnLF9#UOm$YW`0CYlqqBvFjGGA9n-+MAHrT z_@QSK($0EZ*zvGTGHiY$hh1VcNPhCNQ78SjYqcL!8!=hBalGkfY*w*aQsY|5kG%Gi zByC8?&puV6fBZ1hMNU!Fk{_O!>>|RI#Z#M8pXOskjjT(b1LW(a=AgVALp9ylMx&B# z8ZCB~dD$ouZ7thK&N+|>_w7IC$a|0g78g}G>-5z4Cm|m_J1D#132muFc%pWm;$y#xjp@v7@jd8qsd{d9_jsZ%penR* zC>z0AR2TDiREW+w`O95XGDKQ|npCW}quz-V=f$|59ZIrBs5x{ztSY+`=@Pxn23wWk z31{gEf36tm<`4L3MX=^#|A%Hx9zlZgOF*VQn!*DA`wJi{1P`@lSj&TMxI7CtPr5ud z{0VMF$JgW4N?S+sbbZH)@4y(#B05W|lvDh`K{j*-yScc|*s*qo69sxT0)m!@T4>*z zbWbjD;LOnXIYlG%iS1*(RF_hTgs#kJNGOdYe`yF!XO^<@O9#OM4^CD5?Q_ie1+E;R z1=l&EE5I&*8v`GH*NVT3K9X$Zpq)#3k1S;W7kn%^Z+T1%L%?ryh$XX1mNppb&hWXw z-e(T$njOzNvd36OgA0}46v*d$%evB?c&P{XPV&x9HQ#6~;7)bGLbMi4{)wYDFX4uS ze@51#CytJ0pL}tft>tZ3F23IXsHXchsL+%_FIngoQ!d28@tSf#p?w;L`5lYd zaa~=O14A^xE(dzSi@09HuNhempIa)9trr+JH(oG}Gxs^!5KX2=_+f^}(dzgCz&DwQ zR&v%tLSf4T>Q$0NLYfa+mc)1NGU+=2M*FC5i?iz*Le^VG# z4hwlaN5q^gd#@}GoU{@(EE*#4s=``Ou z0KfT)c8eA7%$unmzWXl8V%`n=e=8$dA>z4pFh6|xLuBOLbW@3lLLjGoknQ_eCFB6% zlhN?RXbKkdkD`ZUM&usU32FS4&CMfR^oIxs5tp>-9~&?@i)dXyN9sQozm;GRUnStx zEzlfV26}yQ@F5L@prSX10h{+AgIN7Y0)(tdFN_8cEhqUAe}B_w6U?8se^LiDm0AMq z$sc=s_nah$kQ4?lG%wr5-whO&6(CyDFChQqe5a^OqelC%XD#h5hbBKF!Ve|2{_KjO`ie$3gUAjYZ$Opl zNlx-9lf-D#tA>NL|He?Jf9d&0k88-`GN#1DUiP8Gm8{0}5dW``Mt#D~W~b@qGC)vg zR?z$0#bf}dK^NnK!_=i2VeQA$vIx9s-r`Uep?#v=5#TWDZ6ZaJ1SazZ7Y-@bI1J?0m`7bmClf1$JyDNCd_b~@fU zt)TOpw~$v`_W7jrkGC}{5|l@_%l1n|3dge%bsQK6CJLD;#0sBjX`ZG+Fq%(@k(B}z z<7Ke9tuVYhS%M4tf9-C_Ieks+Rsh3YEw72h6XzP%V_(F<$JPwPD{zQc9^!sj4RLfD z=VXwo!_XfmbrAG@I>z}wo^)PonfpIB&9OHGTFfeHL+W_I@1I9gLty9ktwE0Z2{Xd> zsc6dA#GtEBC+F<{AT~J<(;XEFE{OI-qEx}u=VNm6$m$aye+vz0$JLOdeaBHop-y9r zU&VKzmJAJ3!jTw#U2xV<+^2)QP^Lwq1!?(s7y{E`^Np6e0Cd~J{&0H-!gk=W>iFc< z;o(j%Snmd(q=V6CzF2$5!8pd*S$7grrCU2QL4Hjo^hxkBayXq3KdFDYZg-u;rfFoR zJ4f{?2A-sKe+9eQVd=aAr5saXAz-aNYXG&ISmtAZB-1Kr%MGbDGgr@KQ7=fRs|d`!Y<)%?V;f9o^WR&e+IP-`jGLUl7e(G3S@^nk$aHfwedXUFa)V2e=lW zfzc@F$c_DV*0gpUbFE-DxS1n;5c_mdC)6;Ly;RgO5ajcyaIUr@LpEeaxUa>r(}6xm zF*AL5e-;9b1VV+;r5=B{D7IyWP!_~RLy*mbD_e4zUwN2ubHD_AQLuHhkzur!q95$E z%brRcsxN6$MJSV{)~jb&-h`u_;&m9&N$c|n*hz_N$Z{4yBB7{bRP0zi#dFh>;}-FZ z)bK%llC@1}MqhNQcmB@DO&ZwG1tc7&{MdHPf7^W1-it-W>Miu{fa08ER2=s~i5|OG zIF!h24mNf7Cvqin4-o?&dI0?BBoemsivWhybYGlaz|ox4RXGFyhHzKB6tuq@Ndiu; z2-)+3$@8Kx9_f%?Loa4VKW{}xVb-;l{$%-a=&PN7s8P$Spo)8I%3L2kgvmD%UxEA7 ze_^)Qia>*1&5{frV{XYO&q23uE}z6c#2ZXwgzdC$R*$^flJ zGSb?u1L_l2Ywpu5A9UoVyM)X=^k)@rV!8XD8Iq@GnQ$tlC6Lr5jSC6UCW%YRC8luU zN2U+Y0lSoqpM<0J4|={{%FB~wf)E|WRqHkl5y>pR>0+u8P2!3#!dhxR`-M#De<|pP zEk&LRO|z(}cd#Vf#BB0R8YNXj+kHcTQDG%wg2q1B;;C9$)oLG%!nayfjVyQ{)-U_r z+TR3g9N~V!Bu#uOw!QiXol^NrHfD1>>c=HM%#=ob7Fg-TW+t$VqpIPJv^B{$D`zCs z`$qNn;|cG*q5RU;A?g9NPyjp~e>#&lmEDyf-iws|YIo^Q8#zfP9Um@(p=2WUZq((1 z;$^YD`oWh~T&f@GGoCP1B9>2k5@qw-agKZi25mqjYza;7L&?Ec$l^-RETyN=MhUYN z8m4sufm>J!3}!B4PH~stY10BI^6yTgT`(l+4fL>d(mz$*V24Ytq3-{t+qF%$wPFO6S*Kes11m^JP%VnDZQ? z@cC2uWYsW}npkKhkw6h+e<)B?stA>Rn1H92;UBm#rSUa^@c9mxjNOfrnjF57McQ(M z6kg*wr8qD)FyE)5Y`=SAHBFtrlaST-^|m(fhb`mbc}_ELaEr~?<#IL^0xVLlJZc}x z6hr59wPqg7;dbk>S4)4Y<}_?LG2aUduOXrCd`pt`C>C4k-uME`fBV$+56>QwpnP%- zcJ%qBO&>-Dy0-Su-Tphj%Q~;M!w!A;ZZ|O>bH+OAW_1RIzID&8pY|G{&SxQ?U5i$i zLVYBdm^h%|dB=;yh%qFA&uNV&;TNXrwbD5NuI2PApeE~lE}cGhhXj;;*{J7QuY`?T zTT@dH*uv!MHLjZ1f3;tY^Q6PahU9GeBB>g$A@qPYQ)a0MrCiGdAWu*oS(i`ccEYyQ zPZ+u~U1GvI_qE#aVKkYDXL`ro8FAZ{`b^Smg2S%$&ORf)1PKgz#%_jv^vg4baJtR3 zE1c=U>hb8EeR367&qAwr9!22+fh$Ka+b{_sE2(I!O@GUme_&);cM5Zyw2K^l;V;Bl zG))8))-VFQiomNY!r3vO@K*nGJ1KfR>&?}q2eHScL{xtiHfD4g=IuF4f%T#Ukb;?b zoR>F|SFCK`$N<9{e68$4j)ta3KczTxYQGquGt)2KV&~z-^o|Rva2OOcGhG^gJNeWU zt}qWAyHcz&e>VML%S&?nVQ4) zNyf?V4IRa5*eRB~KtD({B9k{G)`MB@PKcJMv@jfelw9I1Vpn5fvM1t*W)3gbSM&J= zQZvp~9?H$F#NK|rwoT`B0~8co0Mqd}*) z)iP0tf2lMV5f$XOjOojnZ5-Oqm7<($7DEbP&b^@!WRuki#E+$O8t+hFG7&<^GOAn3 zx5y&*(a=8Fo%mXSw4{xz8N%I7&l<=TOc@|H8kBA?F^ZX-t2u!2dat?~7Hr<#?cfdf zur1gFtI0%O4-(bZL!=FcXIaI#wxjrwhYRkZPeVm$E;5-S34z&3UH9 z8>gz-7oJmeQ_v3O6QCR^iQYu^o&88Rr9R6Y`Em7yo=7j=OF1%dFKykfw~iGxS&@gs zf6D)BgA-V}2=7w_z?h^X2uA?3ScN8C0X#B8LSGOv*Mia)lo!tA{#Ew!Th9j^+v6vS z*NOLLqezLpD($QGdhmcP-uX`!Ha;o)pM3he!QN87^=XIxfU%Lg63CUl7tb%G!iD_? zr}S_X@j9rN#Fy80@zH5Rm6d-DKRoV7Hyogi2eDJvUK?WaHN(Q-X@6dG`R%e^}k` zwPc=b&Lq9!RbRebkJfo7EnJUbl<=Z4G-!u(14e#!zANG@dLM=>)oJ7ixwl>Of9SR- zFQVxUR5{Me_t>d$T1sX->785a$KpGm}+gyvE^pzvjgvs9E)>Z@}!AR1}F zCi@q~`yP7Rf!w)!Y$GD9w3#O{e2z^jlSIAY4<$+*5*TqF@aTu9BF;04H5N=RP-B$z zW$$b_iZZrVYu-C)KH!QGJL;%&f0$N|y$7qm&nOt8+m+|zoTGlK)e@47nQ(~ke`Ao`uZ3AI$;z{uBT)ZqITMPA_ptJJV%BBs0b`Jz7`FJD zt6I0?@AR6CR1rvSjyt|d^>Ww^91}Rx-KK-?cIhgOtDoGLToo~7fbg>Og}cZ{zwKrJ zOU6SCZvS3l4R6gNrCD{$2XU?HUoClu07sO*bfG@{F=;}L=V18nf4ZMi2FPlZ##coe zoiF`i*UL-IfY7^f2^;TruwMf#`2|BxySyAw>29eaoX+EI|^)xE&c683^t%IJ&S~x zT>8pSU-PMF35D16pjOMV>l2HjU=@^LwbK&L=u)Si>({lAk>8=c8>O zRuB6{OsW@g;3Mr~e~jZo_4Kk*bNWi}G_^~0KI}sH37Q|If39{d1+Ou}C#i`ItAB+% zp0!nbKK)|f1sQAwY%!O;j+?F~)s9p5siPyQqf*x}h$ViDss`y zZ~NFg6I___klp2>${sAh+lo2GR+1k(RkeP9YZu9jzc`5WO#y}vesS2FwP?4rkupuH z))Y-=AZ2t-f3|Qzq}+!Xyk3wZ$TpIz$fiz^f~L2XPwA=P1-?7kA%o9--K{tHEHhuM zOIT1*P3`nEcpw~ab+v~K3Dxlv14fg5qm&hRBi^sTBDoh*fY)Sjo4reGqv+WK<Gy+dsT{u$JoSuM(Pn?Q2pe~+wCR3+N@q+*fh?8e$=5yHo@ zX`V?X*SAhz<{6Zx-kb14_j!mpjc!5g7~)Kc`*+n;fu8qT19z&OiWKSQs`H8v%0~rp zV`5A1im3jkyL@e5M7}Ps0)dl-~ zYh06Tf9u2^h`!Vs9HJ{ZI|R^9b_;A+lzSCBHW2R=^_rokn@qH6|CrDY`)jm|r~iBH zO;Pl8uJA-C+lD&v=LpfK(56*eN@#@c6HA@PVjg)?~BCRF(QT?^; zowG00g|R*RaOyF#S#eS-IUk@U} z&o^!9Evz3BxRgn#aYgzauJLf@e&hW_q1AJ+{x19eJ5Mo^jPugF{0XZRv(?tm7Z8s& ze-*J#2LKq1v7$B?45k@g`+)#2-mdCm^8OXuH9TxDI!O^s`rc~flNik^Nx-iAQ9n7= z5;gy(TQ7-oXAbPR&~z3|_WrvZ@tAXp;giIA4-_nZn6HHByre$gEKym8^e`DrObjqk zW;F>M6Mv=HW$BL;-Oh^h-W0M(AT|5^YPKT zC8J=lz#Li$B~geoB`QJYWE`FHM04U^dlE6&pgOJ(=V&t=4Ano?ar&(r6-uGqC~N_m z`f_+P%E#|QwpRip!mLwwQAdI1IbnT)FrUtIlU(r*Kc`gHyqI)kww-Bdtgg9QTV}8) z#VLCAv|z%xTP(yj3oW#LuvPd&w5DnfC6iY_&$Eihg7)6?L{pd3uayZTmwttp9X270 z#?&tlaOebRqUgTJ74w(E967sFe?MR&6Jc}}q_gMcFTd~;#8P;+C;vuG^N-_4Q776- zN}bzt^udETSN*!vdwp&d>_k6>oGzGOwLL|mC*-Mx02HN!uU z5*&9CEIVpq5l+cJ&dvGy9L!ovKDg|zzK@$xDHg;zqk2qv^4UXAsF9kcf2@?Q6z2)_ zdgN!uhhep(6x23xOoK2OJy+7WB%FS{D4v25iHrq|+RKW7SQ==1*MwVqP~|p%q4pRx zyiDRhzR4=VERquxMJ08red_OTNSNA37=Oy_=dM`tcBgV$s7*K@v1(PTzH$%;lT=|r zb{wOcDRL(naUrTj{l)G}e`z=*mMx4I>t*!^=0*LFPy*i{J!QV?FBVTrV6ZZbE&VV~ zEpp+FL>$SLPwx`al3Px%H*Hx?5%)@spkx?x@tDf^dfu_GadIR3r4G@^(Yd~pZF!!D zvH&e@siw}PBCzyn~f0y`OqMTj$LMHEB z_xyLQjt*@J!}fF5FcB+aRq0@vzDb9Xb3Agcm-7ks;@4M1%2t(4e`=U2+3&3^H`n{h z^EPKk*JPWYeyY5jia5M3W|C8Scp+W%Z1K*{e!ab8fy6T+J)?c+YlA;_Ak3`E&Nss` zL`%Qph)O!vL;HhTe+wt2y(&6(#?{=?%3rG&367a860*$5-tOefp13-^L73)e%&N3- z#pJ8z!cQYB`QWMj9T(+<=7+Rl7*-4Mg+p$HMf#2HKHb^8#C1=Y5dv7GVVdt)n=IXD z1!~olGWXpYbe-|Xs>1&1wXNio<+AX%oimH zYUSa#?Ul&-@*a-b;WP@y0!w?F)_s-tm<$IW6m|qBn%B4_Ky?ZxcSd9fP~!<-&BZi6 zQMa#23P6SifLpI%S?VfzBfhZd5jKB4XmhpZM)R5vBhx^C=_J8XUap>SF9al6t-tIl zbVA{kcQejQe}793Hg%Vu7%56ugqzfUC$@*WST&`7eiHiqhdP{`5Uv0gEuXuozON8x z*4|E`=u_5Jh4d&3*{n0MwFCL1gNP8es5<*66?ZSiY^+m9$oDM*#79<9iiN?(kI3&y z^?(}R=q*Pz()bG{t{U?Q=(AF~`I$@hU6MX)Ca^2Fe^ns=n!vpB6LQ$kEZ<+D`hE!mwy6b3g}_jsAH?%vCB&k}Zu zB&y8`fAPuZ1lOB>tTk>(+NG&ZP7Lz0N5#^edH%!{tg`o7<8y;-7;Co8Ii*s^|4~b- z5(~73lQH0g+`X-~!mF#Xv5f9Z6tVX)^|0kK_kbP3!iwpbNf~N!OltZaYNrtf}+rylQ*#jpZ-?N{SUSMRxIRybIhIe|YbKHq=&Jo{@7;yHY;a=@v9dQ$qdm z^e5F$on@#@U zse7Kjb6G&0*F^FOdBA9ReF_nYBVU0|+8N8^gqq^VU?3kS_uE+A2|8RUW2Sq+e7`s# ze@#+>io=^^S)S7X%=m>p3t!5ZKK6WoX_K0tZ$tj0L3yNY#IkM5SmiU$o!a1a1cPA% ze5m0^Rgy#x$p{l(E3H^4Ol;{SbO*moS59t{z5H7#3RWHe)odM7KFp6j^21Jv3KNJI zonW`HGIht@<0DC8N9sk}ENrQdkv_2He`S(U`Uj~6)E1vJtNbbq%8N zes9P^bMJ}r{5Uv&FHb)X*PI`Aqa0BkF7Me}voPrgUE<&}ZU+jRL4jM7 zcyklh^+rZ+7#)92bv}MWtc06;g`HJU9Zb-sakrqs-8s0syE~lV?!lddySo!KK(K>r za1HM6P6%!X`@gN)z1pqXyQ!MKn5&+7d)}v8Ja|oJ>(sg&zRn|ZJAXOpTc+*&4DNL% z*7IvbS`bgfbI0|D1MJ0MB_Lzc?tSosLwI#UNN$eE^#U2+UK$YhGom;d-JOZ%$r@V+ zl*>mKvj?L^>-809pXZ(s+=x78)n+vG$i-x;KL*#o=S}TUEjb*`m`!*tYY+9|kzw%(*1&Ysn#> zDngo)dMPLQ9Mi;Pa`=5zO6ZF?V6*`GfA@dareUbRBw|@e*28}38uSj9Fd-d>e%o)cCVn~WUp6oO=bkY z-7A%EQc?FaWi^5&N%^_G7x`;)9nk+71_;xv#GdA{U!0bHEog~F!3!YIUml8O;J=Cy z5c;}+^>A@y+%V!i+u&-1-Sk>LD{czLljLlrnfZBCI;a1d5G9X8+8hq{CiC@kmZuKp z)i%IuEaVF|CqpI`bB4%n(j5jWfLKB%q6P4R$0MWmj0+A|T77cZrU9e2@%sv_)>u!O zT*pzBzh_Md`rj7B#?Ief~fe-L0k#)qDiCJ zekm;D=Z&+3%(c=VBU-D;%>=ybnBJ%G(J6c+Z``3nXW!FJ`U>*%i+`UdlnK7Z3@pYA z8^uwn<5}=bO&H`%<+oz(O-|s~`$#tc!2jSLgTibQt1yS1G9nY3vWEH?9P8hCAIB~Q zmUWYwcF=<^8XIH9Ow)(DK}-UV=fsYbarQirwbnKH{{Zb%%V(S;L6MbCCTfS(|J*+c&)~a-~dL%#khGHWYS>@0dC*sWlX}KO0*X5$|W1Z?r7UXk4u1S+)aT z{+5VJ{^O)_sl{Mh0cGW51x@}T(I+#sZKX!_?NTm&aUwu0(N~WcI5K3O5CO|onZ>E> zA?EKU1)lrk%`YgSZ2h8aWj2N;@T%Zl(mCbDz;(+gMp0B*C;tnZ=t{CHbQN^TKr`Qj zF?6Lrq+cAc!>7*sr47pfaJa1c6?l!|*hg;$?{35y%qgb+h!{+>EJ0@Y z^`I=yf>?kZ1j@~3Jl1Zd8*f3AgaMFxUWuT1{wAg^6w~#8am)+(K9IoA{d(Nu!6o4rTo+XPZ*pYcs{AF4g{mwC6cuYG>z2YFmGyv;dh)| zJC}K3f^0v}MZuq4Vu0Xp=Z|kC$=$W~h^?KwDT|!n7ovHo^YCAT(-cXYycVBzOI8Z9 zeT&EhPrY3_Vj@FS(F)&qPe@j3_#9pha`AW|9{L?g$r|H$+NyJNaW*-4b>4eldsrtZ zM1C`~Vg@<v(&B)EKq&s!`t!K`Pl}>InA~n=M5zdeIs)M`#6KHdWxs z#c`S4rv$ChkFU$`OSS@-bHl$r7gTr3*2@7^{LLCH`9h4--QfpNGhrNFNJ*WxV|&!J zaBs-6$OcdL&|5e#t|QBn|7;dCMfo(4s*OMl+ud;_Gf}8Ukp4l5NEH?m3ZJb?>)W>M zf_y$A>XzW2J3VFz-#%~LHUO~4<3TfM52kRf@$6 zv{K_>%Q3r^PpZP|AEOJ^%nAwEaNpUM_k@B|7z>zPy3wr@oI?1jcs4G>tp?Yh%8!6B zZZkhx_hRe%Q0hBTWlVx5HQjv+nY#J_OCM^CJa3_Ng7b41FexqUGrFwLpa7<^pwwhD z9e=j!010)Rw2wc+UAn#S(?5qPPz@QGr2rTv_|uFI*~GFwBzpSX*!>MGxqkuuN8{6SZ%$bd&;nfAS%ec^s8Ip0V{vf4joEDB`h$f!3Onp@}yoz5K8^lqVueSrQg zy{H}SVhZSb>KIpgVSJI#WJZPOu$Ct>Wq~l$T)GXVj_032^h_lC>sdc3pRed&w%y51)c8N%6fzCG$qH?L9RXx0qYpOF{shTh@~nPA+2*xeqoS=C>N`l7Gj zY-USf2Zo=|eRoQxMpJN%p)szY+3OoTUA4=nYk__A*vak-*LxLEy*z({4G~XE2#p9yV_U@Spu_$~vAv1{dr!~WarJa4+`(Wf(#inv@-g*X?|-0d zGHk;f9p|wTyVD&=_W7Eco@H*QC`|vkY$=}x-gu@?)%?Q5w3c%kitXg)TW3;&C0Tg9 z$;_QmvZgoGrUoi(?8+V6%U?MSRejfoXCSNYH;4g?b{PY7v1GJpFSJP|Spsym^TIiE z)jx0DYS@O&sKe46`rf@O+m&~NPVy9(rDE>XQ44tVMA2oCsxhv0e`lc6PQc4)Ptzxv7-^J7a%`-y_3kF9o5w8H2|l;gzhVuG32(IuTY@(2FN*()udnk zWiZ}2Tulq~JTq>1*GuBND7Y}Gdip9=8*oug7CR36O7_5(R+!>u{FB0?hv@Kk7O|2% zd_}#O`c7t%5b%-hKyxlWW906dt4YfcM%v8GBInP;InY;8+q8aey?^cUVl##iOHvrC zu>4KI#6~iqyC;~j6qf03w^mPX7%iP7=iH7Of!7{Hoy$Q!FrNp-eI||Jnwz^W%vu_Z zHddRps%LQ%N&V)~EEG@^f*@UalpZZxaHlv;d=6)?NYFBPwtj8V#Pe?^3=`MV;&PFk zPnsDn0~9LCK)?bAQyMEb-L+26K5$~^0aM3Ecn$0{1f&)NRn zyg-52mD&FNWdB$i8?9zPpFTwSps;;2i;;;uAQgah8!zQWwuxa~ zzDu`PwJBv?RULGR!cs6Ck3nKy&kAV?5sii(a;N5#hH{@&=Ay9ThAF2z_Dyqi;O+TS z{WmmdI9e*FX~s)~HBQ1bD;s7#3Q4K)%!Mu> zBq7VpLmy+^R72&!EoV9eUw1|nPei3pj9TqwCeM<6_Lma%r*ES%LUSciCw z*)*9RgHrx7D-oZL!V#*t{miW+yCFBvRyK*?!S9zScww9`td~wM(|RZm)u-U=kq7xL zuQEzYKb#4o#~KB|HdOm!sbWc@iP;>coHNGSB70ias=8!6!}z-CQFPS$LX8+>D!UURuE?9yCEao2^)0R&sHg96- z57_$pcV7?jA!MX88F?XJw9+nn!zrrq0%`4LQqpX2E9#EyJfUA)ssgjnvS^?+g=;0{ z9;eQ%7-1!5xebhvrssXl#2}@hWs~>nruHHp5J;y~pgq#Xa5?qC4At}HWTd(55!YLE zXrIWK^l3&OWv8$p?sw^5i0Gmtpz|AeF898FEv}5I3g5J`PT;Atyb2N2Y_{4#J|=}n zG%9XzXUC7XfSkuv^aQo(rlxR{)9&KXmD2-mp7uRjX6TE7X9XmG?8$%>Le5p?;re`V z9|gRY#SJVkHpmIHWStxG7~7=W2s!^PeTsaSuR@}p&YO54xQ_syCVYBC83iv7E-Y{n znT*Gy-~oOWh0s8WNjQHn6nUp}4vBt&zR!9%Y!81pm$IRy^ATd=%61e+Sv`+qf}Y`B z@2|pC_@epod|ouwJ75f&Sm!!;Tz0k>m%%(s5j5#iMBBnA zKBtbmTL|Qq%pg3U=&U>Dmk+xo)zI`&mH^=n8q^P`>cO+SeJX?myz7NGYP|JbL4AWm z$#>a!-D}nJ;>r>+L?%%FO^x7xN?vHysH@)=h(y9+xi-oukT?OVY5C6Q$K&+Z{ss$z zIZm%&HVP}`2Dh`1Q9;TeXQBZ_S5Oj4)8Zw$YtT%$IHP1ChY~OP5?;rX;POqIbE9hQ z5LO6n>wGsiLFB{Zwbt|DUQ8pK4nO~rBT3Vz#k_H5(lL?UtF#FWSz{NQ$)%@cgA?ue z70L#K(A?46#lJ!vM64zpm!dCkJzNxnjdtX1B!ZEKi>%QD7_bz&sTi# z#qR%gU>L+OucTlvmGqBT4;Rp^BhrmYmY`<%;^NsRqM=U)LcVa#opArhx+*N1sS6(w zr<>l|Z*aHNw7FH}yLT#y?}I0VKY5UND2(WS(nCdE7ZF~hrU3UutJr)Lc6up?to|`A z9>aFAzIRV4Ju6Z{y(ictm;?Byzq!vnsLNc;w`tU3`Z|eOPeIK+KOW?cy3BUKdl)b_ z5pI%PGS%f8i=obK;-$pY3IkJi z@9UXA*~VUN_lcVn_=1AzL8$6hu!{rXLHQy>3=MznX8PXEW5^D(+@Y=92M1H&Uqkd% zSKJSsv3in0`RqhML?Fn~|0M%f8(~CTdwaE;ADee5NcQg5TV_rD!e&uQKs9dbE?}rg zxD%QdTgfK4f|*kFhb|Sj?RZpwv`{d%Jzp4{9O~Q56`DEAM;%DeaX9NExjDS#g~@JW z;j^kvr+{5*1v`{+xcm*M@^9k(3qCHLzn`?N2;u=~H_hObt8jXz2X<%yU-Q1lGY(O{ z(J|Ra6HS<*8OZLsXX=* zTlXyze~|bDT!T(($#U4$Tk)-T_u`1D^oo$~j}zBJ^OP||c_K$q(pN1wU*4W}vs3#C z!50BDfAy)q&$IY(?<2koU0huYxZ4`7fnXh$(N#H|09BiLUtm3sCMvKg|Ip*$PF^NG z34hIjU4)P5`^9EB?aKzw8=eEsj5>mfl}zTATgaA)Z~>hU+?3A3qSUb+FgDapRs75= zQfO|4uju;q%PeS}r%^X|!36brk=gz3KnFw5bFhsd9vwf8ddxd`cvE4OfE~N_-VgB; z$?|1E$`7`#QPzG-lUD2UZIGD~uvSju!*2y*GS}yO+ zAkF(yCJD0O>P#gSh0^lyRB3U!n(H<4{Xu%Qq;yZBQJ-WsgDi(-K`WchB}G*GR1jEM zrZvke08aJWh|{!dGwS(P+-~id+Pv9+-M-)uD%~$Q zF;|9UQfS;*WNcALe`w&tH^ytjV2zYO1(b()7PO)_#b*?}tw7NU_n9bo)?=m{(pp@a zFwIEA$ptaF)f!e~#` zjr%}rzT9v5UINc4=t!nK6==q@sX_=C75~cHcxIPbCBj({!N(r3_n4|80yU>(w)oPy zl?GLw%C!Z|v&;W}(7aQ%Zz*n8rd=?q1jOFZ6g`LP~5n*?Oj&3b0 zRn_8d0S^i%)fd+OW2i9sD8SD{56rmk6u!a(_R5HN6XHKLASeSP_?Z@=CrVaEt}S@X zhENm;F;iEdI!f!JmCxxR|K||#aSL+0bepKY`QaxY551bF0z%V8uncZTq6PJxDdF;m zWLS9eDaup$9=3-W0j>9!+_Y+{jv z!Wb1ax54h`+Gi%;SN5(u@C)cn)ee1?dKgyHa#=(J$HQ$9jlM$}45KntHA16l2yZ?O zs!oJWt*vZd>Etdc*7G$Wcl_*Ic2#o5!U5%ea60GNc`y7&$fCTJxqEn|liLs4Q#im| z!rvf+6kjR%jyRqfyO}P>JesHXsN~ zz6YD_{(aW~;9EimL5W)rqN#h{cE zx>0ip)2fNf^?IVT}80NKnH1&)vcze1|aw z9dVZZd7IWpr*x}i|E811L6Thzv7!@&U$8|bDON2g>(*eDIEjjNfe&Ucz395^CQ+H) z8nup4iwuc#NW0Xyv7j80VoxD}|;xDGb{Law5+AeB$MreR;xa^bm{ z5Gv{y^6iQ~N%_HHZ11?%i1j3R@H}tv6;@k}@p25gfquq}a_b`|x7+P^xmW9;s~E9i zT=uw&7(HV0{=``BapL7zsl;(#u5((FWlu#dgFD7xkq(|?2ZfbGBk;tO|M?G(BTqQJ3^#_ElR@DiF-;eBl{p1aGL=;nFodnrq{=0Zp&^3M|V0<`d| zg02n+Cbb)uE!UN`lI{iDTVOp%4V8niSx}ARZ?rC=1)V5Y&Rol&-l*CJaT%`bL8P=t zsj|4YWj-B6e2V^G>%kd|M$FaIJlx95YHXsNXh;^%xOCqItM1|E z<%lA6C_E1XC6j!349xkqzwnlSygt-uxM46Eu`C#yYmOOu^lRoPr7{KRQ-&*YTf~Te z35NDL`yD}W75(GrrI5^eM|4Ye1|St`P+VUv>D%mF;g5!%cg@?~V;I4Iw*=zZWcME) zZK093ELZ?kGKiqq;q!L1s<`jENq0w~ogDFQ(XQNzuXcGbI$xu9i4&QEO9FquhDI#@ zt+sE=zSonr{^Z6x=ehwYqgHNd@j*fRDDZN0C;vkW-cEau*A~V>AEq&p_!*B=nKR~H z{6zAg@(A;?RYI4qV0*Wz6SmId!Ojer2#t18%3M|#O3+smkm-h%+hB*^-_dmw!5tmo~eGyj-zym1t>3qJMJYv0* z1eMW$ktGX}I(f%9MtQ2qh!nehS)YqLgAgvleJp*@yQ>iK0Kh&DT26FJa^F4BB)kh5 zW%!)td4UfFN{xUq6)Y=?Mdn|u=ZCFAuQ8Ff)G~A!Eb;mhidoRY&^S?SY0zzKX)wjc zOuQWI96TI+0CsMAc6NG36gCwXOKCF?D+&f_K~8o~uK%|GcSsxL1_lEfH0`M=Hp^+@ z&J&C)2L^$Cj-aR-pk~4$@?))G>=`et5$yS?Tw3|4GVnOYWxT&|=_`fL6A0 zRi7>82_kk6QQ8lgucbMXpf1nUxp}e({A?4X3fejZq_b_riiYImLc85Gb!i+ZMns|p zJl%zmUBpPrd4xWMX7;K*HJE_HQ*srW%{8ab(2Vtpb>2vc;)e?F7F z5kYHO?WPceOF$`Wlq%M48Ddwc04gQ23TaBT*VPh~dSIfeT@Jk$sLae5K6rkT7*##i zH%e0BSSs*trr0d{R6- zPZDsG>z9t-V;p!#AoJXD^SaeXtB&JigC$6f3qj?d7S|%vxO`HsAa$Of+_&Rt(4f2b zPRqB-b_T?NdNRJF_MCxQ`R{#6f9yo^(3F~^7jGMd>tnYd#INb4{R1?tV++u9*`_o( zEU_Y_Ne+{DF`-eJ($_7#U%e!P{6@}xs&HDOpyJV zH-u#xod%#9Ia3zuQc)((fxl{tWz2#<+ya;@M*Wv{H=Oa(2t?lOwzG0u@7(ZG0LlRMngg3XRe&fHclV4|QFHz-U8MlSHZI+#v)Ar#Lwqe6{1@M*D9vDA|`$P6OqQod09?$>y%?mS+ z9+laG&c_E2n6l9{%D8>85-C-!&zdFLKY#J>`7muVcKexMd+l)vUOM4vEL2B`XBwS_P1QkhB7UO~a}bg`;lx z@xeWDWM$4)LwFMWD4{qTZUt;(8`gzS>J8Dw5T5*}JdJNgbp z8|LAc22(|*P0%3Gy)xbmyFv%Cv z&eFtgAt}831iszL(Mii5g>YJ=YhU+uQ``z^N<0?^B&7?0xL^-~4)KBCi{+lr3>+@V zmt}N@jkRI4j=PZ!bEk{zw_kux|JFgTrenw(uBZm*D~b2Zbea5UV^-t_6igmFnlV;u zZdb=VrEts9Pr1ngejlMaB`mVk+6|(vQu@*2sTkoHn583O_Tj-6%X@EhzEN7R#@S9Xo#>rB8$ z_pE!A-g+o(SH=2;J4QDWiUnlPnS7M>uCcdjovabq{c|PMbx4xwfzj_-R>4#&aE+jU z;Hxxh&!?L-A;!}+`xkSH0Rx7kksy0&y%_Ft!Q;{nw`w3!0gVINoFQ?fI$e%Dq_ z?Yc>S%icB<%?#PTr}9KD#_gfZ!8mJnl3W=(@6S;OI~LrK@O9+Nw_p;_Jg)S|~c^`o>!*NiSc?gETT z+X1yNSq0%YKL)x-yl4Ibbw01}?w+pjtN(0hdzW?oB$#Eb{wG-Nzok{+d{yE{##{aS z3G2uyi2Ug3>2as9`)u{Sy*oQ0b{ygTW)f!MDh16}#zIE=S zJc^!Q^{j6Bzo4D>){H)wx%;#7=8EWcxOh9^33i_JM8~(GZk2<+6MN9d@;*bu)57m- zp!Ju5P}oswh6aVxkCi8%9RrM2D+c{E>tx1y=I`$gFkk7T001CP#+O~0S;~m*6V$H5 z;rlj*g^iN3bW8=kEcOf%2#POvFXJ-6u3ipf=P zmC%&#`OUVFNQmu~bd?5#Eo8dk=@IcBWa=)qGk;N z!q|3ewp^o3Ix#{91wO|@PxHD@u-y+1^w*2i;a3oLed(V&{nvPEcrg2EKT+vRF)vAN zgnQDE!y7M`{W{573a*?NqmkAC6;=T_oi`q9s9um{vYjz9?KC^7yd-rTWx+@wVGP{g89rV!@6Woi@_y9!M$GXZuR7ujPQiC_{yzdYdUE;-zMp(RFTx)zeS$8*9;v0MiJk zsE>&Z(cyVemwD~`$I(e!+AZqE0uf^53xAide%wA@;1af5AV!n^>xjU9`}VvC6&z*K zBj{r9Agv;sTj<_|)BH$-r*Qw7m+2Je4C6o9*lHZ64%vy-F7WS=`XmHy|00FB=yw;* z)&YYUWrgn9n#Z`rYU--3t(FpZ&zRaD*{DEq7p-?*ACjdI08|qdEPqJ^UtXrreQzrs z#TH)4B#e~X*P=*&-#mmK*YEB~&%~`|96d12%LHMEd2wn_?omJ@X8Ws$%~XOTB_9Eh z5FqRK3#60eXVU8ZPQO)S(LBil>F z&j71HyE9rJ*pY#uKj4a{26iwzxPe{6+=gn}KbPKx)5bd0!g?9Sx*s=pN0wF{S|S*l zKa$rr%9TG9*F&7XtQfVk7}3v6-P+)j8aA*2m3C}^*Rdbteo*wU1fkn^s6lpUsm4W6 zORq4B1v|_FJL8}Hmor>PaWZRD9BVU-V>4*{VhW|$pf-lCNngM?S$%hAx#E5c)z+3@ zt)iGpJx|0PalL26&z<)Dlh-jN#@qGiZX@aKPbzZEl$l0M@&V+0Nj!UXz31xD4&9{> p=wnC9G88LkOLq@9D>JA6wQ@1HN6Dy#MMvT0;6b6Kl~I#L`5!v}8V&#e